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Squamous  cell  carcinoma  of  tissues  of  the  head  and  neck  (HNSCC)  continues 
to  be  a  major  cause  of  morbidity  and  mortality  in  many  parts  of  the  world,  and 
survival  is  not  improving.  Much  research  has  been  devoted  to  the  identification 
of  molecular  markers  characteristic  of  the  development  and  progression  of 
HNSCC.  Alterations  in  many  molecular  markers  in  HNSCC  have  been 
demonstrated,  including  genes  related  to  proliferation,  differentiation,  adhesion 
and  others  such  as  those  that  control  invasion  and  metastasis.  Some  of  these 
single  markers  may  indicate  poor  prognosis  or  risk  of  recurrence,  but  none  has 
been  found  to  be  robust  enough  for  clinical  use. 
Limitless  replicative  potential,  or  immortality,  has  been  identified  as  one  of  the 
six  basic  "hallmarks"  of  cancer.  Clinical  follow-up  data  from  our  HNSCC 
cultures,  and  other  studies,  show  a  correlation  between  the  ability  of  HNSCCs 
to  establish  as  cell  lines  in  culture  (i.  e.  become  immortal)  and  poorer  patient 
survival.  In  addition,  40%  of  primary  cell  cultures  derived  from  dysplastic 
premalignant  oral  lesions  are  immortal  in  culture.  Thus,  the  acquisition  of 
immortality  and  invasion  may  be  independent  events.  Previous  work  has 
demonstrated  a  specific  pattern  of  four  biological  markers  associated  with  oral 
SCC  or  dysplasia  immortality  in  cell  culture:  namely  p16  and  RARP  loss,  p53 
mutation,  and  telomerase  activation.  The  changes  in  p16,  p53  and  hTERT 
were  found  in  the  dysplasia  biopsies  from  which  the  cultures  were  derived, 
however  the  in  vitro  changes  in  RAR-,  8  expression  were  not  reproduced  in  the 
biopsy  tissues. 
Microarray  analysis  was  performed  on  32  head  and  neck  keratinocyte  cultures 
using  Affymetrix  U133A/B  genechips.  The  panel  of  cultures  included  normal 
cells,  mortal  and  immortal  cultures  of  dysplastic  keratinocytes  and  mortal  and 
immortal  cultures  from  carcinomas,  all  grown  to  a  standard  protocol. 
The  overall  GEP  revealed  that  many  of  the  well-established  HNSCC  molecular 
markers  associated  with  motility  and  invasion  were  up-regulated  in  the  mortal 
cells,  particularly  in  the  mortal  carcinomas.  Immortal  HNSCC  cells  showed 
elevated  expression  of  cell-cycle  markers  and  loss  of  differentiation  markers. 
In  addition,  a  small  number  of  common  changes  in  gene  expression  in  all  the carcinomas,  regardless  of  replicative  fate,  were  identified.  This  included  several 
transcription  factors. 
A  series  of  49  novel  gene  expression  changes  consistently  associated  with 
immortality  in  dysplastic  keratinocytes  and  SCCs  were  identified.  The  list 
included  genes  involved  in  cell  cycle  control,  signalling,  cellular  metabolism  and 
maintenance  of  cellular  structure.  Validation  of  the  expression  of  these  genes 
by  western  blot  demonstrated  that,  in  general,  the  protein  expression  of  genes 
agreed  with  the  RNA  expression  level  from  the  microarray  data.  However, 
some  heterogeneity  was  evident. 
The  mortal  and  immortal  gene  expression  signatures  were  validated  by  IHC  in 
the  turnours  from  which  the  cultures  were  derived.  The  turnours  that  gave  rise 
to  immortal  cell  cultures  demonstrated  a  relatively  uniform  pattern  of  staining  in 
relation  to  the  novel  markers  of  immortality.  However,  those  tumours  which 
gave  rise  to  mortal  cultures  exhibited  significant  heterogeneity  of  gene 
expression  pattern,  with  areas  characteristic  of  both  the  mortal  and  immortal 
phenotype  present. 
The  patterns  of  gene  expression  characteristic  of  mortal  and  immortal  cells  may 
reflect  the  differing  origin  of  these  populations,  relating  to  different  mechanisms 
involved  in  the  generation  of  HNSCC  subtypes.  The  differences  may  also 
indicate  that  the  mortal  and  immortal  cells  utilise  different  mechanisms  of 
invasion.  In  some  cases,  mortal  and  immortal  cells  exist  in  adjacent  areas 
within  the  same  tumour,  but  it  is  not  clear  whether  the  immortal  HNSCCs  derive 
from  the  adjacent  mortal  cells.  However,  the  presence  of  intermediate  features 
in  vivo  and  in  vitro  raises  the  possibility  that  inter-conversion  between  the  two 
HNSCC  types  may  be  possible,  with  mortal  neoplastic  keratinocytes  gaining  the 
immortal  phenotype 
These  novel  markers  give  us  further  insight  into  the  mechanisms  and 
importance  of  keratinocyte  immortalization.  Surrogate  markers  of  immortality 
could  therefore  be  valuable  for  assessment  of  prognosis  and  therapy  if 
confirmed  in  larger  in  vivo  studies. IV 
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The  work  described  in  this  thesis  is  that  of  the  author,  unless  otherwise  stated. 1 
Chapter  One:  Clinical  and  pathological  aspects  of  head  and  neck 
squamous  cell  carcinoma  and  related  premalignant  lesions. 
1.1  General  introduction 
Squamous  cell  carcinoma  of  tissues  of  the  head  and  neck  (HNSCC)  continues 
to  be  a  major  cause  of  morbidity  and  mortality  in  many  parts  of  the  world. 
Indeed,  head  and  neck  cancer  (90%  of  which  is  HNSCC)  is  the  sixth  most 
common  cancer  worldwide,  with  a  much  higher  incidence  in  particular 
subpopulations,  especially  in  areas  of  France,  the  Indian  sub-continent  and  Far 
East.  This  disease  can  have  devastating  effects  on  the  sufferer,  as  treatment 
often  involves  mutilating  surgery  that  compromises  the  functions  of  the  upper 
aero-digestive  tract,  in  addition  to  the  unfortunate  social  stigma  of  the  facial 
disfigurement  that  treatment  often  involves.  Patients,  particularly  if  at  advanced 
stage  on  presentation,  often  follow  a  protracted  clinical  course  involving 
repeated  recurrences  with  a  requirement  for  long-term  multi-disciplinary  care. 
This  is  distressing  for  the  patient  and  their  family  and  places  a  significant 
financial  and  logistical  burden  on  the  treating  healthcare  institution. 
1.2  Epidemiology 
1.2.1  Incidence 
HNSCC  is  a  heterogeneous  group  comprising  cancers  of  the  lip,  oral  cavity, 
oropharynx,  hypopharynx  and  larynx,  each  having  clinically  and  biologically 
distinctive  features,  but  clearly  linked  by  common  risk  factors  (Takes  et  al., 
1998).  In  the  United  Kingdom,  approximately  8000  new  cases  of  HNSCC  are 
diagnosed  each  year,  with  oral  cancer  comprising  1.6%  of  all  new  malignant 
disease.  Historically,  the  sex  ratio  has  shown  a  male  predominance  (5:  1),  but 
this  has  decreased  as  the  female  incidence  rate  has  risen  (now  1.9:  1).  Patients 
over  50  years  of  age  comprise  85%  of  cases.  (ISID  at  www.  isdscotland.  o[g). 
The  incidence  of  HNSCC  in  the  UK  as  a  whole  has  been  stable  over  the  last  25 
years  at  around  16  per  100,000  population.  However,  this  headline  figure  is 
misleading  and  conceals  important  trends.  In  Scotland,  head  and  neck  cancer 
incidence  increased  by  16.3%  over  the  period  1990-2000  (Table  1.1  shows 
individual  male  and  female  rates).  There  was  also  an  increase  in  the  incidence 2 
of  cancers  of  the  oral  cavity,  both  in  the  UK  as  a  whole,  but  particularly  in 
Scotland,  where  data  from  the  Scottish  Cancer  Registry  (ISID  at 
www.  isdscotland.  o[g)  reveals  an  increase  of  34%  in  males  and  43%  in  females 
over  a  similar  period  (Table  1.2).  This  contrasts  with  the  20%  reduction  in  male 
lung  cancer  incidence  in  Scotland  over  1990-2000,  an  intriguing  phenomenon 
as  HNSCC  and  lung  cancer  share  many  common  risk  factors.  Similar  rises  in 
HNSCC  incidence  have  been  seen  in  many  areas  of  the  world,  particularly  in 
Central  and  Eastern  Europe,  Japan  and  Australia  (La  Vecchia  et  al.,  2004;  La 
Vecchia  et  al.,  1997).  However,  in  the  USA,  the  incidence  of  HNSCC  amongst 
whites  (especially  males)  is  failing  (Ries  et  al.,  2004).  A  reduction  has  also 
been  seen  in  some  areas  of  high  incidence  such  as  India,  Hong  Kong  and 
Brazil  (Sankaranarayanan  et  al.,  1998). 
Another  worrying  feature  hidden  in  the  headline  data  is  the  rise  in  HNSCC 
incidence  in  young  patients  (younger  than  45  years  at  diagnosis)  in  many  high 
incidence  and  European  countries  (Boyle  et  al.,  1995).  Many  of  these  patients 
fall  into  the  traditional  high  risk  factor  groups,  but  an  increasing  proportion  do 
not  (Llewellyn  et  al.,  2003;  Llewellyn  et  al.,  2004;  Rodriguez  et  al.,  2004).  Such 
patients  without  the  traditional  HNSCC  risk  factors  may  constitute  a  distinct 
clinical  and  biological  group  (Koch  et  al.,  1999).  The  notion  that  these  young 
patients  have  a  poor  prognosis  with  a  low  five-year  survival  is  not  supported  by 
studies  in  Scotland,  as  recent  data  revealed  that  the  15-44  year  age  group  had 
a  substantially  higher  five-year  survival  than  any  other  age  group  (ISD  at 
www.  isdscotland.  org).  A  recent  study  in  Scandinavia  also  reported  higher  five 
year  survival  rates  in  young  patients  (Annertz  et  al.,  2002). 
Mortality 
Headline  figures  for  the  overall  five-year  survival  of  patients  with  HNSCC  are 
also  misleading  as  they  conceal  trends  in  particular  subgroups  of  patients. 
These  summary  statistics  do  not  take  into  account  the  diversity  of  stage  and 
anatomical  subsites  involved.  Aggressive  surgical  treatment  of  early  disease  at 
some  subsites,  for  example  lip,  can  produce  five-year  survival  figures  of  80-90% 
(McCombe  et  al.,  2000;  Veness  et  al.,  2001).  However,  in  many  parts  of  the 
world,  including  Scotland,  despite  progress  in  the  understanding  of  the  disease, 
the  headline  survival  rates  for  head  and  neck  cancer  have  not  changed 3 
markedly  over  the  last  few  decades  (ISID  at  www.  isdscotland.  o[g).  The  five- 
year  survival  rate  is  54.3%  for  males  and  56.6%  for  females  (Table  1.1). 
Indeed,  in  Scottish  males,  the  five-year  survival  from  head  and  neck  cancer  has 
fallen  slightly  over  the  period  1977-2001.  Many  reasons  have  been  proposed, 
including  a  less  favourable  case  mix  and  an  increase  in  the  proportion  of 
patients  from  deprived  areas  (Macfarlane  et  al.,  1996).  In  contrast,  over  the 
same  period,  five-year  survival  from  oral  cavity  cancer  improved  by  15%,  in 
both  males  and  females  (ISID  at  www.  isdscotland.  onq). 
The  recent  overall  worsening  of  HNSCC  survival  in  Scottish  males  is 
disappointing.  Whilst  developments  in  primary  surgical  and  oncological 
treatment  have  resulted  in  better  apparent  control  of  primary  disease,  there  has 
been  little  improvement  in  the  management  of  metastatic  disease.  This  is 
becoming  a  problem,  as  an  increasing  proportion  of  patients  now  survive  long 
enough  to  present  with  distant  metastases  (Taneja  et  al.,  2002).  Thus,  it  has 
become  clear  that  the  way  forward  in  tackling  this  devastating  disease  must  be 
on  two  fronts.  Emphasis  must  be  placed  on  prevention  and  early  detection  of 
HNSCC  lesions  and  the  careful  clinical  and  pathological  monitoring  of  any 
lesions  that  may  harbour  an  increased  risk  of  development  of  HNSCC.  The 
Health  Education  Board  for  Scotland  (HEBS)  has  highlighted  this  in  recent 
media  campaigns.  Additionally,  advancement  in  the  knowledge  of  the  biology 
and  pathogenesis  of  HNSCC  may  result  in  the  development  of  molecular  based 
prognosis  assessment  tools  and  therapies,  which  may  help  to  reduce  the 
burden  of  continued  disease,  foremost  for  the  patient,  but  also  on  the 
healthcare  system. 4 
Summary  statistics  Period  Males  Females 
Rank  2001  4  10 
Relative  frequency  2001  5.6%  2.4% 
Registrations  2001  687  313 
Deaths  2003  252  113 
Change  in  incidence 
N 
1992-2001  +11.6%  +21.80% 
Relative  survival 
1  year 
5  years 
1997-2001  78.7 
54.3 
77.3 
56.6 
Table  1.1  Summary  statistics  for  cancer  of  the  head  and  neck  in  Scotland 
This  Table  comprises  the  most  recent  data  from  Scottish  Health  statistics,  ISID 
Scotland,  released  on  26  November  2004  (ISD  at  www.  isdscotland.  org).  This 
covers  IARC  classification  codes  ICD-9  140-149,160-161;  ICD-10  COO-C14, 
C30-C32. 
Summary  statistics  Period  Males  Females 
Relative  frequency  1999  1.9%  0.9% 
Registrations  1999  222  113 
Deaths  2001  81  35 
Change  in  incidence 
N 
1989-99  +35.4%  +43.5% 
Relative  survival 
-1  year 
-5  years 
1995-99  72.8 
43.1 
71.1 
51.3 
Table  1.2  Summary  statistics  for  oral  cavity  cancer  in  Scotland 
This  Table  comprises  data  collected  for  IARC  classification  codes  ICD-9  143- 
145;  ICD-10  C03-CO6.  Data  from  Scottish  Health  statistics,  ISD  Scotland  (ISD 
at  www.  isdscotland.  org). 5 
1.3  Risk  factors 
1.3.1  Tobacco  and  alcohol 
The  main  risk  factors  for  HNSCC  are  tobacco  usage  (in  any  form)  and  alcohol 
consumption,  but  this  varies  significantly  between  subsites.  A  recent  report 
found  a  20  fold  increased  risk  of  oral  and  pharyngeal  cancer  below  age  46  for 
heavy  smokers,  with  a  five-fold  increase  for  heavy  drinkers.  The  combination  of 
heavy  smoking  and  drinking  led  to  an  increased  risk  of  almost  50  fold 
(Rodriguez  et  al.,  2004).  In  Western  populations,  the  most  common  sites  for 
small,  asymptomatic  SCC  lesions  within  the  oral  cavity  are  the  ventral  aspect  of 
the  tongue  and  floor  of  the  mouth,  presumably  because  this  is  where  such 
carcinogens  collect.  Oral  cancer  is  also  prevalent  in  particular  communities, 
such  as  in  the  Indian  subcontinent,  where  other  forms  of  tobacco  consumption, 
such  as  betel  quid  chewing,  are  prevalent:  indeed,  in  some  Indian 
subpopulations,  HNSCC  accounts  for  almost  half  of  all  cancers  in  males 
(Sanghvi,  1981;  Saranath  et  al.,  1993). 
Carcinogens  produced  by  tobacco,  for  example  benz-(a)-pyrene  and 
nitrosamines,  are  known  to  produce  the  precise  types  of  guanine  nucleotide 
transversions  found  in  critical  genes  involved  in  HNSCC  development,  such  as 
p53  (Burns  et  al.,  1993;  Chang  et  al.,  1994).  The  role  of  alcohol  is  less  clear, 
but  it  appears  to  act  as  a  co-carcinogen  by  being  metabolised  to  acetaldehyde. 
This  can  damage  DNA  and  trap  glutathione,  an  important  peptide  in 
detoxification  of  carcinogens  (reviewed  in  Poschl  &  Seitz,  2004;  Seitz  et  al., 
2001).  Alcohol  can  also  induce  CYP2E1,  an  enzyme  involved  in  activation  of 
various  pro-carcinogens  found  in  alcoholic  beverages  and  tobacco  smoke. 
1.3.2  Human  papilloma  virus 
Human  papilloma  virus  (HPV)  has  also  been  implicated  in  HNSCC  development 
(Gillison  et  al.,  2000),  but  this  has  proved  controversial  (Ha  et  al.,  2002a).  One 
case  control  study  found  an  increased  risk  of  HNSCC  with  the  presence  of  high 
risk  HPV  types  (HPV16)  in  exfoliated  oral  cells,  in  concert  with  heavy  alcohol 
consumption  and  tobacco  use  (Smith  et  al.,  2004).  However,  the  concordance 
between  oral  HPV  status  and  HPV  positivity  of  the  tumour  in  this  study  was 
weak  and  thus  the  data  is  open  to  other  interpretation.  Much  of  the  data  on  the 6 
role  of  HPV  in  HNSCC  carcinogenesis  is  semiquantitative  and  hampered  by 
difficulties  in  interpretation.  The  recent  study  by  Ha  and  co-workers  utilised 
quantitative  PCR  in  assessment  of  HPV  DNA  copy  number  in  oral 
carcinogenesis.  This  study  concluded  that  sufficient  copy  numbers  of  HPV  to 
allow  a  causal  association  to  be  inferred  were  only  present  in  1  of  102 
premalignant  oral  lesions  and  1  of  34  oral  SCCs  (Ha  et  al.,  2002a). 
Recent  evidence  more  convincingly  implicates  HPV  in  a  less  aggressive  form  of 
HNSCC,  particularly  in  tonsillar  and  oropharyngeal  cancers,  but  to  a  lesser 
extent  in  oral  cancer  (Herrero  et  al.,  2003;  Ringstrom  et  al.,  2002).  These  HPV- 
positive  oropharyngeal  cancers  are  clinically  and  biologically  distinct  and  such 
patients  had  an  improved  prognosis  (Gillison  et  al.,  2000).  Braakhuis  and  co- 
workers  have  shown  that  HNSCC  with  transcriptionally  active  HPV  DNA  fail  to 
show  the  pattern  loss  of  heterozygosity  (LoH)  at  chromosomes  3p,  9p  and  17p 
normally  associated  with  HNSCC  (Braakhuis  et  al.,  2004b).  The  implications  of 
this  will  become  apparent  in  later  discussion  of  the  importance  of  such 
chromosomal  loci. 
1.3.3  Other  risk  factors 
A  multitude  of  other  factors  has  been  implicated.  The  development  of  lip  cancer 
is  primarily  related  to  exposure  to  UV  irradiation  (Ju,  1973).  Marijuana  has  also 
been  postulated  to  play  a  role  by  increasing  mutagen  sensitivity  (Zhang  et  al., 
1999),  but  the  evidence  from  cohort  studies  does  not  support  such  a  link 
(Hashibe  et  al.,  2002;  Rosenblatt  et  al.,  2004).  Poor  diet,  particularly  a  low 
consumption  of  fruit  and  vegetables  has  been  implicated  (Macfarlane  et  al., 
1995).  This  has  been  pinpointed  as  a  potential  cause  of  the  increase  in  HNSCC 
incidence  in  young  people,  although  it  is  likely  that  such  an  effect  is  additive  to 
that  of  high  tobacco  and  alcohol  consumption  (Llewellyn  et  al.,  2004;  Mackenzie 
et  al.,  2000).  These  collective  risk  factors  may  account  for  the  higher  incidence 
of  HNSCC  in  socially  and  economically  deprived  communities,  notably  in  the 
West  of  Scotland  (Macfarlane  et  al.,  1996).  Nutrients,  such  as  folic  acid,  may  be 
protective  (Pelucchi  et  al.,  2003).  A  small  number  of  patients  may  have  an 
increased  susceptibility  to  oral  cancer  because  of  inherited  genetic  defects 
(Prime  et  al.,  2001).  In  disorders  of  DNA  repair  mechanisms,  such  as 7 
xeroderma  pigmentosurn,  these  is  an  increased  incidence  of  secondary 
malignancies,  including  oral  cancer  (Patton  &  Valdez,  1991). 
Genetic  susceptibility  and  environmental  risk  factors  often  interact.  About  40% 
of  Japanese  carry  a  mutant  allele  of  the  acetaldehyde  dehydrogenase-2 
(ALDI-12)  gene  that  encodes  an  inactive  enzyme.  This  mutant  ALDI-12  allele  is  a 
strong  risk  factor  for  head  and  neck  cancer  and  oesophageal  cancer  among 
heavy  alcohol  drinkers  in  Japan  (Yokoyama  et  al.,  2002).  Polymorphisms  in 
alcohol  dehydrogenase-2  (AIDI-12)  also  affects  risk  of  head  and  neck  cancer  in 
alcoholics  (Yokoyama  et  al.,  2001).  Indeed,  it  has  been  calculated  that  the 
polymorphisms  in  the  ALID2  and  ALIDI-12  genes  account  for  82%  of  the 
population  attributable  risks  for  HNSCC  in  Japanese  alcoholics  (Yokoyama  et 
al.,  2001). 
There  is  some  variation  in  the  risk  factors  associated  with  different  subsites 
within  the  upper  aero-digestive  tract.  Smoking  and  alcohol  in  combination  is  a 
higher  risk  factor  for  oral  cavity  and  pharyngeal  cancer  than  for  larynx  (Baron  et 
al.,  1993).  The  differences  may  lie  in  the  presence  of  unspecified  factors  in  the 
oral  cavity  and  pharynx,  but  not  in  the  other  upper  aero-digestive  tract  sites, 
which  potentiates  the  effects  of  alcohol  and  smoking  in  the  oral  cavity  and 
pharynx.  Separate  analysis  of  smoking  and  alcohol  in  relation  to  risk  at  the 
various  subsites  also  reveals  that  the  highest  risk  for  either  factor  is  in  the  oral 
cavity  and  lowest  in  the  larynx  (Franceschi  et  al.,  1990;  La  Vecchia  et  al.,  1990). 
Various  dietary  factors  have  been  reported  as  having  differential  effects  in  terms 
of  risk  including  red  chilli  and  tea  drinking  (pharynx)  (Notani  &  Jayant,  1987). 
Patients  who  present  with  none  of  the  traditional  risk  factors  predominantly  have 
oral  cavity  cancers  (Wiseman  et  al.,  2003). 
1.4  Prognostic  factors  in  HNSCC 
Many  clinical  prognostic  factors  in  SCC  are  well  established.  These  include 
anatomical  site,  tumour  size,  lymph  node  status,  the  presence  of  distant 
metastases  and  certain  histological  subtypes  (Quon  et  al.,  2001;  Tralongo  et  al., 
1999;  Woolgar  et  al.,  1999).  Histological  examination  also  adds  tumour  grade 
(a  measure  of  differentiation),  depth  of  invasion  and  the  presence  of  invasion 
related  to  nerves  or  lympho-vascular  channels.  Much  of  this  information  is 
summarised  in  the  TNM  classification  (Sobin  &  Wittekind,  2002).  Whilst  useful 8 
at  a  population  level,  these  prognostic  factors  may  be  limited  in  their  predictive 
value  for  the  identification  of  patients  who  have  a  high  risk  of  recurrence, 
relapse  or  death  (Fries  et  al.,  1976).  As  a  result,  many  other  clinico-pathological 
staging  and  prognosis  systems  have  been  developed,  with  varying  degrees  of 
success,  and  with  limited  acceptance  (Groome  et  al.,  2001). 
As  is  often  the  case  for  lung  cancer  patients,  the  risk  of  the  development  of 
continued  or  subsequent  malignant  disease  in  patients  with  HNSCC  is  high. 
Many  patients  will  develop  either  synchronous  or  metachronous  second  (or 
subsequent)  upper  aero-digestive  tract  turnours.  The  probability  of  developing 
a  second,  metachronous  HNSCC  in  the  five  years  after  initial  treatment  is 
approximately  22%  (de  Vries  et  al.,  1986;  Schwartz  et  al.,  1994). 
1.5  Field  cancerization 
There  is  evidence  that  primary  HNSCC  and  subsequent  disease  (and 
premalignant  lesions)  are  derived  by  additional  mutations  acquired  within  a 
'field'  of  genetically  altered  cells  within  the  mucosa  (Bedi  et  al.,  1996).  The 
mucosa  affected  may  be  clinically  and/or  histologically  normal.  This  has  been 
termed  'field  cancerization',  (Slaughter  et  al.,  1953).  These  alterations  arise 
from  exposure  of  large  areas  of  the  epithelium  of  the  upper  aero-digestive  tract 
to  carcinogens  and/or  growth  promoters  in  tobacco  or  alcohol  (Bedi  et  al., 
1996).  Thus,  whilst  these  tumours  are  ultimately  clonally  divergent,  they  share 
certain  common  cytogenetic  features  with  the  rest  of  the  field  (Braakhuis  et  al., 
2003).  The  abnormalities  may  be  due  to  epigenetic  or  genetic  changes  induced 
in  the  field  of  exposed  cells.  Jang  and  co-workers  have  also  suggested  that,  in 
a  minority  of  cases,  there  may  be  mucosal  spread  of  malignant  or  premalignant 
cells  within  the  oral  cavity,  resulting  in  multiple,  discrete  tumours  that  are  truly 
clonal  in  origin  (Jang  et  al.,  2001).  The  mechanism  of  this  effect  has  not  been 
elucidated. 
Consequently,  some  of  the  genetic  changes  characteristic  of  a  particular 
primary  HNSCC  can  often  be  found  in  clinically  and  histological  normal  mucosa 
up  to  a  distance  of  7  cm  away  from  the  primary  tumour  (Braakhuis  et  al.,  2003; 
Tabor  et  al.,  2002a).  This  has  obvious  repercussions  for  decisions  relating  to 
the  size  of  excision  margins  required  at  the  time  of  primary  surgical 9 
management.  Thus,  second  or  subsequent  HNSCCs  may  be  of  three  types: 
they  may  be: 
*  "True"  recurrence;  derived  from  incomplete  eradication  of  the  primary 
scc 
9  Second  "field  cancers";  these  may  have  a  different,  but  overlapping, 
spectrum  of  genetic  changes  having  developed  from  an  intervening  field 
of  abnormal  oral  mucosa  (Braakhuis  et  al.,  2002). 
9  Second  primary  tumours,  with  a  clonally  independent  origin. 
1.6  Premalignant  lesions 
The  presence  of  extensive  areas  of  genetically  abnormal  epithelium  raises  the 
possibility  of  precursor  lesions,  which  may  be  amenable  to  preventative 
intervention.  These  lesions  may  be  clinically  evident,  and  are  often  referred  to 
as  premalignant  lesions  (PMLs).  Clinically  evident  mucosal  lesions  that 
possess  an  increased  risk  of  progression  to  HNSCC  predominantly  appear  as 
white  patches  (leukoplakia)  or,  less  commonly,  as  red  patches  (erythroplakia). 
These  lesions  are  illustrated  in  Figure  1.1A  and  C.  Other  conditions,  such  as 
lichen  planus,  may  have  premalignant  potential  (Epstein  et  al.,  2003). 
1.6.1  Malignant  transformation  in  PMLs 
The  evidence  that  oral  leukoplakia  has  premalignant  potential  is  mainly  based 
on  cohort  studies  in  hospital-based  populations.  This  introduces  an  element  of 
case  selection  bias  into  the  assessment  of  the  proportion  of  these  patients  who 
develop  HNSCC  within  their  PML.  The  consequence  of  this  is  a  large  range  of 
malignant  transformation  rates  from  multiple  studies,  whose  populations  are  not 
readily  comparable  (Table  1.3).  Recent  studies  estimated  the  prevalence  of 
homogeneous  oral  leukoplakia  in  the  general  population  of  the  USA  at  0.37% 
(Scheifele  et  al.,  2003).  Extrapolation  of  this,  in  conjunction  with  the  incidence 
of  HNSCC  in  European  countries  where  there  is  reasonable  integrity  of  cancer 
registry  data,  indicates  that  the  true  malignant  transformation  rate  of  oral 
leukoplakia  is  probably  less  than  1%  per  year  (Scheifele  &  Reichart,  2003). 
Malignant  transformation  may  be  higher  in  the  small  proportion  of  leukoplakias 
that  are  dysplastic,  but  regression  of  dysplastic  changes  may  also  be  seen, 10 
particularly  where  there  is  cessation  of  the  precipitating  risk  factor(s)  (Pindborg 
et  al.,  1977). 
Various  clinical  parameters  alter  the  malignant  transformation  rate  of 
leukoplakia.  In  Western  populations,  lesions  located  on  the  floor  of  the  mouth 
and  ventral  surface  of  the  tongue  have  been  shown  to  have  a  higher  malignant 
potential  than  other  areas  of  the  mouth  (Kramer  et  al.,  1978),  although 
Schepman  and  co-workers  could  not  substantiate  this  in  a  later  study 
(Schepman  et  al.,  1998).  Thus,  the  concept  of  high-risk  sites  is  not  well 
supported  in  the  literature.  However,  it  is  surely  significant  that  the  proposed 
"high-risk"  PML  sites  are  also  those  that  are  most  commonly  associated  with 
early  oral  cancer  lesions.  Erythro-leukoplakia  or  46  speckled"  leukoplakia,  a  form 
of  non-homogenous  leukoplakia  (Figure  1.113)  also  has  a  higher  malignant 
transformation  rate  (Mehta  et  al.,  1981),  presumably  related  to  the  presence  of 
areas  of  erythroplakia  within  the  lesion.  The  concurrent  presence  of  infection 
with  Candida  species  also  correlates  with  the  presence  of  oral  epithelial 
dysplasia  (McCullough  et  al.,  2002). 
In  contrast,  the  malignant  transformation  rate  of  erythroplakia  is  much  higher. 
Erythroplakia  is  much  rarer  than  leukoplakia,  but  often  reveals  carcinoma-in-situ 
or  frank  carcinoma  at  the  time  of  original  diagnosis  (Mashberg,  1977; 
Mashberg,  1978;  Shafer  &  Waldron,  1975).  Subsequently,  a  substantial 
proportion  of  patients  will  develop  a  SCC  over  the  following  five-year  period. 
The  reasons  for  the  high  prevalence  of  dysplasia  in  erythroplakias  are  not  clear. 
It  has  been  suggested  this  may  due  to  a  greater  frequency  of  p53  mutations  in 
erythroplakias  (Qin  et  al.,  1999),  but  once  smoking  status  has  been  taken  into 
account,  this  does  not  seem  to  be  the  case  (Lazarus  et  al.,  1995;  Lazarus  et  al., 
1996). 11 
Figure  1.1  . 
Clinically  premalignant  lesions 
A 
B 
C 
A.  leukoplakia  of  anterior  floor  of  mouth/ventral  tongue 
B.  erythro-leukoplakia  of  soft  palate  complex 
erythroplakia  of  right  anterior  pillar  of  fauces 
Photographs  courtesy  of  Professor  DG  MacDonald  (A  and  C)  and  Dr  John 
Eveson,  @  Bristol  Biomedical  Image  Archive,  University  of  Bristol  (B) 12 
Study/year  Country  No  of 
patients 
follow- 
Up 
(years) 
%  malignant 
transformation 
(Pindborg  et  al.,  1968)  Denmark  248  3.9  4.4 
(Silverman  &  Rosen, 
1968) 
USA  117  1-11  6.0 
(Kramer  et  al.,  1970)  UK  187  unclear  4.8 
(Mehta  et  al.,  1972)  India  117  10  0.9 
(Silverman  et  al.,  1976)  India  4762  2  0.9 
(Banoczy,  1977)  Hungary  670  9.8  6.0 
(Silverman  et  al.,  1984)  USA  257  7.2  17.5 
(Lind,  1987)  Norway  157  9.3  8.9 
(Lummerman  et  al., 
1995) 
USA  240  20  13.8 
(Schepman  et  al.,  1998)  Netherlands  166  2.5  12 
(Shiu  et  al.,  2000)  Taiwan  435  10  14 
(Cowan  et  al.,  2001)  N.  Ireland  165  20  15 
(Sudbo  et  al.,  2001  a)  Norway  150  9  24 
Table  1.3  Selected  studies  on  malignant  transformation  of  dysplastic  oral 
leukoplakia. 
The  table  is  adapted  from  a  review  by  Reibel  (Reibel,  2003),  with  some  added 
information  from  more  recent  studies. 13 
1.7  The  relationship  between  PMLs  and  HNSCC 
It  is  impossible  to  be  precise  as  to  the  fraction  of  HNSCC  that  are  preceded  by 
PIVII-s.  Indeed,  in  some  patients,  the  precursor  lesion  may  not  be  clinically 
evident.  Certainly,  many  patients  present  initially  with  advanced  HNSCC,  but  it 
is  unclear  to  what  extent  previous  PMLs  may  have  been  missed  due  to 
infrequent  intraoral  examinations.  However,  as  the  risk  factors  for  the 
development  of  oral  premalignant  lesions  are  very  similar  to  those  for  HNSCC 
itself  (Hashibe  et  al.,  2003),  it  seems  reasonable  that  a  proportion  of  patients 
will  develop  their  SCC  within  a  histopathologically  evident  precursor  lesion, 
whether  or  not  it  is  clinically  visible.  Histological  studies  indicate  that,  as  a 
minimum  estimate,  in  the  region  of  36%  of  SCCs  have  adjacent  dysplastic 
areas  (Bouquot  et  al.,  1988).  This  clearly  leaves  a  large  proportion  of  SCCs 
that  either  have  developed  in  epithelium  that  was  not  previously  dysplastic,  or 
have  completely  subsumed  the  original  dysplastic  lesion.  Pindborg  found  that  a 
proportion  of  carcinomas  developed  in  lesions  that  had  not  shown  dysplasia  in 
previous  biopsies  (Pindborg  et  al.,  1977).  Another  study  concluded  that 
leukoplakia  was  associated  with  48%  of  oral  SCCs  (Hogewind  et  al.,  1989). 
This  indicates  that  whilst  commonly  associated  with  HNSCC,  PMLs  are  not 
obligatory  precursor  lesions. 
1.8  Epithelial  dysplasia  and  PML  prognosis 
Assessment  of  epithelial  dysplasia  on  histological  sections  has  been  the 
traditional  method  of  judging  the  potential  for  malignant  change.  Dysplasia  is 
the  sum  of  atypical  structural  and  cytological  features  within  the  epithelium  and 
is  traditionally  graded  as  mild,  moderate  or  severe  (Figure  1.2  A-C).  Once  the 
histopathological  features  of  dysplasia  affect  the  full  thickness  of  the  epithelium, 
but  with  no  evidence  of  invasion,  the  term  carcinoma-in-situ  is  used  (Figure  1.2 
D).  Despite  WHO  guidelines  to  standardise  assessment  (Pindborg  et  al  1997), 
evaluation  of  changes  within  the  epithelium  remains  subjective  (Pindborg  et  al., 
1985)  and  poorly  reproducible  (Abbey  et  al.,  1995;  Onofre  et  al.,  1997). 
Some  studies  have  demonstrated  a  relationship  between  increased  histological 
grade  and  increased  risk  of  malignant  transformation  (Schepman  et  al.,  1998; 
van  der  Waal  et  al.,  1997)  but  others  have  failed  to  corroborate  this  (Partridge  et 14 
al.,  ;  Saito  et  al.,  2001).  The  disparity  most  likely  arises  from  a  combination  of 
the  subjectivity  of  dysplasia  assessment  and  a  lack  of  knowledge  of  the  relative 
importance  of  the  individual  histopathological  features  (Warnakulasuriya,  2001). 
Indeed,  the  morphological  changes  seen  in  a  dysplastic  epithelium  may  merely 
be  surrogate  features  that  are  additional  and  superfluous  to  the  important 
changes  occurring  in  the  genome  and  transcriptome  of  the  progressing 
precancerous  oral  lesion  i.  e.  epiphenomena  (Partridge  et  al.,  2000b).  It  is  clear 
that  although  certain  histological  features  of  dysplasia  are  associated  with  risk 
of  malignant  transformation  in  oral  leukoplakia  in  general,  there  is  a  poor 
correlation  between  the  histological  grade  of  dysplasia  (as  mild,  moderate  or 
severe)  and  the  prognosis  of  an  individual  lesion.  Such  confusion  clearly 
demonstrates  the  inadequacies  of  the  present  predictive  methodologies  for  a 
patient. 
1.9  Treatment  of  PMLs 
Despite  initial  promise,  medical  treatment  of  PMLs  with  the  aim  of  reducing  the 
malignant  transformation  rate  has  proven  disappointing.  Vitamin  A  (retinyl 
palmitate)  or  its  synthetic  retinoid  derivatives  have  been  used  for  treatment  of 
oral  leukoplakia  and  prevention  of  second  primary  cancers  (Hong  &  Doos, 
1985;  Hong  et  al.,  1986;  Koch,  1978).  Retinol/retinoids  are  known  to  play  an 
important  role  in  regulating  keratinocyte  differentiation  and  high  dose  retinoids 
can  reverse  epithelial  dysplasia  and  precipitate  resolution  of  oral  leukoplakia 
(Hong  et  al.,  1986).  However,  they  cause  significant  toxicity  and  the  beneficial 
effect  is  transient,  as  the  clinical  lesion  often  returns  after  cessation  of  treatment 
(Lodi  et  al.,  2004).  The  initial  promise  that  retinoids  might  prevent  second 
cancers  developing  (Hong  et  al.,  1986)  has  not  been  confirmed  in  recent  trials 
(van  Zandwijk  et  al.,  2000).  The  biology  of  retinoids  will  be  discussed  in  more 
detail  later. 
Based  on  promising  preclinical  data,  inhibition  of  cyclooxygenase  2  (COX2)  is 
one  of  the  novel  treatments  currently  being  actively  tested  in  various  cancer 
models.  This  includes  upper  aero-digestive  tract  turnours,  either  for  cancer 
prevention  or  treatment  (reviewed  in  Altorki  et  al.,  2004;  Dannenberg  & 
Subbaramaiah,  2003).  Antioxidants  are  another  class  of  agents  that  may  offer 
promise  for  treatment  of  oral  PMLs.  For  example,  oral  administration  of  N- 15 
acetyl-L-cysteine  reduced  the  frequency  of  DNA  adducts  and  abnormal 
micronuclei  in  oral  mucosa  in  healthy  smokers  (Van  Schooten  et  al.,  2002)  and 
oral  dysplasias  showed  a  clinical  and  histological  response  to  lycopene,  a 
naturally  occurring  carotenoid  (Singh  et  al.,  2004). 
For  many  patients,  surgery  provides  the  only  available  method  for  control  of 
their  disease,  but  multifocal  lesions  are  not  amenable  to  curative  surgical 
intervention.  Indeed,  recent  studies  have  suggested  that  surgical  removal  of 
leukoplakias  with  chromosomal  aneuploidy  may  be  futile  (Sudbo  et  al.,  2004). 
Allied  to  this,  the  failures  of  medical  treatment  and  the  uncertainty  in 
assessment  of  these  lesions  have  led  to  the  search  for  other  predictors  of 
prognosis  in  HNSCC  and  malignant  transformation  in  PIVII-s.  It  is  hoped  that 
these  markers  may  also  reveal  promising  targets  for  therapy,  both  in  malignant 
and  premalignant  disease. Ib 
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Figure  1.2  Oral  epithelial  clysplasia 
Features  assessed  after  the  method  of  Kramer  et  al  (Kramer  et  al.,  1978). 
Generally,  in  mild  dysplasia  (A)  abnormal  tissue  and  cytological  features  are 
confined  to  the  deep  third  of  the  epithelium,  moderate  (B)  to  middle  and  deep 
thirds  and  severe  dysplasia  (C)  extends  into  the  superficial  third  of  the 
epithelium.  This  can  be  modified  up  or  down  depending  on  cytological  features. 
Carcinoma  in  situ  (CIS)  (D)  refers  to  similar  features  to  severe  dysplasia 
affecting  the  whole  thickness  of  the  epithelium. 17 
Chapter  Two:  Carcinogenesis 
Over  the  past  three  decades,  much  evidence  has  accumulated  that 
carcinogenesis  is  a  multi-step  process  in  which  various  genetic  and  epigenetic 
alterations  in  normal  cells  cooperate  in  the  generation  of  highly  malignant 
derivatives.  Despite  the  complexity  of  cancer  genomes  and  the  large  number  of 
possible  cellular  pathways  to  target,  Hanahan  and  Weinberg  have  suggested 
that  alterations  in  six  basic  cellular  functions  are  required  (Hanahan  & 
Weinberg,  2000).  The  six  "hallmarks"  of  cancer  are  illustrated  in  Figure  2.1. 
These  features  involve  not  only  the  neoplastic  cell  population  per  se,  but  also 
interactions  with  the  tumour  stroma. 
Figure  2.1  The  "hallmarks"  of  cancer. 
The  Figure  shows  the  six  consistent  features  or  "hallmarks"  of  most  cancers,  as 
described  by  Hanahan  and  Weinberg.  Reproduced  from  the  review  by 
Hanahan  and  Weinberg  (Hanahan  &  Weinberg,  2000) 
The  "hallmarks"  comprise  some  of  the  most  complex  basic  cellular  control 
mechanisms  and  as  such,  there  are  multiple  points  of  intervention  that  may  lead 18 
to  similar  effects.  Conversely,  one  particular  defect  may  have  a  different  effect 
in  different  cell  types  and  the  effect  may  even  differ  within  cells  of  the  same  type 
under  different  environmental  contexts.  Thus  limiting  such  If  capabilities"  to  six  in 
number  does  not  predicate  against  multiple  pathways  which  cells  may  take  on 
their  way  to  becoming  malignant.  Thus,  certain  common  alterations  (e.  g.  p53 
mutation)  may  only  be  present  in  a  proportion  of  a  particular  cancer  type,  but 
defects  in  the  p53  pathway  may  be  more  common  (Save  et  al.,  1998). 
Similarly,  the  timing  and  the  order  in  which  these  capabilities  are  acquired  may 
vary  extensively. 
2.1  Invasion  and  metastasis 
The  defining  feature  of  malignant  disease  is  its  ability  to  escape  normal 
biological  constraints  and  invade  into  surrounding  tissues.  These  invasive  cells 
may  then  travel  to  locoregional  or  distant  sites,  either  by  direct  spread  or 
dissemination  in  the  lymphatic  or  vascular  systems.  Secondary  tumours 
(metastases)  may  then  develop.  The  process  has  been  likened  to  a  cascade 
with  barriers  to  be  overcome  at  each  stage  (Pantel  &  Brakenhoff,  2004). 
Consequently,  it  has  now  become  apparent  that  it  is  too  simplistic  to  regard 
malignant  disease  solely  in  terms  of  the  neoplastic  cell  population  (Hanahan  & 
Weinberg,  2000).  Cellular  (fibroblasts,  endothelial  and  inflammatory  cells)  and 
non-cellular  elements  (matrix  proteins)  within  the  microenvironment  play 
important  roles  in  establishing  a  suitable  environment  for  the  development  of  a 
malignant  neoplasm.  In  certain  tumour  types  such  as  the  basal  cell  carcinoma, 
development  of  the  tumour  is  very  dependent  on  the  correct  microenvironment 
as  removal  from  this  results  in  involution  of  the  tumour  (Pollack  et  al.,  1982). 
In  normal  mucosa,  the  architecture  and  function  of  the  epithelium  is  maintained 
by  a  complex  interaction  between  the  epithelial  cells  and  their 
microenvironment.  The  dynamic  interplay  with  the  extracellular  matrix  (ECM) 
controls  various  functions  within  the  epithelial  cell  such  as  differentiation, 
proliferation  and  apoptosis.  These  functions  are  vital  in  the  control  of  growth 
and  development,  healing  and  the  tissue  response  to  injury  (Streuli,  1999). 
Multiple  cellular  products  and  components  of  the  ECM,  including  adhesion 
molecules,  such  as  the  integrins,  and  the  transforming  growth  factor-beta  (TGF- 
fl)  signalling  pathway,  mediate  this  control.  Alterations  in  the  microenvironment 19 
of  a  tumour  may  result  from  similar  genetic  damage  to  that  which  precipitated 
the  neoplastic  growth  in  the  epithelial  cells  (Park  et  al.,  2000).  Alternatively, 
tumour  cells  can  induce  the  formation  of  a  "tumour  stroma"  via  the  aberrant 
secretion  of  growth  factors  or  induction  of  growth  factor  receptors  (Mueller  & 
Fusenig,  2002).  Certain  haernopoietic  growth  factors,  such  as  G-CSF  and  GM- 
CSF  in  addition  to  tumour  derived  TGF-,  8  may  be  important  in  this  regard 
(Obermueller  et  al.,  2004).  The  cellular  components  of  the  tumour  stroma  may 
then  reciprocally  influence  the  tumour  cells. 
TGF-fl  plays  a  double-edged  role  in  carcinogenesis  (Akhurst  &  Derynck,  2001). 
In  the  early  stages,  TGF-fl  acts  as  a  potent  tumour  suppressor,  as  it  inhibits 
growth  and  induces  apoptosis  (Derynck  et  al.,  2001;  Tang  et  al.,  1998).  Further 
effects  may  include  suppression  of  telomerase  activity  and  the  induction  of 
senescence  (Katakura  et  al.,  1999;  Zhao  et  al.,  2003).  However,  later  in  the 
carcinogenic  process,  this  growth  inhibitory  effect  is  lost  and  TGF-fl  acts  to 
promote  the  malignant  phenotype  (Barrack,  1997).  This  results  in  increased 
angiogenesis  and  motility,  promotion  of  epithelial-mesenchymal  transition 
(EMT)  and  escape  from  apoptosis  (Lu  et  al.,  2004;  Prime  et  al.,  2004).  The 
alteration  in  the  effect  of  TGF-,  8  has  been  related  to  defects  in  the  receptors  and 
their  signalling  pathways,  particularly  via  the  SMAD  transcription  factors 
(Maliekal  et  al.,  2003).  Defects  in  TGF-,  8  signalling  in  HNSCC  have  been 
demonstrated,  but  many  HNSCC  cell  lines  maintain  a  full  or  partial  inhibitory 
response  to  TGF-,  8  (Malliri  et  al.,  1996).  However,  even  a  partial  defect  in  TGF- 
fl  signalling  through  the  receptor  T,  8R-11,  has  been  shown  to  result  in  the 
emergence  of  the  malignant  phenotype,  with  increased  proliferation  and 
invasion  in  vitro  (Huntley  et  al.,  2004). 
Further  functions  of  TGF-,  8  may  include  the  acquisition  of  a  motile  phenotype 
that  allows  neoplastic  cells  to  disseminate  locally  and  to  distant  sites.  This  may 
be  possible  via  a  partial  epithelial-mesenchymal  transition  (EMT).  In  normal 
embryogenesis,  this  fundamental  process  governs  morphogenesis  (Shook  & 
Keller,  2003),  but  in  tumours,  it  promotes  loss  of  intercellular  adhesion  and 
induces  cell  motility  (Mueller  &  Fusenig,  2004).  The  TGF-,  8  pathway  is  one  of 
many  that  have  been  implicated  in  induction  of  EMT.  In  breast  carcinoma,  the 
transcription  factor  TWIST  is  suppressed  and  this  allows  EMT  to  occur,  due  to 
loss  of  E-cadherin  mediated  effects  (Kang  &  Massague,  2004).  Loss  of  E- 20 
cadherin  expression  by  promoter  methylation  has  been  reported  in  HNSCC 
(Chang  et  al.,  2002;  Chow  et  al.,  2001).  The  main  consequence  of  loss  of  E- 
cadherin  is  nuclear  accumulation  of  fl-catenin,  but  whilst  this  has  been 
described  in  gastric  adenocarcinoma,  there  is  no  convincing  evidence  that  this 
occurs  to  any  significant  degree  in  HNSCC  in  vivo  (Chow  et  al.,  2001; 
Patturajan  et  al.,  2002).  However,  it  is  possible  that  other  modulators  of  EMT, 
such  as  certain  receptor  tyrosine  kinases,  will  play  a  role.  However,  HNSCC 
cell  lines  showing  decreased  E-Cadherin  expression  also  have  higher  levels  of 
vimentin  and  other  markers  of  EMT  (Taki  et  al.,  2003). 
Many  turnours  show  changes  in  the  spectrum  of  cell  adhesion  molecule  (CAM) 
expression  including  alteration  in  E-Cadherin  and  various  integrins.  These 
CAMs  mediate  adhesion  to  the  ECM  and  are  involved  in  a  variety  of  functions 
such  as  motility,  proliferation  and  differentiation  via  various  intracellular 
pathways,  such  as  activation  of  focal  adhesion  kinase  (FAK)  (Akiyama,  1996). 
Numerous  studies  have  demonstrated  changes  in  the  expression,  distribution 
and  functions  of  integrins  in  tumour  cells.  Aberrant  expression  and  function 
promotes  cell  migration,  invasion  and  angiogenesis  (Brooks  et  al.,  1994)  in 
cancer  and  may  suppress  apoptosis  (Thomas  &  Speight,  2001).  Consistent 
upregulation  of  certain  integrin  subunits,  such  as  aV,  86,  in  oral  cancer  suggests 
that  this  may  play  a  more  active  role  in  oral  carcinogenesis  (Thomas  et  al., 
2001  a;  Thomas  et  al.,  2001  b). 
Alterations  in  stromal  remodelling  can  also  contribute  to  the  tumour-stroma 
interaction  and  may  modulate  the  activity  of  the  neoplastic  cell  population. 
Many  enzymes,  including  the  matrix  metal  loprotei  nases  (MMPs),  remodel  the 
extracellular  matrix.  This  family  of  zinc-dependent  endopeptidases  plays  a 
crucial  role  in  ECM  turnover,  but  alterations  in  the  expression  of  various  MMPs 
and/or  their  inhibitors  have  been  reported  in  many  cancers.  The  levels  of 
various  MMPs  may  be  increased  by  many  signals  including  TGF-,  B,  epithelial 
growth  factor  receptor  (EGFR)  and  Vascular  Endothelial  Growth  Factor  (VEGF) 
(Hiratsuka  et  al.,  2002;  O-Charoenrat  et  al.,  2000b;  Rougier  et  al.,  1997). 
MMPs  promote  carcinogenesis  by  multiple  mechanisms,  including  cell  growth, 
migration  and  angiogenesis  (Pepper,  2001),  due  not  solely  to  ECM  turnover,  but 
also  to  the  release  of  matrix-bound  growth  factors  (Belotti  et  al.,  2003)  and 
interaction  with  various  classes  of  cell  adhesion  molecules  (Coussens  et  al., 21 
2002).  Alterations  in  many  MMP  family  members  and  some  of  their  inhibitors 
have  been  found  in  HNSCC  including  MMP2,  MMP9  and  TIMP2  (Katayama  et 
al.,  2004;  O-Charoenrat  et  al.,  2001;  Ruokolainen  et  al.,  2004).  High  levels  of 
MMP9  in  HNSCCs  has  been  correlated  with  advanced  T  stage,  an  infiltrative 
pattern  of  growth  and  poor  prognosis  (0-Charoenrat  et  al.,  2001;  Ruokolainen 
et  al.,  2004).  However,  this  has  not  been  reproduced  in  vitro,  perhaps  due  to 
difficulties  in  fully  reconstituting  the  ECM  in  tissue  culture  (Robinson  et  al., 
2003). 
Analysis  of  tumour  cell  motility  by  a  combination  of  methods  has  led  to  the 
conclusion  that  there  are  many  different  mechanisms  of  tumour  cell  motility. 
(Friedl  &  Wolf,  2003;  Sahai,  2005)  The  two  main  types,  with  subgroups,  are 
illustrated  in  Figure  2.2.  Collective  type  motility  involves  the  movement  of 
clusters  of  cells  and  is  dependent  on  the  production  of  MMPs  at  the  invasive 
front  to  clear  a  path  for  the  tumour  to  move  (Nabeshima  et  al.,  2002).  This 
method,  although  common  in  epithelial  malignancy,  is  poorly  understood,  as  it  is 
difficult  to  model  in  vitro.  There  are  also  two  types  of  individual  motility. 
Mesenchymal  motility  is  related  to  EMT,  and  requires  the  production  of  MMPs 
to  degrade  the  ECM  (reviewed  in  Friedl  &  Wolf,  2003).  On  the  other  hand, 
amoeboid  movement,  which  is  characteristically  seen  in  haematological 
malignancy,  demonstrates  no  such  requirement,  nor  an  EMT.  It  is  very  similar 
to  the  rounded  Rho-  and  Rock-dependent  form  of  motility  that  has  been 
described  (Sahai  &  Marshall,  2003).  This  allows  the  cell  to  squeeze  through  the 
ECM,  rather  than  degrading  it.  It  also  is  likely  that  cells  are  able  to  switch  their 
mechanism  of  motility  in  response  to  different  environments  (Wolf  et  al.,  2003). 22 
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The  figure  illustrates  the  present  understanding  of  the  different  mechanisms  of 
invasion  of  cancer  cells  and  their  varying  dependence  on  different  molecular 
programmes  (triangles).  From  individual  (top)  to  collective  (bottom)  movements 
integrins  and  proteases  play  an  increasing  role  in  cell-ECM  interaction.  The 
most  common  pattern  of  invasion  in  epithelial  cancers  is  collective  movement 
as  clusters.  Reproduced  from  (Friedl  &  Wolf,  2003). 23 
2.2  Angiogenesis 
Tumour  angiogenesis  is  another  vital  component  of  lisuccessful"  malignant 
neoplasia.  The  ability  to  stimulate  the  development  of  new  blood  vessel  growth 
allows  a  tumour  to  continue  to  grow  without  the  potential  hindrance  of  hypoxia 
and  consequent  ischaemic  necrosis.  Growth  factors  such  as  Vascular 
Endothelial  Growth  Factor  (VEGF)  and  various  Fibroblast  Growth  Factors 
(FGFs)  may  initiate  the  development  of  tumour  vasculature  (Compagni  et  al., 
2000;  Giavazzi  et  al.,  2003).  The  increase  in  activity  may  be  due  to  increased 
production  of  such  factors  by  the  tumour  cells  under  stimulation  by  the  EGFR 
family  (0-Charoenrat  et  al.,  2000c),  but  alternatively  may  be  due  to  release  of 
stores  of  ECM-bound  growth  factors  by  increased  ECM  turnover  (Whitelock  et 
al.,  1996).  Increased  numbers  of  particular  VEGF  receptor  subtypes  have  been 
associated  with  the  initiation  of  malignant  disease  (reviewed  in  Mueller  & 
Fusenig,  2002)  and  VEGF  overexpression  is  associated  with  poor  overall 
prognosis  (Uehara  et  al.,  2004).  Various  integrin  subunit  complexes  and  MMPs 
are  also  pro-angiogenic  (Brooks  et  al.,  1994;  Pepper,  2001). 
Assessment  of  angiogenesis  in  tumours  is  difficult,  but  microvascular  density 
has  often  been  used  as  a  surrogate  marker.  This  is  dependent  on  the 
immunohistochemical  identification  of  endothelial  lined  channels,  but  some 
turnours,  including  HNSCC  may  construct  a  pseudo-vasculature  using  tumour- 
lined  channels  for  blood  supply  (Folberg  &  Maniotis,  2004;  Shieh  et  al.,  2004). 
In  HNSCC  carcinogenesis,  some  groups  have  demonstrated  that  the  vascularity 
of  oral  tissues  increased  with  disease  progression  from  normal  mucosa  to 
through  the  grades  of  dysplasia  to  carcinoma  (Macluskey  et  al.,  2000;  Pazouki 
et  al.,  1997),  whilst  others  have  found  no  such  increase  (Tae  et  al.,  2000).  An 
increase  in  VEGF  has  been  noted  in  HNSCC  and  this  is  related  to  EGFR 
overexpression  (0-charoenrat  et  al.,  2002).  In  particular,  increases  in  VEGF-A 
and  VEGF-C  have  been  correlated  with  the  presence  of  lymph  node 
metastases  (Shintani  et  al.,  2004). 24 
2.3  Self  sufficiency  in  growth  signals 
Normal  cells  require  mitogenic  stimuli  to  initiate  and  sustain  proliferation.  Many 
of  these  signals  are  mediated  by  autocrine  or  paracrine  signals  that  are  relayed 
to  the  nucleus  from  the  cell  surface  by  various  classes  of  transmembrane 
receptor.  Alterations  in  several  of  these  critical  pathways  were  originally 
identified  as  a  consequence  of  research  into  oncogenic  viruses  (Harvey,  1964). 
Such  viruses  have  sequences  in  their  genome  that  are  similar  to  genes  found  in 
normal  human  cells.  These  sequences  were  aberrantly  expressed  subsequent 
to  integration  into  the  host  genome.  These  genes,  termed  oncogenes,  have 
subsequently  been  shown  to  belong  to  several  functional  groups  of  genes, 
many  of  which  are  involved  in  the  transmission  of  mitogenic  stimuli  from  the  cell 
surface  to  the  nucleus. 
2.3.1  Growth  factors  and  their  receptors 
Many  of  the  alterations  in  oncogenes  involve  growth  factors  and  their  receptors. 
Tumours  may  produce  their  own  growth  factors  to  act  in  an  autocrine/paracrine 
manner  on  the  tumour  cell  population  (e.  g.  FGF-1,  Myoken  et  al.,  1994).  This 
obviates  the  normal  control  exercised  by  the  microenvironment. 
Overexpression  of  growth  factor  receptors  will  also  increase  the  intensity  of  the 
signal.  One  example  is  overexpression  of  the  epidermal  growth  factor  receptor 
(EGFR),  a  member  of  the  EGFR/c-erbB  family  of  growth  factor  receptors.  This 
family  of  receptors  binds  six  major  ligands,  namely,  epidermal  growth  factor 
(EGF),  transforming  growth  factor-alpha  (TGF-a),  betacellulin,  heparin-binding 
epidermal  growth  factor-like  growth  factor  (HB-EGF),  amphiregulin  and 
heregulin  (O-Charoenrat  et  al.,  2000a;  Prigent  &  Lemoine,  1992).  Ligand 
binding  promotes  dimerisation  of  receptor  subunits  and  activation  of  the  intrinsic 
tyrosine  kinase  activity  of  the  cytoplasmic  domain  of  the  receptor.  The  signal  is 
then  propagated  to  the  nucleus  via  a  cascade  of  intracellular  kinases.  These 
include  the  Stat  family  of  signal  transducers,  which  may  also  show  altered 
expression  in  tumours  (Grandis  et  al.,  1998b). 
EGF  is  required  for  proliferation  of  oral  keratinocytes  in  culture,  which  illustrates 
the  dependence  of  these  cells  upon  this  signalling  pathway.  Thus,  it  is  not 
surprising  that  alterations  of  EGF  signalling  are  seen  in  many  epithelial  cancers 25 
(Cheng  et  al.,  2002;  Cowley  et  al.,  1986;  Hendler  &  Ozanne,  1984;  Ito  et  al., 
2001;  Perry  et  al.,  1998).  Overexpression  of  EGFR  may  allow  the  neoplastic 
keratinocytes  to  respond  inappropriately  to  low  levels  of  ligand  in  the 
extracellular  environment.  EGFR  upregulation  has  been  demonstrated  in  many 
cancers  including  HNSCC  (Ozanne  et  al.,  1986),  although  it  does  not  seem  to 
be  a  ubiquitous  alteration.  Inhibition  of  EGFR  or  TGF-a  expression  using 
antisense  oligonucleotides  leads  to  a  decrease  in  the  proliferation  of  HNSCC 
cells  lines,  with  limited  effects  on  normal  cells  in  culture  (Grandis  et  al.,  1998a; 
Rubin  Grandis  et  al.,  1997). 
However,  Stanton  and  co-workers  noted  that  the  relative  overexpression  of 
EGFR  was  higher  in  primary  HNSCC  cell  cultures  than  in  their  matched  tumour 
samples  (Stanton  et  al.,  1994).  Indeed,  the  expression  of  EGFR  in  the  turnours; 
was  higher  than  normal  tissue  in  only  two  of  ten  samples.  Whilst  this  suggests 
that  there  is  potential  for  EGFR  overexpression  in  at  least  a  subset  of  cells 
within  most  HNSCC  lesions,  it  does  not  explain  why  some  tumours  over- 
express  EGFR  and  others  do  not.  The  same  work  also  suggested  that 
overexpression  of  EGFR  is  a  late  event  in  HNSCC  carcinogenesis,  since  cells 
derived  from  two  premalignant  lesions  that  progressed  to  SCC  over  a  short 
period  did  not  have  high  levels  of  EGFR  expression  (Stanton  et  al.,  1994).  The 
small  number  of  premalignant  lesions  analysed  may  be  a  limiting  factor  in  this 
conclusion,  as  much  larger  studies  have  concluded  that  EGFR  is  upregulated  in 
dysplastic  oral  tissues  (Shin  et  al.,  1994b).  Even  in  these  studies,  the  EGFR 
upregulation  demonstrated  in  dysplastic  lesions  is  somewhat  modest  (in  some 
cases  2  fold,  assessed  by  immunohistochemistry),  compared  to  the  much  larger 
increase  in  EGFR  expression  which  occurs  in  HNSCC  (Shin  et  al.,  1994b). 
Alterations  in  the  other  family  members  (c-erbB2,  c-erbB3  and  c-erbB4)  have 
also  been  reported,  but  their  role  in  HNSCC  carcinogenesis  is  less  clear  (0- 
Charoenrat  et  al.,  2002). 
Nevertheless,  clinicopathological  studies  found  that  high  levels  of  EGFR  and 
TGF-a  in  HNSCC  were  a  statistically  significant  predictor  of  recurrent  disease 
and  poor  overall  survival  (Grandis  et  al.,  1998c).  Similar  data  in  other  epithelial 
malignancies  has  lead  to  the  development  of  novel  anti-EGFR  therapies  for  use 
in  many  cancers,  including  HNSCC.  Initial  preclinical  and  phase  1/11  trials 
appeared  promising  (Bonner  et  al.,  2002),  but  the  results  of  recent  larger  trials 26 
of  EGFR  inhibition  with  chemotherapy  and  radiotherapy  have  shown  limited 
improvements  in  disease  free  survival,  with  only  a  minority  of  patients 
responding  (reviewed  in  Raben  et  al.,  2004). 
2.3.2  Signal  transduction 
Components  of  various  intracellular  signal  transduction  pathways  have  also 
been  implicated  as  oncogenes.  Such  signalling  networks  include  the  Ras-Raf- 
MAPKinase  pathway,  which  is  downstream  of  many  growth  factor  receptors. 
The  Ras  proteins  were  amongst  the  first  to  be  assigned  a  function  related  to  cell 
growth  and  proliferation  (Yuspa  et  al.,  1983).  This  family  of  proteins  controls 
the  activity  of  several  key  signalling  pathways.  Three  members  of  the  family 
HRAS,  KRAS  and  NRAS  are  mutated  in  20%  of  human  tumours  (Bos,  1989). 
Point  mutations  in  RAS  lead  to  constitutive  activation  by  compromising  the 
GTPase  activity  of  RAS,  leading  to  accumulation  of  RAS  in  an  active  form 
(Tabin  et  al.,  1982).  This  increases  the  signalling  traffic  in  several  pathways, 
resulting  in  loss  of  control  over  cell  growth  and  an  increase  in  invasiveness  and 
angiogenesis  (reviewed  by  (Shields  et  al.,  2000). 
The  reported  frequency  of  RAS  alterations  in  HNSCC  varies  in  the  literature 
(reviewed  in  Downward,  2003).  Several  studies  have  documented  a  very  low 
frequency  of  RAS  mutation  in  HNSCC  in  the  UK,  despite  the  high  proportion  of 
tobacco  smokers  (Chang  et  al.,  1991;  Yarbrough  et  al.,  1994;  Yeudall  et  al., 
1993).  A  similar  pattern  has  been  found  in  premalignant  lesions  (Matsuda  et  al., 
1996).  However,  in  populations  where  tobacco  is  chewed,  or  used  in 
association  with  betel  quid  (pan),  the  prevalence  of  activating  RAS  point 
mutations  may  be  as  high  as  35%  (Chang  et  al.,  1991).  Alterations  in  targets 
downstream  of  RAS,  such  as  BRAF,  are  also  rare  in  HNSCC  (Weber  et  al., 
2003). 
2.3.3  Targets  in  the  cell  cycle 
The  cell  cycle  comprises  a  highly  regulated  series  of  steps  that  result  in  the 
duplication  of  the  cellular  DNA  and  subsequent  cytokinesis  (Figure  2.3).  The 
machinery  of  the  cell  cycle  is  thus  intimately  involved  in  the  control  of  cell 
proliferation.  The  regulatory  elements  of  the  cell  cycle  includes  Cyclins,  Cyclin 27 
dependent  kinases  (CDKs)  and  various  negative  regulators,  including  inhibitors 
of  Cyclin/CDK  complexes. 
One  of  the  ultimate  targets  of  the  mitogenic  cell-surface  signals  is  Cyclin  D1 
(Loyer  et  al.,  1996;  Quelle  et  al.,  1993).  This  is  a  member  of  the  family  of  D- 
type  Cyclins  and  is  involved  in  control  of  the  transition  from  G1  to  S  phase  of 
the  cell  cycle  (Figure  2.4).  Upon  induction  by  mitogeneic  stimuli,  Cyclin  D1 
expression  increases  forming  transient  functional  complexes  with  cdk4  and 
cdk6.  Interaction  of  this  complex  with  retinoblastoma  protein  (Rb)  results  in  Rb 
phosphorylation  (Kato  et  al.,  1993).  This  removes  the  inhibitory  effect  of  Rb  on 
certain  transcription  factors,  such  as  E2F,  which  allows  transcription  of  proteins 
required  for  G1/S  phase  transition  (Figure  2.4). 
Investigations  in  many  different  cancers,  including  breast  carcinomas, 
lymphomas  and  SCCs  have  demonstrated  frequent  amplification  of 
chromosome  locus  11q13  (Schuuring,  1995).  This  locus  contains  several 
putative  oncogenes,  including  Cyclin  D1,  also  known  as  PRAD1  (Motokura  et 
al.,  1991).  Loss  of  control  of  Cyclin  D1  expression  may  be  attained  by 
chromosomal  translocation,  DNA  amplification,  abrogation  of  controls  in 
mitogenic  signalling  pathways  and  retroviral  integration.  The  resulting 
overexpression  accelerates  passage  of  the  cell  through  G1  phase  and  reduces 
the  requirement  for  mitogens  (Quelle  et  al.,  1993). 
A  number  of  workers  have  demonstrated  that  Cyclin  D1  overexpression  is  a  late 
change  in  HNSCC  carcinogenesis  (Schoelch  et  al.,  1999)  and  have  related 
such  overexpression  to  poor  prognosis  (Bova  et  al.,  1999).  The  proportion  of 
patients  with  Cyclin  D1  overexpression  varies  greatly,  particularly  in  those 
studies  based  on  immunohistochernistry  (Lam  et  al.,  2000).  The  subjectivity  in 
assessment  of  Cyclin  D1  by  lHC  may  account  in  part  for  the  great  variation  in 
proportion  of  tumours  and  subsequent  conclusions.  Detection  of  Cyclin  D1 
amplification  may  be  a  more  sensitive  measure  of  deregulation  of  Cyclin  D1 
expression,  but  it  does  not  account  for  all  possible  routes  by  which  deregulation 
may  be  achieved.  Amplification  has  been  described  in  30-50%  of  primary 
tumours,  but  in  virtually  all  HNSCC  cell  lines  (Callender  et  al.,  1994;  Jares  et  al., 
1994;  Okami  et  al.,  1999;  Rousseau  et  al.,  2001;  Sartor  et  al.,  1999).  The 
presence  of  amplification  of  Cyclin  D1  has  been  related  to  aneuploidy,  which 28 
has  also  been  related  to  poor  prognosis  (Callender  et  al.,  1994;  Nimeus  et  al., 
2004).  However,  work  in  our  own  group  did  not  identify  any  consistent 
overexpression  of  Cyclin  D1  expression  in  cell  cultures  from  dysplastic  lesions 
or  HNSCC  (McGregor  et  al.,  2002).  Thus,  whilst  it  seems  likely  that 
deregulation  of  Cyclin  D1  does  play  a  role  in  the  development  of  at  least  subset 
of  HNSCC  there  are  other  points  in  the  machinery  controlling  G1/S  transition 
that  may  also  be  altered  in  the  process  of  carcinogenesis. 29 
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Figure  2.3  The  cell  cycle 
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Illustration  of  the  phases  of  the  cell  cycle  and  its  regulators.  The  major  Cyclins, 
Cyclin  dependent  kinases  and  cdk  inhibitors  are  shown  (see  text  for 
discussion). 
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G1  =  gap  phase  1;  S=  DNA  synthesis  phase;  G2  =  gap  phase  2;  M=  mitosis. 
Adapted  from  Goodger,  1997  (Goodger  et  al.,  1997). 
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Figure  2.4  Control  of  GI  to  S  phase  transition  by  the  retinoblastorna 
protein  pathway 
Phosphorylation  of  Rb  is  accomplished  by  the  CyclinD1/cdk4/6  complex.  This 
complex  is  under  the  control  of  p16,  and  to  a  lesser  extent,  p2l.  p2l  also  acts 
on  genes  expressed  in  S-phase,  together  with  p27,  to  inhibit  the  progress  of  S- 
phase 
( 
p27 
KIN 
restriction  point  P=phosphorylation 
1  phase  S  phase 31 
2.4  Insensitivity  to  anti  growth  signals 
The  abrogation  of  inhibitors  of  the  cell  cycle  may  also  contribute  to  the  loss  of 
tight  control  of  cycle  progression.  Other  possible  targets,  which  may  render 
Cyclin  D1  overexpression  redundant,  include  alterations  in  Rb  itself,  or  in 
p16  INK4a 
,  an  inhibitor  of  the  Cyclin  D1/CDK4/6  complex. 
2.4.1  Retinoblastoma  protein 
In  its  hypophosphorylated  form,  Rb  acts  to  block  G1/S  transition.  It  may  also  be 
involved  in  the  promotion  of  terminal  differentiation  and  permanent  exit  from  the 
cell  cycle  (Adams,  2001).  Rb  also  regulates  the  expression  of  p16  INK4a  via  a 
negative  feedback  loop  (Li  et  al.,  1994).  Inactivation  of  Rb,  by  point  mutation  or 
by  interaction  with  HPV  protein  E7,  deregulates  the  G1/S  transition  and  allows 
the  cell  a  selective  growth  advantage.  In  HNSCC,  Rb  mutation  appears  to  be  a 
rare  event  (Ambrosch  et  al.,  2001).  Alterations  in  Rb  expression  have  been 
reported  in  some  cancers,  including  non-small  cell  lung  cancer  (Jin  et  al.,  2001), 
oesophageal  SCC  (Xing  et  al,  1999),  and  to  a  variable  extent  in  HNSCC 
(Ambrosch  et  al.,  2001;  Pande  et  al.,  1998;  Schoelch  et  al.,  1999).  When 
alteration  in  Rb  expression  occurs,  this  may  be  early  in  the  carcinogenic 
process  (Pande  et  al.,  1998). 
2.4.2  Cyclin  dependent  kinase  inhibitors 
It  is  more  common  for  the  alteration  within  the  Rb  pathway  to  involve  inhibitors 
of  the  Cyclin/CDK  complexes,  such  as  p16  INK4a  (hereafter  referred  to  as  p16)  or 
p27  KIP1  (hereafter  referred  to  as  p27).  Inhibitors  of  the  cell  cycle  belong  to  two 
main  families  -  the  ink4  family  which  includes  p14,  p15,  p16  and  p18  or  the 
Cip/Kip  family,  which  includes  p2l,  p27  and  p57. 
2.4.2.1  The  INK4  family  of  Cyclin  dependent  kinase  inhibitors 
The  INK4  proteins  are  products  of  the  complex  INK4a  locus  on  chromosome 
9p2l.  p16  transcripts  include  exons  la,  2  and  3  whilst  an  alternate  reading 
frame  (ARF)  uses  exon1fl,  which  is  located  upstream  from  exon  la  (Quelle  et 
al.,  1995).  This  comprises  the  first  exon  of  p14ARF,  with  exons  2  and  3  the 32 
same  as  p16.  These  alternative  products  have  separate  promoters  and  perform 
very  different  actions  within  the  cell. 
2.4.2.2  pl  6 
p16  was  initially  identified  in  co-immunoprecipitation  experiments  with  CDK4 
(Xiong  et  al.,  1993).  Subsequent  investigation  has  demonstrated  it  to  be  a 
specific  inhibitor  of  the  Cyclin  D  kinases,  CDK4  and  CDK6  (Serrano  et  al.,  1993) 
and  to  be  able  to  destabilise  cdk4/Cyclin  D1  complexes  in  vitro  (Sandhu  et  al., 
2000).  Thus,  Rb  phosphorylation  is  inhibited  and  the  G1/S  transition  of  the  cell 
cycle  does  not  proceed.  Regulation  of  p16  expression  is  primarily  at  the 
transcriptional  level  and  increased  p16  levels  have  been  related  to  a  number  of 
stimuli  including  replicative  senescence  (discussed  later),  oncogenic  RAS 
(Serrano  et  al.,  1997)  and  inactivation  of  Rb,  presumably  due  to  the  loss  of 
negative  feedback  (Parry  et  al.,  1995). 
Alterations  in  p16  were  initially  described  in  many  cancer  cell  lines,  including 
those  derived  from  bladder,  lung,  pancreas  and  head  and  neck  cancer  (Cairns 
et  al.,  1995;  Liu  et  al.,  1995).  Abnormalities  reported  include  homozygous 
deletion  (often  of  small  segments)  or  point  mutation.  The  linkage  with  cancer 
was  further  strengthened  by  the  identification  of  germline  mutations  of  p16  in 
patients  with  a  familial  form  of  malignant  melanoma  (Ranade  et  al.,  1995). 
Epigenetic  silencing  of  p16  expression  by  promoter  methylation  has  been 
identified  as  another  method  of  transcriptional  loss  (Merlo  et  al.,  1995).  In  cell 
lines  demonstrating  this  phenomenon,  re-establishment  of  p16  expression  was 
possible  by  treatment  with  a  demethylating  agent,  such  as  5-aza-2- 
deoxycytidine  (McGregor  et  al.,  2002;  Merlo  et  al.,  1995). 
In  HNSCC,  the  predominant  mechanisms  of  p16  inactivation  are  homozygous 
deletion  and  promoter  methylation.  The  prevalence  of  p16  mutations  is  low 
(Jefferies  et  al.,  2001;  Tsai  et  al.,  2001).  Promoter  methylation  may  be 
concurrent  with  homozygous  deletion  indicating  that  initial  epigenetic 
inactivation  may  be  made  permanent  by  subsequent  deletion  (Shintani  et  al., 
2001).  From  many  different  studies,  it  has  been  estimated  that  around  60-80% 
of  all  primary  HNSCCs  have  either  a  genetic  or  epigenetic  alteration  in  p16 
(Reed  et  al.,  1996;  Shintani  et  al.,  2001).  There  is  however,  much  variation  as 
studies  based  solely  on  immunohistochemical  detection  of  p16  expression  have 33 
found  a  lower  prevalence  of  alteration  (Tsai  et  al.,  2001).  Discrepancies  in  the 
frequency  of  deletions  and  mutations  detected  in  primary  tumours  when 
compared  to  cell  lines  has  also  been  reported  (Sartor  et  al.,  1999;  Zhang  et  al., 
1994).  These  studies  concluded  that  the  difference  in  p16  alterations  might  be 
the  result  of  adaptation  to  tissue  culture.  However,  the  presence  of  normal  cells 
within  the  mixed  tumour  samples,  which  may  have  masked  small  deletions,  was 
not  investigated  in  either  study. 
Loss  of  p16  expression  in  various  SCCs  has  been  linked  with  poor  prognosis. 
For  example,  p16-negative  lung  SCC  patients  having  a  significantly  lower  five 
year  survival  than  those  with  p16-positive  turnours  (Huang  et  al.,  2000;  Jin  et 
al.,  2001).  In  HNSCC,  loss  of  p16  has  been  related  to  a  poorer  prognosis  in 
patients  with  SCC  of  anterior  tongue  (Bova  et  al.,  1999).  Yuen  and  coworkers 
found  a  link  with  more  locally  advanced  disease,  but  not  with  overall  survival 
(Yuen  et  al.,  2002),  a  finding  confirmed  by  other  studies  (Geisler  et  al.,  2002; 
Ogi  et  al.,  2002). 
Many  clinical  studies  have  also  found  p16  alterations  in  dysplastic  oral 
epithelium  (Ambrosch  et  al.,  2001;  Papadimitrakopoulou  et  al.,  1997; 
Shahnavaz  et  al.,  2001).  Papadimitrakopoulou  and  coworkers  described  loss  of 
p16  protein  expression  in  38%  of  oral  leukoplakias  and  a  good  correlation  was 
found  with  LOH  at  9p2l  (Papadimitrakopoulou  et  al.,  2001).  This  work,  along 
with  similar  studies  in  Barrett's  oesophagus,  indicates  that  alterations  in  p16  are 
common,  early  abnormalities  in  SCC  (Wong  et  al.,  2001).  Interestingly, 
hype  rmethylatio  n  has  been  reported  as  the  predominant  mechanism  of  loss  of 
pl  6  expression  in  severely  dysplastic  lesions,  especially  in  lesions  of  the  floor  of 
the  mouth  (Kresty  et  al.,  2002).  In  terms  of  assessment  of  the  risk  of  malignant 
transformation,  loss  of  p16  expression  appears  to  have  predictive  value  only  in 
combination  with  other  markers,  such  as  p53  overexpression  (Gallo  et  al., 
1997). 
Work  previously  conducted  in  the  Beatson  Institute  for  Cancer  Research  has 
focused  on  p16  alterations  in  HNSCC  and  oral  dysplastic  lesions  in  vitro.  Loss 
of  p16  expression  was  found  in  all  19  immortal  carcinoma  and  six  of  seven 
immortal  dysplasia  cultures,  but  only  in  one  of  six  mortal  carcinoma  and  one  of 
eight  mortal  dysplasia  cultures  (Loughran  et  al.,  1996;  McGregor  et  al.,  2002; 34 
McGregor  et  al.,  1997).  In  the  carcinoma  cultures,  p16  was  inactivated  by 
homozygous  deletion  in  8  of  18  cultures  and  by  transcriptional  silencing  in  the 
remaining  10  (Loughran  et  al.,  1996).  In  two  of  these  cell  lines,  p16  transcripts 
were  readily  detectable  after  treatment  with  demethylating  agents.  In  addition 
to  this,  we  have  previously  demonstrated  p1  6  re-expression  after  treatment  with 
5-aza-2-  deoxycytidine  in  2  of  5  immortal  dysplasia  cultures,  but  in  none  of  the 
immortal  carcinomas  (McGregor  et  al.,  2002).  These  results  confirm  the 
importance  of  homozygous  deletion  and  DNA  methylation  as  mechanisms  of 
p16  inactivation,  consistent  with  that  described  elsewhere  in  the  literature. 
Additionally,  they  suggest  a  relationship  between  p16,  replicative senescence 
and  the  acquisition  of  immortality,  rather  than  with  the  malignant  phenotype  per 
se.  This  issue  will  be  discussed  in  detail  later. 
2.4.2.3  pl4ARF 
p14  has  a  role  in  the  p53  signalling  pathway,  as  it  binds  to  MDM2,  targeting  it 
for  degradation  (Zhang  et  al.,  1998b).  This  results  in  blockage  of  MDM2- 
mediated  p53  degradation  and  stabilisation  of  p53  (see  later).  The 
consequence  of  this  is  p53  dependent  cell  cycle  arrest  or  apoptosis.  p14ARF 
has  also  been  implicated  in  non-p53  mediated  events,  such  as  an  ability  to 
inhibit  rRNA  processing  and  other  effects  on  gene  expression  (Ayrault  et  al., 
2004).  Expression  of  p14ARF  is  under  the  control  of  E2F  (Dimri  et  al.,  2000), 
thus  the  Rb  and  p53  pathways  are  linked  (Bates  et  al.,  1998;  Robertson  & 
Jones,  1998).  Increased  expression  of  ARF  has  also  been  related  to  sustained 
oncogenic  signals,  such  as  those  resulting  from  Myc  overexpression  or  Ras 
mutation  (Zindy  et  al.,  1998).  Such  effects  may  be  unrelated  to  p53  function. 
Loss  of  p19ARF  (the  mouse  homologue  of  human  p14ARF)  expression  has 
been  shown  to  predispose  to  cancer  early  in  life  (Kamijo  et  al.,  1997).  However, 
despite  this  and  the  high  frequency  of  alterations  reported  in  the  INK4  locus, 
specific  p14ARF  abnormalities  have  been  found  with  much  less  regularity  than 
those  in  p16.  As  all  of  the  cell  cycle  inhibitory  functions  of  p14ARF  are 
contained  within  the  sequence  of  the  unique  1fl  exon,  the  significance  of 
mutations  in  exon  2,  which  is  shared  with  p16,  is  disputed  (Quelle  et  al.,  1997). 
The  frequency  of  either  mutations  in,  or  deletion  of,  exon  1fl  in  oral 
carcinogenesis  has  been  reported  to  be  very  low  (Kresty  et  al.,  2002;  Munro  et 35 
al.,  1999;  Shahnavaz  et  al.,  2001).  However,  epigenetic  abnormalities  in  the 
p14ARF  promoter  have  been  reported  in  oesophageal  cancer  (Smeds  et  al., 
2002)  and  oral  SCC  (Shintani  et  al.,  2001).  Interestingly,  the  study  by  Smeds 
and  coworkers  found  no  relation  between  p14ARF  promoter  methylation  with 
p53  status,  indicating  that  the  non-p53  mediated  effects  of  p14ARF  may  be  of 
greater  importance  (Smeds  et  al.,  2002).  Despite  this,  at  present,  there  is  no 
convincing  evidence  that  abnormalities  in  p14ARF  play  an  important  role  in  the 
development  of  oral  cancer. 
2.4.3  The  cip/kip  family  of  Cyclin  dependent  kinase  inhibitors 
This  family  of  CDKNs  includes  p27,  p2l  WAF1  and  p57.  These  inhibit  a  wider 
spectrum  of  Cyclin/CDK  complexes  including  Cyclin  E/cdk2,  Cyclin  A/cdk2  and 
Cyclin  D/cdk4.  This  results  in  cell  cycle  arrest  by  intervention  at  various  points 
in  the  cell  cycle  (see  Figure  2.3). 
2.4.3.1  p27 
KIPI 
The  cellular  level  of  p27  is  responsive  to  a  wide  variety  of  growth  inhibitory  and 
stimulatory  signals,  including  TGF-fl  and  growth  factors  (Polyak  et  al.,  1994).  In 
various  cell  types,  including  fibroblasts,  epithelial  cells  and  T  lymphocytes, 
downregulation  of  p27  in  response  to  mitogenic  stimulation  allows  the  cell  to 
progress  from  a  quiescent  to  a  dividing  state  (Eblen  et  al.,  1995;  Malek  et  al., 
2001).  The  main  regulation  of  p27  expression  is  post-transcriptional,  as 
mitogen-stimulated  cells  degrade  p27  in  an  ubiquitin-dependent  manner  via  the 
proteosome  (Kawada  et  al.,  1997).  This  complex  regulation  of  quiescent  and 
dividing  cells  demonstrates  the  importance  of  p27  in  cell  differentiation  and 
development  (Zhang  et  al.,  1998a),  but  functions  in  the  control  of  cellular 
senescence  (Munro  et  al.,  2001),  susceptibility  to  apoptosis  and  cell  adhesion 
have  also  been  demonstrated  (reviewed  in  Sgambato  et  al.,  2000). 
Many  cancer  studies  have  demonstrated  poor  prognosis  related  to  loss  of  p27 
expression  (summarised  in  Slingerland  &  Pagano,  2000).  The  mechanism  of 
such  an  effect  is  probably  enhanced  degradation  of  p27,  although  other 
mechanisms,  such  as  sequestration  by  Cyclins  D1  and  D2  cannot  be 
discounted  (Bouchard  et  al.,  1999).  In  HNSCC,  low  p27  expression  in  tongue 
tumours  is  associated  with  an  increased  risk  of  lymph  node  metastases  and 36 
poor  overall  survival  (Mineta  et  al.,  1999).  This  loss  of  p27  immunoreactivity 
has  also  been  demonstrated  in  clysplastic  oral  lesions  (Jordan  et  al.,  1998). 
2.4.3.2  p2l  wm' 
Inhibition  of  several  Cyclin/CDK  complexes  by  p2l  WAR  (p2l)  results  in  cell  cycle 
arrest.  p2l  is  one  of  the  main  downstream  effectors  of  p53  mediated  cell  cycle 
arrest  in  either  G1  or  G2  (Waldman  et  al.,  1995).  p2l  also  binds  to  PCNA, 
which  may  interrupt  DNA  replication  (McCormick  &  Hall,  1992). 
Loss  of  expression  or  mutation  of  p2l  are  infrequent  in  HNSCC  (Ibrahim  et  al., 
2003).  Indeed,  Van  Oijen  and  co-workers  found  increased  p2l  expression  in 
HNSCC  and  dysplastic  tissue  and  this  can  occur  in  HNSCCs  with  no  functional 
p53  (van  Oijen  et  al.,  1998).  Others  have  substantiated  this,  by  showing  that 
p53  mutation  did  not  necessarily  lead  to  deregulation  of  downstream  targets 
such  as  p2l,  Bax  and  BcI-2,  (Lavieille  et  al.,  1998  2272).  Thus,  p53 
independent  functions  of  p2l  may  be  advantageous  to  the  neoplastic  cell, 
including  resistance  to  apoptosis  (Javelaud  &  Besancon,  2002;  Wang  &  Walsh, 
1996).  In  dysplastic  oral  lesions,  p2l  was  increased  in  60%  of  samples,  the 
intensity  and  amount  of  parabasal  staining  increasing  with  a  more  advanced 
histological  grade  (van  Oijen  et  al.,  1998).  However,  others  have  found  no 
differences  in  p2l  level  when  comparing  lesions  which  progressed  to  SCC  and 
those  which  did  not  (Hogmo  et  al.,  1998).  These  conflicting  findings  indicate 
that  loss  of  p2l  is  not  useful  as  a  marker  of  progression  in  HNSCC. 
2.4.4  p53 
The  ability  of  the  cell  to  delay  DNA  synthesis  and  mitosis  in  order  to  allow  repair 
of  DNA  damage  due  to  various  injurious  stimuli  is  an  important  mechanism  in 
the  protection  of  the  integrity  of  the  cell  and  its  genome.  Signals  arising  from 
DNA  damage,  mitotic  spindle  damage,  hypoxia,  nucleotide  deprivation  and 
oncogene  activation,  amongst  others,  represent  stresses  to  which  the  cell  must 
respond.  The  p53  tumour  suppressor  protein  sits  at  this  pivotal  point  in  control 
of  the  cell  cycle  and  other  cellular  responses  to  such  stresses.  The  two  main 
responses  of  the  cell,  namely  cell  cycle  arrest  and  apoptosis,  are  mediated,  at 
least  in  part,  by  the  activity  of  p53. 37 
p53  is  a  transcription  factor,  whose  activity  is  regulated  primarily  at  the  post- 
translational  level.  The  half-life  of  wild  type  p53  is  very  short  under  normal 
conditions.  This  is  due  to  its  interaction  with  the  mouse  double  minute  2  protein 
(MDM2).  This  interaction  interferes  with  the  p53  transactivation  domain,  thus 
rendering  p53  unable  to  assemble  fully  the  machinery  required  for 
transcriptional  activation  (Oliner  et  al.,  1993).  The  interaction  with  MDM2  also 
leads  to  the  degradation  of  p53  by  the  ubiquitin-proteasome  pathway,  as  MDM2 
has  been  demonstrated  to  act  as  a  p53-specific  E3  ubiquitin  protein  ligase 
(Honda  et  al.,  1997).  One  of  the  genes  targeted  by  activated  p53  is  MDM2, 
thus  forming  the  basis  of  a  negative  feedback  loop  (Wu  et  al.,  1993). 
Stimulation  of  p53  stabilisation  and  activation  can  be  achieved  via  several 
signalling  pathways  that  form  the  primary  responses  to  cellular  stresses  (Figure 
2-5).  Injurious  stimuli,  such  as  ionising  or  ultraviolet  radiation  and  certain 
chemotherapeutic  agents,  such  as  adriamycin,  elicit  a  rapid  induction  of  p53 
activity  via  non-transcriptional  means.  The  DNA  damage  caused  by  such 
agents  is  relayed  via  signalling  pathways  such  as  ataxia  telangiectasia-mutated 
(ATM)  and  ataxia  telangiectasia-related  (ATR)  proteins  (Enoch  &  Norbury, 
1995;  Tibbetts  et  al.,  1999).  These  signal  via  the  protein  kinases  Chk2  and 
Chk1  (Liu  et  al.,  2000)  respectively,  with  the  result  being  phosphorylation  of  p53 
(Hirao  et  al.,  2000;  Liu  et  al.,  2000).  A  schematic  representation  of  these 
pathways  is  seen  in  Figure  2.5.  Other  cellular  stresses  are  mediated  via  other 
intracellular  signalling  pathways  (reviewed  in  Giaccia  &  Kastan,  1998).  For 
example,  deregulated  expression  of  various  oncogenic  signals,  such  as  ElA, 
Ras,  Myc  and  fl  catenin  leads  to  a  p53  response  via  the  induction  of  p14ARF 
(de  Stanchina  et  al.,  1998;  Zindy  et  al.,  1998).  ARF  can  bind  to  MDM2, 
reducing  binding  to  p53  and  thus  inducing  p53  stabilisation  (Honda  &  Yasuda, 
1999)  Thus,  the  response  of  p53  to  oncogenic  stimuli  may  be  an  important 
direct  tumour  suppressive  role. 
The  phosphorylation  of  p53  is  one  of  the  major  mechanisms  for  regulation  of  its 
activity.  The  protein  can  be  phosphorylated  on  many  amino  acid  residues, 
including  serine  15  and  20,  which  are  the  main  targets  for  the  ATMATR 
pathways  (Dumaz  &  Meek,  1999;  Fiscella  et  al.,  1993;  Tibbetts  et  al.,  1999). 
These  residues  lie  in  the  transactivation  domain  that  regulates  binding  to 
MDM2.  Phosphorylation  within  this  domain  reduces  affinity  for  MDM2  and  thus 38 
reduces  p53  degradation.  However,  p53  activity  can  also  be  modified  by 
acetylation  (Li  et  al.,  2002)  or  glycosylation  of  various  amino  acid  residues 
(reviewed  by  Brooks  &  Gu,  2003).  This  may  lead  to  increased  DNA  binding. 
Activation  of  p53  induces  many  genes  including  p2l  (Figure  2.5).  This,  at  least 
in  part,  is  responsible  for  cell  cycle  arrest  in  G1  (Waldman  et  al.,  1995). 
Participation  of  p53  in  other  cell  cycle  checkpoints,  such  as  at  G2/M  and  GO/G1 
has  also  been  described,  but  the  molecular  mechanisms  have  not  been 
established  (Itahana  et  al.,  2002;  Taylor  &  Stark,  2001).  The  functions  of  p53  in 
replicative  senescence  may  also  be  mediated  via  these  pathways  (Shay  et  al., 
1991).  This  will  be  discussed  in  a  subsequent  section. 
The  other  cellular  response  that  may  be  elicited  is  apoptosis,  mediated  in  some 
cells  by  Bax,  a  member  of  the  bc12  family  of  apoptosis  promoters  (Miyashita  & 
Reed,  1995).  Induction  of  other  genes,  such  as  PUMA,  is  also  pro-apoptotic 
(Nakano  &  Vousden,  2001).  The  appropriate  cellular  response  depends  on  the 
context  in  which  p53  stimulation  is  achieved.  If  p53  signalling  co-exists  with 
stimulation  of  factors  related  to  cell  survival,  cell  cycle  arrest  may  predominate. 
2.4.4.1  p53  in  cancer 
Loss  of  p53  function  is  well  documented  in  many  cancers,  including  HNSCC.  In 
rodents,  homozygous  disruption  of  p53  results  in  predisposition  to  malignancy, 
with  an  increased  cancer  risk  also  present  in  p53  heterozygous  animals  (Harvey 
et  al.,  1993;  Jacks  et  al.,  1994).  Disruption  of  p53  function  is  often  achieved  by 
point  mutation,  but  p53  function  can  also  be  inactivated  by  interaction  with  viral 
proteins  such  as  HPV16  E6  (Shay  et  al.,  1993).  Mutation  of  p53  most 
frequently  occurs  in  the  DNA  binding  domain  (Olivier  et  al.,  2002),  a 
consequence  of  which  is  reduced  DNA  binding  and  transcriptional  activation 
capacity,  in  addition  to  inhibition  of  MDM2  binding.  This  results  in  stabilisation 
of  p53,  explaining  the  increased  levels  of  mutated  protein  often  reported  by 
immunohistochemical  studies.  Often  the  remaining  wild  type  allele  also 
becomes  deleted.  Patients  with  mutant  p53  show  defects  in  cell  cycle  control 
and  apoptosis,  but  also  have  an  increased  tendency  to  genomic  instability 
(Shao  et  al.,  2000;  Shin  et  al.,  2001  a). 39 
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Figure  2.5  Upstream  and  downstream  events  in  the  p53  pathway 
DNA  damage  signals  to  p53,  resulting  in  the  activation  of  various  intracellular 
responses.  p53  exerts  its  control  on  cell  cycle  progression  mainly  through  p2l 
and  its  inhibitory  effect  on  CyclinA/cdk4.  The  activity  of  p53  is  regulated 
primarily  by  its  interaction  with  MDM2. 
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A  high  proportion  of  patients  who  inherit  mutated  p53  (i.  e.  are  heterozygous  for 
the  wild  type  allele)  develop  cancer,  often  at  an  early  age  (Srivastava  et  al., 
1990).  Sporadic  mutations  in  p53  have  also  been  noted  with  an  overall 
frequency  in  cancer  of  50-55%  (Hollstein  et  al.,  1991).  The  importance  of 
tobacco  in  the  prevalence  of  guanine  nucleotide  transversions  in  p53  in 
smoking  related  cancers,  such  as  lung,  bladder  and  HNSCC,  was  mentioned 
earlier.  The  low  prevalence  of  p53  mutations  in  lesions  from  never-smokers 
bears  witness  to  this  (Lazarus  et  al.,  1995).  Most  of  the  mutations  are  in  the 
DNA  binding  domain  encoded  by  exons  5-8.  These  have  been  termed  the 
"hotspot",  regions  in  which  mutations  are  claimed  to  account  for  in  excess  of 
90%  of  the  total  (Hollstein  et  al.,  1991).  We  have  previously  shown  that  two  of 
seven  immortal  dysplasia  cultures  have  mutations  outwith  this  area  (McGregor 
et  al.,  2002).  Thus,  emphasis  solely  on  sequencing  exons  5-8  in  many  studies 
may  have  resulted  in  under-reporting  of  the  prevalence  of  p53  mutation  in  vivo. 
The  link  between  p53  mutation  and  protein  stabilisation  has  resulted  in  a 
plethora  of  immunohistochemically  based  studies  of  p53  malfunction.  However, 
the  complexity  of  the  regulation  of  p53  protein  level  makes  interpretation  of  this 
data  difficult,  particularly  when  no  attempt  is  made  to  analyse  the  DNA 
sequence.  Additionally,  the  large  number  of  variables  in  methodology  and 
assessment  of  p53  staining,  together  with  the  use  of  many  different  p53 
antibodies,  makes  drawing  clear  conclusions  problematic.  A  poor  correlation  of 
p53  mutation  with  increased  immunoreactivity  has  been  demonstrated  in  some 
studies  (Burns  et  al.,  1993).  The  effect  of  particular  mutations  on  p53  protein 
structure  may  explain  this,  for  example,  the  creation  of  a  premature  stop  codon, 
or  a  frameshift,  which  creates  a  truncated  protein.  In  addition,  some  tumours 
express  elevated  levels  of  p53  without  mutation  (Bradley  et  al.,  2001).  Such 
difficulties  have  resulted  in  many,  often  contradictory  studies  relating  p53  level 
to  outcome,  including  overall  survival  and  freedom  from  recurrence. 
The  reported  frequency  of  p53  mutation  in  HNSCC  varies  from  study  to  study 
and  is  dependent  on  the  methodology  utilised.  Most  of  these  studies  confine 
sequencing  to  exons  5-8/9  (Kashiwazaki  et  al.,  1997;  Koch  et  al.,  1996; 
Matsuda  et  al.,  1996;  Rowley  et  al.,  1998).  However,  in  a  study  by  Kropveld 
and  co-workers,  p53  was  mutated  in  91  %  of  HNSCC,  with  33%  of  these  outwith 41 
the  core  domain  of  exons  5-8/9  (Kropveld  et  al.,  1999).  This  is  considerably 
higher  than  in  most  other  studies.  Overall,  p53  sequencing  consistently 
demonstrates  that  50-55%  of  HNSCC  have  mutations  in  exons  5-8/9,  with 
approximately  20%  present  in  the  other  exons  (2-4  and  10-11).  This  gives  an 
approximate  overall  prevalence  of  p53  mutation  in  HNSCC  of  75%.  The 
mutations  found  in  the  primary  tumours  have  also  been  found  in  metastatic 
lesions  (Burns  et  al.,  1994;  Tabor  et  al.,  2002b),  indicating  that  p53  mutated 
clones  may  be  positively  selected  during  HNSCC  progression.  The  difficulties 
outlined  above  with  immunohistochemical  prognosis  have  resulted  in 
contradictory  conclusions  about  p53  (reviewed  in  (Nylander  et  al.,  2000),  but 
mutations,  particularly  in  the  DNA  binding  domain,  have  been  associated  with 
poor  prognosis  (Mineta  et  al.,  1998;  Yamazaki  et  al.,  2003). 
The  prevalence  of  p53  mutations  in  some  precancerous  lesions  of  the  head  and 
neck  indicates  that  this  may  be  an  early  step  in  HNSCC  carcinogenesis  (Boyle 
et  al.,  1993).  The  reported  rate  of  mutation  is  less  than  that  for  invasive 
disease,  with  the  highest  rate  recorded  in  severe  dysplasia  within  erythroplakia 
(50%,  Qin  et  al.,  1999).  Other  workers  have  even  suggested  that  p53  mutation 
is  the  initiating  event  in  HN  carcinogenesis  (Braakhuis  et  al.,  2004a).  However, 
in  a  study  of  sequential  biopsies  from  patients  who  eventually  developed 
HNSCC  within  a  dysplastic  lesion,  p53  mutations  (in  exons  5-8)  were  only  found 
in  pre-invasive  lesions  in  two  of  ten  patients  (Shahnavaz  et  al.,  2000).  The 
conclusion  drawn  from  this  was  that  p53  mutations  occur  late  in  disease 
progression,  but  this  assumes  that  any  p53-mutated  clone  present  in  the  tissue 
would  be  present  in  the  portion  of  the  premalignant  lesion  actually  analysed. 
Tissue  heterogeneity  within  the  epithelium,  as  demonstrated  later  in  this  thesis, 
probably  dictates  that  this  is  not  necessarily  so. 
Increased  p53  immunoreactivity  has  been  described  in  dysplastic  oral  lesions, 
often  variably  related  to  the  grade  of  dysplasia  (Lippman  et  al.,  1995;  Sauter  et 
al.,  1994;  Shin  et  al.,  1994a).  This  may  be  a  genuinely  early  change,  as 
increased  immunoreactivity  is  seen  in  all  grades  of  dysplasia  (Regezi  et  al., 
1995).  Alterations  in  the  spatial  distribution  of  p53  staining  have  been 
suggested  as  of  more  value  than  staining  intensity.  The  presence  of  suprabasal 
p53  staining  in  high-grade  dysplasia  is  associated  with  an  increased  risk  of 
malignant  transformation  (Cruz  et  al.,  2002).  However,  some  groups  have  found 42 
that  the  link  between  p53  expression  and  HNSCC  carcinogenesis  is  less  robust 
(Murti  et  al.,  1998)  and  that  the  link  may  reduce  with  long  term  follow-up  (Lee  et 
al.,  2000).  However,  the  prognostic  value  of  the  combined  p53  and  p16  status 
is  more  powerful  than  for  either  alone  (Gallo  et  al.,  1997). 
2.5  Evasion  of  apoptosis 
As  seen  earlier  in  the  discussion  of  p53  function,  one  of  the  possible  responses 
of  the  cell  to  damage  and  stress,  is  the  activation  of  programmed  cell  death  or 
apoptosis.  Apoptosis  is  an  energy  dependent  process  of  II  cell  suicide",  and  can 
be  induced  by  activation  of  receptors  on  the  cell  surface,  such  as  FAS  and  TNF- 
a  receptor  (the  Is  extrinsic"  pathway,  Wajant,  2002).  Additionally  the  DNA 
damage  signalling  pathways  via  p53  result  in  the  upregulation  of  pro-apoptotic 
mediators,  such  as  Bax  (an  example  of  the  "intrinsic"  pathways  Wajant,  2002). 
Bax  in  turn  stimulates  mitochondria  to  release  cytochrome  C  (Jurgensmeier  et 
al.,  1998).  Signalling  via  FAS,  or  release  of  cytochrome  C,  results  in  the 
activation  of  the  caspase  cascade,  via  the  initiation  caspases,  such  as  caspase 
9  (Figure  2.6).  The  product  of  this  is  activation  of  several  effector  caspases, 
such  as  caspases  3,6  and  7  (Slee  et  al.,  2001).  These  effect  the  cell  death 
programme,  by  destruction  of  the  organelles  and  dissolution  of  the  genome 
(reviewed  in  Okada  &  Mak,  2004). 
The  abrogation  of  apoptosis  in  cancer  generally  was  confirmed  by  the  finding 
that  the  oncogene  bcl  2,  which  is  overexpressed  by  translocation  in  follicular 
lymphoma,  has  profound  anti-apoptotic  effects  (Tsujimoto  et  al.,  1984a; 
Tsujimoto  et  al.,  1984b).  It  is  also  a  transcriptional  target  of  p53,  with  activated 
p53  reducing  bcl  2  expression  (HaIdar  et  al.,  1994).  Overexpression  of  bcl  2 
has  been  described  in  the  early  stages  of  various  epithelial  malignancies, 
including  lung,  breast  and  bladder,  but  this  is  often  followed  by  loss  of 
expression  in  advanced  disease  (Ghosh  et  al.,  1999;  Mauri  et  al.,  1999; 
Nakopoulou  et  al.,  1998).  However,  whilst  this  has  not  been  found  to  be  a 
consistent  effect  in  HNSCC  (Piattelli  et  al.,  2002),  a  general  trend  towards  a 
reduced  bax/bcl  2  ratio  has  been  found  in  tumour  samples,  but  not  in  pre- 
invasive  lesions  (Lavieille  et  al.,  1998). 43 
The  most  common  defect  in  pro-apoptotic  signalling  reported  in  HNSCC  is  loss 
of  p53  function  by  mutation.  Mice  with  p53  deficiency  show  defects  in  apoptosis 
in  vivo  (Lotem  &  Sachs,  1993).  In  terms  of  human  tumour  biology,  this  may 
manifest  itself  as  resistance  to  chemotherapy.  There  have  been  clear  links 
made  between  specific  p53  mutations  and  resistance  to  doxorubicin  in  breast 
cancer  (Aas  et  al.,  1996),  and  response  to  chemotherapy  in  HNSCC 
(CabeIguenne  et  al.,  2000). 44 
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Figure  2.6  Apoptosis  -  an  overview 
The  graphic  shows  some  of  the  various  pathways  to  apoptosis  including 
signalling  via  p53  (DNA  damage  response),  FAS  receptor  and  c-myc.  The 
pathways  converge  on  the  release  of  cytochrome  c  from  mitochondria.  Once 
released,  cytochrome  c  interacts  with  apoptotic  protease  activating  factor  1 
(APAF1)  and  procaspase  9.  In  the  presence  of  ATP,  caspase  9  is  activated, 
leading  to  the  activation  of  downstream  effector  caspases.  Survival  signals, 
such  as  those  mediated  by  IGF1  may  reduce  the  pro-apoptotic  signalling  in 
some  pathways. 
This  figure  has  been  reproduced  from  (Pelengaris  et  al.,  2002). 45 
2.6  Limitless  replicative  potential 
The  genetic  changes  described  above  allow  proliferation  of  cancer  cells  outwith 
the  strict  controls  placed  on  normal  cells.  Such  unrestricted  growth  should 
allow  tumours  to  develop  unhindered.  However,  there  are  further  multiple 
barriers  to  the  limitless  proliferation  of  cells.  Hayflick  originally  demonstrated 
that  cells  have  a  finite  replicative  potential  (Hayflick,  1965).  The  concept  of  the 
96  repl  ico  meter'  was  then  introduced  (Hayflick,  1997),  this  being  a  method  for  the 
cell  to  count  the  number  of  divisions  and  cease  dividing  after  the  maximum  limit 
had  been  reached.  This  cessation  of  growth  and  division  has  been  termed 
replicative  senescence. 
2.6.1  Barrier  1:  Replicative  senescence 
Normal  diploid  embryonic  cells,  including  fibroblasts  and  epithelial  cells  undergo 
approximately  40-70  population  doublings  before  entering  the  stable,  but  viable 
state  of  replicative  senescence  (Hayflick,  1965).  There  is  now  much 
accumulated  evidence  that  senescence  is  controlled,  at  least  in  part,  by  attrition 
of  telomeric  DNA.  The  observation  that  telomeres  shorten  both  in  vivo  and  in 
vitro  suggests  that  telomeric  attrition  is  the  most  likely  "counting"  mechanism  for 
cell  divisions  (Allsopp  et  al.,  1995).  Other  cellular  clocks  have  been  proposed, 
including  a  progressive  increase  in  DNA  methylation  as  senescence 
approaches  (Machwe  et  al.,  2000).  The  cellular  signals  that  elicit  senescence 
include  activation  of  the  DNA  damage  response  (d'Adda  di  Fagagna  et  al., 
2003). 
Telomeres  are  repetitive  DNA  sequences  (TTAGGG)  on  the  ends  of 
chromosomes.  A  complex  of  proteins  binds  the  telomeric  DNA,  which  is 
important  in  the  maintenance  of  the  complex  structure  of  the  telomere  (Figure 
2.7  A).  The  96  end  replication  problem"  dictates  that  some  of  these  repeats  are 
lost  when  DNA  is  copied  (Levy  et  al.,  1992),  although  larger  portions  may  also 
be  lost  through  homologous  recombination  at  the  telomere  (Wang  et  al.,  2004). 
Telomerase  was  first  described  in  yeast  (Greider  &  Blackburn,  1985).  It  is  a 
holoenzyme  complex,  consisting  of  a  reverse  transcriptase  component  (TERT, 
on  chromosome  5p15.33)  and  a  RNA  template  (TERC/TR)  and  is  responsible 46 
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Figure  2.7  Telomere  structure  and  the  role  of  telomerase 
A:  Schematic  diagram  of  the  structure  of  the  telomere,  showing  the  formation  of 
D  and  T  loops,  in  conjunction  with  various  telomere  associated  proteins.  These 
act  to  protect  the  telomeric  end  of  the  chromosome. 
B:  The  action  of  telomerase.  hTERT  catalyses  the  addition  of  new  telomere 
repeats,  with  hTR  as  the  template. 
Reproduced  from  Mathon  and  Lloyd,  2001  (Mathon  &  Lloyd,  2001) 
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for  synthesis  of  the  TTAGGG  repeats  on  the  end  of  chromosomes  in  germline 
cells  (Figure  2.7  B). 
In  normal  somatic  tissues,  telomerase  activity  is  generally  absent,  but  is  present 
at  low  levels  in  the  proliferative  (stem)  cells  in  continually  renewing  tissues, 
such  as  epithelia  (Hade-Bachor  &  Boukamp,  1996;  Kolquist  et  al.,  1998).  In 
these  cells,  telomerase  expression  may  depend  on  the  proliferative  state  of  the 
tissue. 
Expression  of  hTERT  and  hTR  have  also  been  described  in  the  basal  cells  of 
normal  oral  mucosa  (Fujimoto  et  al.,  2001).  Such  activity  may  retard,  but  does 
not  abolish  telomere  attrition  (Oh  et  al.,  2004)  and  is  lost  if  the  cells  enter 
terminal  differentiation  or  a  quiescent  state  (Sharma  et  al.,  1995).  As  normal 
oral  keratinocytes  approach  senescence,  telomerase  expression  reduces.  This 
may  be  due  to  hype  rmethyl  atio  n  of  the  hTERT  promoter  (Shin  et  al.,  2003). 
The  normal  regulation  of  telomerase  expression  is  complex.  Transcription  of 
hTERT  is  modulated  by  multiple  signals  including  members  of  the  Myc  family  of 
transcription  factors,  Spl  (Park  et  al.,  2001),  and  human  papilloma  virus  E6 
(Klingelhutz  et  al.,  1996).  It  is  also  postulated  that  alternative  splicing  of  the 
hTERT  gene  may  contribute  to  control  of  telomerase  activity  (Ulaner  et  al., 
2000),  but  this  has  not  been  confirmed  under  physiological  conditions  (Kotoula 
et  al.,  2002;  Liu  et  al.,  1999).  Repression  of  hTERT  expression  may  be  under 
the  control  of  various,  as  yet  unidentified  transcriptional  repressors,  such  a  gene 
from  a  possible  candidate  region  on  chromosome  3p  (Cuthbert  et  al.,  1999).  Rb 
and  E21F  may  also  have  hTERT  repressive  activity,  either  directly  or  indirectly 
(Crowe  &  Nguyen,  2001). 
In  cell  culture,  it  has  been  demonstrated  that  telomerase  activity  is  closely 
related  to  hTERT  expression  and  that  in  alterations  of  telomerase  activity,  such 
as  those  mentioned  above  in  relation  to  senescence,  hTERT  reduces,  whilst 
hTR  remains  constant  (Shin  et  al.,  2003).  However,  in  a  mouse  model, 
ha  plo  insufficiency  of  hTR  disrupted  telomere  maintenance  (Chiang  et  al.,  2004). 
In  vivo  studies  have  also  shown  hTR  to  be  upregulated  in  some  solid  tumours, 
including  cervical  carcinoma  and  non-small  cell  lung  carcinoma  (Soder  et  al., 
1998;  Soder  et  al.,  1997).  Additionally,  the  coordinate  upregulation  of  hTR  and 
hTERT  has  been  demonstrated  in  many  tumours  in  vivo  (Stanta  et  al.,  1999),  as 48 
has  hTR  downregulation  upon  proliferation  in  the  small  number  of  telomerase- 
positive  cells  in  normal  tissue  (Sugihara  et  al.,  1999).  This  clearly  supports  a 
role  for  hTR  expression  in  the  regulation  of  telomerase  activity  in  vivo.  The 
mechanisms  of  regulation  of  hTR  expression  have  not  been  elucidated. 
Ectopic  expression  of  TERT  in  human  diploid  fibroblasts  (HDFs)  is  sufficient  for 
immortal  isation.  This  indicates  the  importance  of  telomere  dependent  pathways 
in  the  establishment  of  barriers  to  growth  in  this  type  of  cell.  However,  this  does 
not  apply  to  mammary  epithelial  cells  or  keratinocytes,  both  of  which  require 
additional  alterations  to  allow  immortalisation  to  occur  (Muntoni  et  al.,  2003). 
The  additional  alterations  that  are  necessary  in  human  oral  keratinocytes  most 
likely  include  loss  of  p16  expression.  In  one  mortal  cell  culture,  which  had  lost 
expression  of  p16,  ectopic  expression  of  hTERT  was  sufficient  to  result  in 
immortal  isation,  without  pressure  toward  p53  mutation.  Mortal  cultures  which 
had  intact  pl  6  expression,  were  not  immortalised  (Muntoni  et  al.,  2003). 
As  mentioned  earlier,  p16  has  been  suggested  as  playing  a  central  role  in  the 
establishment  of  replicative  senescence.  Recent  elegant  investigations  in 
fibroblasts  have  indicated  that  p16  does  not  have  an  essential  role  in  fibroblast 
senescence  (Brookes  et  al.,  2004;  Herbig  et  al.,  2004),  although  this  is  still 
disputed  (Bond  et  al.,  2004).  More  importantly,  the  experiments  demonstrated 
that  the  mechanism  by  which  senescence  is  achieved  could  vary  even  between 
cells  within  the  same  culture  (Herbig  et  al.,  2004).  Thus  in  terms  of 
senescence,  it  seems  likely  that  individual  cells  may  differ  in  their  response  to 
multiple  signals,  resulting  in  the  development  of  mosaic  cultures.  Senescence 
triggered  by  coordinate  upregulation  of  p14  and  p16  has  been  reported  in 
murine  fibroblasts,  but  a  role  for  p14  in  keratinocyte  senescence  has  not  been 
established  (Munro  et  al.,  1999). 
In  human  keratinocytes,  senescence  is  a  two-stage  phenomenon,  with  initial 
replicative  arrest  mediated  by  p16,  and  its  effect  on  the  Rb  pathway  (Kiyono  et 
al.,  1998;  Loughran  et  al.,  1994).  This  has  been  termed  mortality  stage  0  (MO). 
The  upstream  pathways  are  unclear,  but  roles  for  loss  of  expression  of  the 
transcription  factor  Idl  (Alani  et  al.,  2001)  and  increase  in  the  expression  of  14- 
3-3a  have  been  suggested  (Dellambra  et  al.,  2000;  Rheinwald  et  al.,  2002). 
The  rise  in  p16  expression  may  also  be  mediated  by  telomeric  attrition  (Jacobs 49 
&  de  Lange,  2004),  but  the  effector  pathways  are  yet  to  be  fully  elicited  (Zheng 
et  al.,  2004).  Some  groups  have  suggested  that  the  accumulation  of  p16  in 
keratinocyte  cell  culture  is  related  to  inadequate  culture  environment  and  that 
only  co-culture  with  feeders  prevents  the  accumulation  of  p16  (Ramirez  et  al., 
2001).  This  has  not  been  borne  out  by  experimentation  in  mortal  cells  in  our 
laboratory  as,  despite  co-culture  with  feeders,  the  accumulation  of  p16  still 
occurs  (McGregor  et  al.,  2002). 
Once  the  growth  arrest  mediated  by  p16  has  been  overcome,  the  continued 
telomeric  attrition  results  in  the  activation  of  p53,  as  described  earlier.  This  is 
termed  mortality  stage  1  (Ml)  (Figure  2.8).  Shortened  telomeres  activate  p53 
via  ATM,  as  the  uncapped  telomere  is  recognised  in  a  similar  manner  to  a 
double  strand  DNA  break.  A  single  short  telomere  may  be  sufficient  for  this 
pathway  to  be  activated  (Hemann  et  al.,  2001),  and  the  effect  may  be  mediated 
by  alterations  in  the  binding  of  telomere-related  proteins  to  shortened  telomeric 
DNA  (Karlseder  et  al.,  2002).  It  is  also  possible  that  senescence  can  occur  in 
the  absence  of  telomere  shortening.  Some  types  of  cell,  including  certain 
keratinocytes,  may  be  telomerase  positive  and  yet  these  cells  still  undergo 
senescence  (Kang  et  al.,  1998).  The  main  effector  in  this  case  was  reported  to 
be  p16  (Kang  et  al.,  2004).  However,  in  many  instances  these  results  may 
merely  reflect  whether  MO  or  M1  is  being  investigated. 
2.6.2  Overcoming  senescence 
Escape  from  senescence  can  occur  in  many  ways,  largely  dependent  on  the 
cell  type,  but  most  require  alterations  at  some  point  in  the  p53  and  Rb  pathways 
(Shay  et  al.,  1991).  Fibroblasts  require  loss  of  signalling  via  Rb,  but  not  the  loss 
of  p16  function  per  se  (Wei  et  al.,  2003).  This  may  be  because  fibroblast 
senescence  is  maintained  primarily  by  p53  (Beausejour  et  al.,  2003).  Other  cell 
types,  such  as  normal  human  mammary  epithelia  cells,  may  spontaneously 
escape  senescence  (Romanov  et  al.,  2001).  In  human  oral  keratinocytes, 
inactivation  of  p16  is  invariably  associated  with  the  immortal  phenotype  in 
HNSCC  cell  cultures  (Munro  et  al.,  1999).  Inactivation  of  the  DNA  damage 
signal  is  also  required  and  this  is  most  commonly  acquired  by  mutation  of  p53. 
Cells  that  have  escaped  senescence  proliferate  until  a  second  major  replicative 
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Figure  2.8  Barriers  to  immortalisation 
Schematic  representation  of  the  relationship  of  telomere  length  and  passage 
through  senescence  and  crisis.  Human  cells  must  surmount  both  replicative 
senescence  and  crisis  to  become  immortal.  Replicative  senescence  is 
controlled  by  the  actions  of  the  pRb,  p53  and  telomere  maintenance  pathways. 
Telomere  stabilisation  permits  cells  to  avoid  crisis  and  become  immortal 
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2.6.3  Barrier  2:  Crisis  and  immortalisation 
Following  further  cell  division,  multiple  telomeres  in  each  cell  become  critically 
short  and  uncapped.  This  generates  dicentric  chromosomes  and  genomic 
instability  (Ducray  et  al.,  1999).  This  barrier  to  indefinite  growth,  known  as  M2 
or  crisis,  results  in  cell  death  rather  than  cell  cycle  arrest  (Figure  2.8).  Crisis 
has  been  suggested  to  precipitate  tumour  development  and  progression  in 
animal  models  and  in  human  breast  cancer  via  the  promotion  of  genomic 
instability.  The  presence  of  anaphase  bridges  in  mitotic  cells,  either  in  culture 
or  in  tumours,  has  been  used  as  a  surrogate  marker  of  telomere  dysfunction  as 
it  demonstrates  the  presence  of  chromosome  fusions  (Gordon  et  al.,  2003; 
Rudolph  et  al.,  2001).  Moreover,  in  mice,  such  imbalanced  chromosomal 
translocations  are  associated  with  the  immortalisation  process  (Rudolph  et  al., 
1999)  and  cancer  (Artandi  et  al.,  2000),  including  the  erosion  of  telomeres  and 
the  development  of  p53  mutations  (Shao  et  al.,  2000).  Thus,  in  some 
circumstances,  variants  emerge  from  crisis  to  become  immortal.  This  is 
accomplished  by  the  correction  of  telomere  dysfunction,  by  either  up-regulation 
or  reactivation  of  telomerase  or  by  alternative  methods,  which  involve 
recombination  (alternative  lengthening  of  telomeres,  ALT)  (Bryan  et  al.,  1997). 
Despite  telomerase  activity  in  many  tumours,  it  is  clear  that  telomerase 
activation  is  a  double-edged  sword  (reviewed  in  Masutomi  &  Hahn,  2003). 
Absence  of  telomerase  activity  results  in  a  limited  lifespan,  via  the  activation  of 
senescence,  but  if  senescence  is  bypassed,  this  can  result  in  genomic 
instability.  However,  telomerase  activation  reduces  chromosomal  instability  by 
stabilising  the  telomere,  but  allows  cells  to  become  immortal.  Once  telomerase 
has  been  activated,  the  telomeres  appear  to  be  maintained  at  a  very  short 
setting  in  some  tumours.  This  allows  for  a  measure  of  continued  genomic 
instability  (Chin  et  al.,  2004;  Gisselsson  et  al.,  2001;  Gordon  et  al.,  2003). 
Expression  of  telomerase  is  increased  in  HNSCC,  both  in  cells  derived  from 
dysplastic  oral  lesions  and  from  turnours  (McGregor  et  al.,  2002;  Parkinson  et 
al.,  1997).  The  level  of  activity  is  related  to  tumour  grade,  as  the  highest  levels 
have  been  demonstrated  in  poorly  differentiated  HNSCC  (Kannan  et  al.,  1997). 
increases  in  both  hTERT  and  hTR  expression  have  been  described  (Downey  et 
al.,  2001  ;  Kim  et  al.,  2001;  Zhang  &  Zhang,  1999).  Whilst  increased 52 
telomerase  activity  has  been  noted  in  dysplastic  oral  lesions  (Mao  et  al., 
1996a),  reports  linking  the  grade  of  dysplasia  with  telomerase  activity  have 
been  variable  (Miyoshi  et  al.,  1999;  Mutirangura  et  al.,  1996;  Zhang  &  Zhang, 
1999).  In  most  studies,  a  proportion  of  the  turnours  are  telomerase-negative. 
These  findings  suggest  that  the  immortal  and  invasive  phenotypes  may  be 
acquired  independently  in  HNSCC  development.  This  concept  will  be  explored 
more  fully  below  and  later  in  this  thesis 
2.6.4  ALT 
Whilst  many  tumour  types  have  high  levels  of  telomerase  activity,  some  do  not. 
There  may  be  several  reasons  for  this.  However,  the  presence  of  immortal, 
telomerase  negative  cell  lines  is  indicative  of  the  existence  of  other  telomere 
lengthening  mechanisms  (Bryan  et  al,  1995).  These  cells  have  very  long  and 
heterogeneous  telomeres,  and  there  is  evidence  of  elongation  of  these 
telomeres  by  the  alternative  lengthening  of  telomeres  (ALT)  mechanism  (Bryan 
et  al.,  1997),  which  involves  intratelomeric  recombination  and  copy  templating 
for  the  synthesis  of  telomeric  DNA  (Dunham  et  al.,  2000).  Whilst  ALT  has  been 
shown  to  occur  in  oral  keratinocytes  under  certain  circumstances  in  vitro  (Opitz 
et  al.,  2001),  there  is  presently  no  evidence  that  ALT  occurs  in  HNSCC 
carcinogenesis  (Henson  et  al.,  2002;  Loughran  et  al.,  1997). 
2.6.5  Evidence  for  senescence  and  immortalisation  in  vivo 
In  studies  from  the  Beatson  Institute  for  Cancer  Research,  about  60%  of 
primary  HNSCCs  are  immortal,  as  are  all  the  HNSCC  recurrences  (although  the 
latter  are  more  limited  in  number)  (Burns  et  al.,  1993;  Edington  et  al.,  1995). 
Numerous  studies  link  the  process  of  immortality  with  genetic  instability.  p53 
mutations,  p16  loss,  LOH  and  aneuploidy  are  all  characteristics  of  cells  that 
have  escaped  senescence  and  become  immortal  (Edington  et  al.,  1995; 
Loughran  et  al.,  1997).  It  is  very  unlikely  that  the  acquisition  of  the  immortal 
phenotype  is  merely  a  culture  phenomenon  since  the  genetic  signature  of 
immortal  HNSCC  cell  lines  is  also  found  in  a  large  subset  of  HNSCC  turnours 
and  dysplasias  in  vivo  (Loughran  et  al.,  1997;  Mao  et  al.,  1996b;  Rosin  et  al., 
2000;  Weber  et  al.,  1998).  In  addition,  the  presence  of  unbalanced 
chromosome  translocations  and  anaphase  bridges  in  over  80%  of  HNSCC 53 
tumours  in  vivo  is  suggestive  of  their  escape  from  senescence  (Gordon  et  al., 
2003). 
Despite,  the  importance  of  immortality  in  the  generation  of  the  majority  of 
HNSCC,  it  is  becoming  clear  from  work  conducted  in  the  Beatson  Institute  and 
others  that  a  subset  of  tumours  may  develop  into  invasive  carcinomas  without 
acquiring  immortality.  Furthermore,  other  published  data  on  uncultured  tumour 
samples  reveal  minor  subsets  of  oral  carcinomas  that  have  no  detectable  LOH 
(Field  et  al.,  1995)  or  unbalanced  translocations  (Weber  et  al.,  1998),  or  are  still 
diploid  (Sudbo  et  al.,  2003).  The  conclusion  that  the  ability  of  SCCs  to  establish 
as  cell  lines  in  culture  (i.  e.  become  immortal)  correlates  with  poorer  survival  is 
supported  in  the  literature  (Shimada  et  al.,  2003).  This  suggests  that  some 
primary  SCCs  can  still  be  mortal  in  vivo;  whereas  in  others  an  immortal 
population  has  developed  by  further  mutation  and  this  is  responsible  for  local 
recurrence  and  metastasis.  Offner  et  al  found  that  disseminated  tumour  cells  in 
bone  marrow  from  a  variety  of  primary  tumour  types  (presumed  to  be  micro- 
metastases)  rarely  have  p53  mutations  and  are  therefore  unlikely  to  be 
immortal,  unlike  the  primary  tumours;  in  contrast,  p53  mutations  in  the  primary 
tumour  appear  to  favour  lymphatic  dissemination  of  lung  carcinoma  cells  (Offner 
et  al.,  1999). 
The  existence  of  mortal  SCCs  is  supported  by  in  vivo  data  that  some  HNSCC 
are  telomerase  negative  (Mao  et  al.,  1996a)  and,  as  mentioned  above,  there  is 
currently  no  evidence  for  ALT  mechanisms  in  head  and  neck  cancer  (Henson  et 
al.,  2002).  Additionally,  subsets  of  HNSCC  have  a  low  level  of  fractional  allele 
loss  and  develop  without  the  characteristic  genomic  changes  (LoH  at  3p,  9p 
and  17p)  that  may  underpin  the  development  of  immortality  (Nunn  et  al.,  1999). 
Others  have  extended  this  observation  to  bladder  cancer,  showing  that  all 
superficial  transitional  cell  carcinomas  (TCCs)  were  mortal  whereas  invasive 
TCCs  spontaneously  bypassed  senescence  by  acquiring  genetic  alterations 
involving  p16/pRb  loss  and  an  additional  alteration  (p53  mutation,  changes  at 
chromosome  20q,  3p  or  8p)  (Yeager  et  al.,  1998).  Another  study  on 
glioblastorna  divided  the  turnours  into  three  groups:  telomerase  positive, 
te  Io  me  rase-  negative-ALT  positive  and  telomerase  negative  ALT  negative;  they 
concluded  that  the  third  group  of  turnours  do  not  have  a  telomere  maintenance 
mechanism  of  any  kind  and  that  these  turnours  appeared  to  have  a  better 54 
prognosis  (Hakin-Smith  et  al.,  2003)  Given  that  all  data  available  shows  that 
telomere  erosion  denies  mammalian  cells  an  indefinite  lifespan  (Bodnar  et  al., 
1998;  Niida  et  al.,  1998),  this  data  seems  persuasive  evidence  for  the  existence 
of  mortal  tumours  in  vivo. 
Like  HNSCCs,  both  mortal  and  immortal  dysplasias  exist,  though  the  balance  is 
in  favour  of  the  former  (60:  40)  (McGregor  et  al.,  2002;  McGregor  et  al.,  1997). 
Of  the  19  dysplasia  biopsies  for  which  we  have  derived  primary  cultures,  6  of  7 
of  the  immortal  cultures  showed  four  molecular  changes:  loss  of  p16  INMA  and 
retinoic  acid  receptor-beta  (RAR-P)  expression,  p53  mutations  and  high 
telomerase  activity;  whereas  11  of  12  mortal  cultures  lacked  these  changes 
(McGregor  et  al.,  2002;  McGregor  et  al.,  1997;  Muntoni  et  al.,  2003).  The  two 
exceptions  have  an  intermediate  phenotype  (McGregor  et  al.,  2002;  McGregor 
et  al.,  1997).  No  evidence  of  HPV  infection  was  found  in  any  of  the  cultures.  An 
important  conclusion  from  this  evidence  is  that  acquisition  of  immortality  and 
invasiveness  may  be  independent  events  in  cancer  progression,  since  some 
dysplasias  are  immortal  and,  conversely,  some  carcinomas  are  mortal. 55 
2.7  Genomic  instability 
One  further  overarching  feature  may  hold  all  these  alterations  together  and  act 
as  an  enabling  backdrop  upon  which  the  other  abilities  may  appear.  This  is 
genomic  or  chromosomal  instability.  Genomic  instability  is  characterised  by  the 
occurrence  of  losses  and  gains  of  chromosomal  segments  or  even  whole 
chromosomes.  A  large  proportion  of  human  turnours  demonstrate 
abnormalities  in  both  the  number  and  structure  of  their  chromosomes 
(Hittelman,  2001). 
2.7.1  How  does  genomic  instability  arise? 
Chromosomal  instability  may  arise  by  multiple  mechanisms.  The  basis  of 
instability  consequent  to  telomeric  attrition  has  been  discussed  above. 
Abrogation  of  the  DNA  damage  signal,  by  loss  of  signalling  via  p53  or 
intermediates  within  the  p53  DNA  damage  pathway  (Figure  2.5),  results  in 
unrepaired  damage  and  this  may  lead  to  chromosomal  aberrations  (Shao  et  al., 
2000).  Loss  of  the  DNA  damage  recognition  signal  after  the  loss  of  p53, 
together  with  telomeric  attrition,  results  in  the  cell  entering  crisis  (Feldser  et  al., 
2003).  The  fusion  of  chromosome  ends,  seen  in  tumours  as  anaphase  bridges, 
drives  chromosomal  instability  via  breakage-fusion-bridge  cycles. 
Amongst  the  other  mechanisms,  which  may  operate  in  certain  tumours,  are 
chromosomal  segregation  defects  (Minhas  et  al.,  2003).  The  cellular  machinery 
active  in  mitosis  is  complex  and  alterations  detected  in  tumour  cells  include 
spindle  abnormalities,  centrosome  amplification  (Mayer  et  al.,  2003)  and 
abnormal  cytokinesis  (reviewed  by  Gollin,  2004).  Amplification  of  certain  genes 
which  control  mitotic  spindle  activity  has  been  described.  One  such  important 
gene  is  Aurora  A  (serine  threonine  kinase  15).  Amplification  of  this  gene  has 
been  associated  with  centrosome  amplification  and  the  formation  of  multipolar 
spindles  (Jeng  et  al.,  2004;  Zhou  et  al.,  1998).  In  mammary  carcinogenesis, 
amplification  of  Aurora  A  has  been  associated  with  the  transition  from  in  situ 
disease  to  invasive  carcinoma  (Hoque  et  al.,  2003). 
Investigations  in  colorectal  cancer  have  demonstrated  that  defects  in  single 
genes  can  result  in  genomic  instability  (Rajagopalan  et  al.,  2003).  This  in  turn 56 
leads  to  further  loss  of  genomic  material,  as  assessed  by  loss  of  heterozygozity 
(LoH). 
2.7.2  Karyotypic  abnormalities 
The  largest  scale  abnormality  seen  in  genetically  unstable  cells  is  karyotypic 
alteration,  such  as  tetraploidy  and  aneuploidy.  These  may  arise  from  non-  or 
partial  disjunction  of  cells  in  mitosis.  Aneuploidy  has  been  reported  in  many 
cancers,  reflecting  the  complex  karyotypes  that  may  result  from  genomic 
instability.  The  presence  of  aneuploid  cells  in  HNSCC  carcinogenesis  has  been 
known  for  some  time  (Munck-Wikland  et  al.,  1994;  Munck-Wikland  et  al.,  1992). 
The  presence  of  aneuploidy  in  oral  tissues  may  even  precede  the  development 
of  a  clinically  or  histopathologically  evident  lesion  (Ai  et  al.,  2001;  Sudbo  et  al., 
2001b).  Analysis  of  modal  chromosome  number  in  a  panel  of  HNSCC  cultures 
indicated  that  almost  all,  regardless  of  whether  mortal  or  immortal,  showed 
some  karyotypic  abnormality  (Edington  et  al.,  1995).  This  demonstrates  the 
likelihood  that  multiple  pathways  to  alterations  in  the  karyotype  exist,  not  merely 
those  that  involve  passage  through  crisis. 
In  recent  work  using  DNA  image  cytometry  to  assess  the  DNA  content  of  nuclei 
from  HNSCC  and  various  dysplastic  lesions,  Sudbo  and  colleagues  have  shown 
that  leukoplakias  from  the  oral  cavity  containing  aneuploid  cells  are  more  likely 
to  develop  into  turnours  (Sudbo  et  al.,  2001  a).  However,  the  risk  of  progression 
to  SCC  did  not  increase  further  as  the  proportion  of  aneuploid  cells  in  the 
sample  increased.  Such  lesions  are  also  more  likely  to  be  aggressive  and 
spread  to  other  sites,  compared  to  diploid  or  tetraploid  leukoplakias  (Sudbo  et 
al.,  2001a;  Sudbo  et  al.,  2004).  However,  the  malignant  transformation  rate  in 
these  studies  is  high,  compared  to  other  reports  of  leukoplakia  progression  the 
HNSCC.  Thus,  it  is  likely  that  the  study  population  is  biased  towards  lesions 
that  were  clinically  or  histologically  more  advanced.  However,  these  finding  are 
clearly  important  and  merit  careful  confirmation  in  independent  patient  groups 
with  a  prospective  study  design. 
2.7.3  Comparative  genomic  hybridisation  and  loss  of  heterozygozity 
Comparative  genomic  hybridisation  (CGH)  is  a  powerful  tool  for  the  analysis  of 
gains  and  losses  across  the  whole  genome  and  has  therefore  been  widely  used 57 
in  the  analysis  of  tumours.  It  appears  that  particular  types  of  cancer  have 
characteristic  (although  not  ubiquitous)  patterns  of  genetic  alteration.  This  may 
now  be  conducted  on  a  high  throughput,  genome-wide  scale  using  array  CGH, 
which  combines  microarray  technology  with  the  ability  to  explore  chromosomal 
changes.  This  technique  allows  detection  of  single  copy  number  changes. 
Loss  of  heterozygozity  (LoH)  indicates  consistent  loss  at  specific,  predefined 
loci.  This  tool  has  been  widely  used  but  is  less  powerful  as  known  markers 
must  be  used  to  investigate  particular  areas  of  interest  in  the  genome. 
The  areas  which  are  consistently  altered  in  HNSCC  are  gains  on  3q,  5p  8q  and 
11q13,  and  losses  on  3p,  9p  and  17p  (Bockmuhl  et  al.,  1996;  Brzoska  et  al., 
1995;  Hermsen  et  al.,  1997;  Roz  et  al.,  1996;  Soder  et  al.,  1995;  van  der  Riet  et 
al.,  1994),  although  this  varies  by  subsite  to  some  extent  (Huang  et  al.,  2002). 
Late-stage  and  high  grade  tumours  have  large  numbers  of  gains  and  losses 
(Hermesen  et  al.,  2001  Bockmuhl,  1996).  In  general,  SCCs  have  more 
alterations  than  dysplastic,  non-invasive  lesions  (Weber  et  al.,  1998).  LoH  has 
also  been  associated  with  poor  prognosis,  particularly  at  distinct  regions  within 
3p  (Partridge  et  al.,  1996)  or  within  22q  (Ashman  et  al.,  2003),  but  little  evidence 
of  specific  patterns  of  abnormality  related  to  risk  of  metastasis  per  se  (Patmore 
et  al.,  2004). 
Loss  of  heterozygozity  at  3p,  9p  and  selected  other  loci,  including  17p  has  been 
associated  with  development  of  SCC,  even  within  lesions  exhibiting  only  mild 
dysplasia  (Lee  et  al.,  2000;  Mao  et  al.,  1996b;  Rosin  et  al.,  2000).  These  areas 
have  been  mentioned  previously  in  relation  to  certain  markers  related  to  the 
development  of  HNSCC,  namely  p53  (17p),  pl6ink4a  (9p2l)  and  RAR-fl  (see 
next  section)  or  a  putative  telomerase  inhibitor  on  3p.  Other,  yet  unidentified 
tumour  suppressor  genes  may  reside  in  other  areas  that  show  high  prevalence 
of  LoH  (Partridge  et  al.,  1999). 
Much  of  the  evidence  for  field  cancerization  in  HNSCC  development  has  come 
from  LoH  analysis  of  multiple  premalignant  and  malignant  lesions  (Taboret  al., 
2002a).  These  lesions  often  have  a  common  pattern  of  LoH,  indicating  a 
common  origin,  with  divergence  at  other  loci  later  within  the  field  (Jang  et  al., 
2001).  Others  have  found  that  other  "early"  markers,  particularly  at  9p2l  can  be 
maintained  over  a  large  area  of  the  mucosa  (Guo  et  al.,  2001).  This  analysis 58 
can  be  used  to  detect  abnormal  cells  in  clinically  normal  mucosa  and  in  the 
resection  margins  of  SCC  and  dysplastic  lesions  to  assess  the  subsequent  risk 
of  development  of  HNSCC  (Partridge  et  al.,  2000a;  Rosin  et  al.,  2002;  van 
Houten  et  al.,  2004;  Zhang  et  al.,  2001). 
The  large  number  of  such  publications  on  patterns  of  LoH  has  resulted  in  the 
development  of  a  model  of  HNSCC  development,  much  along  the  lines  of  the 
Fearon  &  Vogelstein  model  of  colorectal  carcinogenesis  (Fearon  &  Vogelstein, 
1990).  This  model,  proposed  by  Califano  and  coworkers,  is  based  on  a 
progressive  accumulation  of  genetic  alterations  (assessed  by  LoH)  on 
comparison  of  normal,  dysplastic  oral  mucosa  (of  varying  grade)  and  HNSCC 
(Califano  et  al.,  1996).  The  model  is  illustrated  in  schematic  form  in  Figure  2.9. 
However,  this  model  has  certain  weaknesses,  including  the  apparently  false 
assumption  that  lesions  must  progress  through  the  various  grades  of  dysplasia 
before  development  of  SCC.  Additionally,  it  is  possible  that  the  "early  IP 
alterations  detected  (3p,  9p,  17p)  reflect  the  escape  of  the  cells  from  the  growth 
barrier  of  senescence  (RAR-fl,  p16  and  p53  loss  respectively).  The  subsequent 
massive  increase  in  LoH  detected  may  be  the  result  of  subsequent  genomic 
instability  during  ti  crisis  11 
,  an  idea  supported  by  the  much  greater  frequency  of 
allele  loss  reported  in  immortal  HNSCC  cultures  compared  to  mortal  cultures 
(Edington  et  al.,  1995).  This  would  give  rise  to  LOH  at  multiple  sites,  some  of 
which  may  not  be  associated  directly  with  alterations  in  any  particular  gene  in 
relation  to  cancer  progression.  As  described  above,  HNSCCs  and  premalignant 
lesions  often  exhibit  aneuploidy,  which  is  another  feature  in  cells  that  have 
passed  through  crisis.  The  ongoing  increase  in  LoH  in  late  stage  tumours  may 
merely  reflect  continuing  genomic  instability,  and  be  a  function  of  the  amount  of 
time  the  cell  has  been  immortal,  rather  than  related  to  the  disease  process  per 
se.  In  this  way,  immortality  may  be  related  to  disease  progression  and  poor 
prognosis  in  HNSCC- 
2.7.4  Microsatellite  instability 
Microsatellites  are  areas  of  repetitive  DNA  scattered  randomly  throughout  the 
genome.  Alterations  can  occur  if  DNA  replication  is  not  conducted  carefully.  If 
controls  on  normal  DNA  replication  are  lost,  as  may  be  the  case  in  mismatch 
repair  defects,  areas  of  microsatellite  DNA  can  be  added  or  lost.  This  is  termed 59 
microsatellite  instability  (MI).  In  HNSCC,  MI  has  been  demonstrated  with 
increasing  frequency  as  lesions  progress  from  normal  to  dysplastic  and  finally  to 
carcinoma  (Ha  et  al.,  2002b).  The  technique  has  also  been  used  to  detect 
circulating  tumour  cells  in  patients  with  SCC  of  the  oesophagus  (Eisenberger  et 
al.,  2003). 60 
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Figure  2.9  A  model  of  the  clinical,  pathological,  and  molecular 
progression  of  oral  cancer 
This  model  was  proposed  by  Califano  et  al  (Califano  et  al.,  1996). 
Panel  A  shows  the  possible  clinical  presentation  of  oral  cancer.  Molecular 
approaches  have  yielded  considerable  understanding  of  the  field  cancerization 
hypothesis  originally  proposed  by  Slaughter  (Slaughter  et  al.,  1953).  Although 
these  lesions  may  have  histopathological  differences,  as  shown  in  B,  they  are 
often  clonally  related,  arising  from  the  same  field  of  genetic  alterations. 
The  possible  histological  features  seen  in  progression  from  normal-appearing 
mucosa  to  invasive  cancer  are  depicted  in  Panel  B.  Normal-appearing  mucosa 
may  harbor  early  genetic  changes  (Panel  C),  often  with  loss  of  9p2l  (possible 
inactivation  of  p16).  Further  clinical  progression  to  dysplasia  is  associated  with 
further  genetic  changes.  Carcinoma-in-situ  often  harbours  most  of  the  genetic 
changes  described  in  invasive  carcinoma. 61 
2.8  Retinoids  and  differentiation 
Alterations  in  differentiation  may  also  be  linked  with  many  of  the  genetic 
alterations  described  above.  Within  a  stratified  squamous  epithelium,  cells 
undergo  an  organised  series  of  morphological  changes,  culminating  in  the 
presence  of  flattened  cells  on  the  surface  of  the  tissue,  which  may,  or  may  not, 
proceed  to  become  fully  keratinised.  Control  of  the  process  of  differentiation  is 
complex  and  is  accompanied  by  sequential  expression  of  a  number  of 
cytoskeletal  protein  families,  including  the  cytokeratins,  and  involucrin  (Presland 
&  Dale,  2000).  Alterations  in  differentiation  have  been  described  in  HNSCC 
(Kannan  et  al.,  1994;  Rheinwald,  1982),  and  the  level  of  differentiation  is  one  of 
the  important  clinico-pathological  assessments  of  tumours  in  general. 
Vitamin  A  and  its  analogues  are  known  to  play  an  important  role  in  regulating 
the  differentiation  of  epithelial  cells  (Kautsky  et  al.,  1995),  by  binding  to  and 
activating  members  of  the  retinoic  acid/retinoid  receptors,  two  families  of 
transcription  factors  that  are  members  of  the  steroid  hormone  superfamily 
(reviewed  in  Sun  &  Lotan,  2002).  Vitamin  A  is  normally  obtained  from  the  diet 
and  is  transported  and  metabolised  in  the  body  by  a  family  of  transport  proteins, 
cellular  retinol  or  retinoic  acid  binding  proteins  (reviewed  in  Harrison  &  Hussain, 
2001;  Noy,  2000;  Vieira  et  al.,  1995).  In  vivo,  there  is  a  strong  feedback 
mechanism  tightly  regulating  and  limiting  the  serum  level  of  vitamin  A  at  high 
dietary  levels.  However,  synthetic  vitamin  A  analogues  ("retinoids")  can  escape 
this  dose  limiting  mechanism  and  therefore  their  administration  can  result  in 
much  higher  levels  of  retinoid  acid  metabolites  in  vivo. 
Retinoids  regulate  gene  expression  and  thus  modulate  differentiation  and 
growth  in  cells  (Lotan,  1996).  Thus,  there  has  been  much  interest  in  the  effects 
that  deregulation  of  this  system  may  have  in  carcinogenesis.  There  are  two 
main  classes  of  retinoid  receptor  -  RAR  and  RXR,  both  with  several  subtypes. 
The  RAR  family  has  three  main  subtypes  a,  fl  and  y  plus  alternatively  spliced 
variants.  Studies  have  shown  that  RARs  are  present  in  normal  tissue,  some 
showing  RAR-a  and  RAR-y  present  at  all  sites.  Lotan  and  co-workers  found 
RARP  was  only  prominent  in  normal  tissue  from  non-keratinised  intra-oral  sites, 
despite  the  same  group  earlier  finding  no  site  difference  in  distribution  (Lotan, 
1996;  Xu  et  al.,  1994).  Four  isoforms  of  RAR-,  8  have  been  described.  RAR,  81 62 
and  RAR,  83  differ  from  RARfl2  in  the  5'UTR  and  A  coding  region  (see  Figure 
4.11).  RAP,  84  is  generated  by  alternative  splicing  in  exon  1  (Zelent  et  al., 
1991).  Isoform  RAR-,  82  has  been  specifically  linked  with  mediation  of  retinoic 
acid  inhibition  of  growth  in  certain  cells  (Toulouse  et  al.,  2000). 
In  a  variety  of  premalignant  lesions  the  level  of  RARcc  was  found  to  be  slightly 
lower  than  in  normal  epithelium,  but  the  most  dramatic  change  consistently 
found  during  oral  cancer  development  is  the  increasingly  large  reduction  in 
RARP  levels  on  progression  from  hyperplasia  to  dysplasia  to  SCC  (Chakravarti 
et  al.,  2001;  Lotan  et  al.,  1995;  Xu  et  al.,  1994).  Loss  of  RARP  expression  has 
been  reported  in  a  variety  of  other  epithelial  malignancies,  including  lung, 
prostate,  and  breast  (Kikugawa  et  al.,  2000;  Xu  et  al.,  1997). 
In  SCC  and  dysplastic  tissue,  the  close  correlation  of  keratin  19  expression  and 
RAR-fl  expression  is  lost,  representing  aberrations  in  differentiation  (Hu  et  al., 
1991).  It  is  also  associated  with  acquisition  of  the  immortal  phenotype,  as  is 
loss  of  p16  (McGregor  et  al.,  1997).  The  loss  of  RARP  mirrors  the  change  from 
senescence  to  immortality  in  culture  and  work  in  our  laboratory  has  shown  that 
this  is  an  early  event  in  the  development  of  dysplastic  lesions  (McGregor  et  al., 
1997).  However,  Lee  and  coworkers  found  that  loss  of  RARP  gave  a  SCC  risk 
ratio  of  0.9,  suggesting  that,  loss  of  RAR-,  8  alone  was  not  necessarily 
associated  with  poor  prognosis.  This  may  be  due  to  the  modulatory  effect  of 
other  receptors  including  RAR-y  (Lee  et  al.,  2000). 
The  mechanism  of  the  loss  of  RARP  expression  does  not  seem  necessarily  to 
be  deletion,  since  expression  of  RAR,  8  receptors  can  often  be  re-induced  by 
retinoids  (Kurie  et  al.,  2003;  Lotan  et  al.,  1995).  However,  many  studies  have 
implicated  epigenetic  silencing  by  promoter  methylation  in  the  abolition  of  RARj8 
expression  (Virmani  et  al.,  2000),  and  it  has  also  been  linked  with  aberrant 
histone  deacetylation  (Sirchia  et  al.,  2000;  Suh  et  al.,  2002).  Reduction  in  RAR- 
,8  expression  in  some  immortal  dysplasia  cell  cultures  can  be  reversed  by  the 
use  of  de-methylating  agents  such  as  5'aza2'deoycytidine  (McGregor  et  al., 
2002).  The  inducibility  of  RARP  correlates  with  clinical  response  in  leukoplakia 
(Lotan,  1996). 63 
Recently,  retinoids  have  been  implicated  in  the  regulation  of  telomerase.  Not 
only  does  constitutive  expression  of  telomerase  inhibit  differentiation  (Cerezo  et 
al.,  2003),  but  Pendino  and  coworkers  also  found  that  during  retinoid  treatment, 
hTERT  is  down-regulated  and  that  this  occurs  by  two  pathways:  an  immediate 
RAR-mediated  pathway  and  another  indirect  pathway  (Pendino  et  al.,  2001).  In 
normal  cells,  expression  of  telomerase  components  is  reduced  in  response  to 
differentiation  (Yashima  et  al.,  1998).  A  link  to  p53  has  also  been  suggested 
with  stabilised  p53  marking  increased  retinoid  resistance  (Lippman  et  al.,  1995). 
Historically,  vitamin  A  or  synthetic  retinoid  derivatives  have  been  extensively 
tested  in  terms  of  reversing  leukoplakias  and  prevention  of  second  primary 
cancers.  The  rationale  for  this  was  initially  based  on  evidence  that  cancer  risk  is 
greater  in  animals  or  humans  with  vitamin  A  deficiency.  High  dose  retinoids  can 
reverse  histologically  evident  dysplasia,  but  have  significant  skin  toxicity 
(reviewed  in  Lodi  et  al.,  2004).  Lower  doses  of  retinoids  in  combination  with 
interferon  a  and  vitamin  E  are  also  effective,  but  genetic  abnormalities  persist 
(Hong  et  al.,  1986;  Papadimitrakopoulou  et  al.,  1999;  Shin  et  al.,  2001  b). 
Disappointingly,  the  initial  promise  that  retinoids  might  prevent  second  cancers 
developing  has  not  been  confirmed  in  more  recent  trials  (Hong  et  al.,  1990; 
Khuri  et  al.,  2003;  van  Zandwijk  et  al.,  2000). 64 
2.9  Other  markers 
A  large  number  of  studies  have  identified  a  variety  of  other  gene  expression 
changes  in  HNSCCs  compared  to  normal  oral  mucosa  by  analysis  of  RNA 
extracted  from  biopsy  tissue  or  by  immunohistochernistry.  In  several  studies, 
the  expression  of  a  large  number  of  individual  markers  has  been  correlated  with 
outcome  in  univariate  analysis  (Table  2.1).  Not  surprisingly,  these  changes 
affect  a  wide  range  of  cellular  processes  known  to  be  involved  in  cancer 
progression  in  many  cancers,  such  as  kinase  signalling  pathways;  cell 
cycle/apoptosis;  cell  adhesion,  motility  and  invasion;  angiogenesis; 
im  mortal  isation;  chemokines  and  inflammation. 
2.9.1  Cyclooxygenase  2 
Alterations  in  cyclooxygenase  2  (COX2)  have  been  described  in  many  cancers. 
COX2  involvement  was  suspected  from  observations  that  patients  treated  with 
long-term  non-steroidal  anti-inflammatory  drugs  (NSAIDs)  showed  a  reduced 
incidence  of  colorectal  adenomas  and  adenocarcinomas  (Thun  et  al.,  1991; 
Waddell  &  Loughry,  1983).  Subsequent  investigation  demonstrated 
overexpression  of  COX2  in  colorectal  adenoma  and  adenocarcinomas 
(Eberhart  et  al.,  1994). 
COXs  are  members  of  a  family  of  dual  function  enzymes,  prostaglandin 
endoperoxide  synthases,  involved  in  the  generation  of  prostaglandins,  an 
important  class  of  biological  regulators:  COXs  catalyse  the  first  stage,  the 
formation  of  prostaglandin  H2  from  the  fatty  acid,  arachidonic  acid.  COX1  is 
widely  expressed  in  cells,  whereas  COX2  is  inducible  by  mitogens  and  is  also 
highly  expressed  in  many  cancer  types  (reviewed  by  Goodin  &  Shiff,  2004). 
COX2  expression  is  increased  in  high  risk  oral  dysplasias  (Sudbo  et  al.,  2003), 
probably  as  a  consequence  of  EGF  receptor  overexpression  and  activation 
(Matsuura  et  al.,  1999).  Moreover,  normal  human  mammary  epithelia  with 
silenced  pl  6  overexpress  COX2  and  show  features  of  premalignancy  (Crawford 
et  al.,  2004). 
Various  mechanisms  have  been  proposed  to  explain  how  COX2  may  contribute 
to  cancer  progression:  by  producing  reactive  oxygen  species  as  a  by-product  of 
its  catalytic  activity,  stimulating  proliferation,  inhibiting  apoptosis,  modulating 65 
Pathways  affected  Changes  in  expression  References 
Signalling  pathways  EGF  receptor  &  cerbB2  (Ang  et  al.,  2002;  Chen  et 
al.,  2003;  Ulanovski  et  al., 
2004) 
IL13  receptor  a2  (Kawakami  et  al.,  2003) 
phosphatidyl  i  nos  itol-3  kinase  catalytic  (Estilo  et  al.,  2003) 
a  peptide 
RASSF1A  (Kuroki  et  al.,  2003) 
Smad  ubiquitin  ligase  (Smurf2)  (Fukuchi  et  al.,  2002) 
Cell  cycle/apoptosis  cdc2  (Wada  et  al.,  2004) 
p53  mutation  (Geisler  et  al.,  2002; 
Mineta  et  al.,  1998;  Nathan 
et  al.,  2000;  Nogueira  et 
al.,  1998) 
p16 
INMA 
(Bova  et  al.,  1999;  Geisler 
et  al.,  2002) 
p14 
ARF 
(Ogi  et  al.,  2002) 
Cyclin  D1  (Bova  et  al.,  1999; 
Nogueira  et  al.,  1998) 
polo-like  kinase  1  (Knecht  et  al.,  1999) 
surviving  (Lo  Muzio  et  al.,  2003) 
DAP-kinase  (Brock  et  al.,  2003) 
Adhesion/motility  E-cadherin  (Chang  et  al.,  2002;  Chow 
et  al.,  2001;  Lim  et  al., 
2004) 
S100  Ca  ++  regulated  protein  A4  (Moriyama-Kita  et  al., 
2004) 
CD44  (Gonzalez-Moles  et  al., 
2003) 
hyaluronan  (Kosunen  et  al.,  2004) 
metalloproteinase  (MMP)-9  (Katayama  et  al.,  2004) 
tissue  inhibitor  of  MMPs  (TIMPs)1/2/3 
moesin  (Kobayashi  et  al.,  2004) 
DCC  (Ogi  et  al.,  2002) 
periostin  (Bao  et  al.,  2004) 
Angiogenesis  VEGF  (Shintani  et  al.,  2004; 
Uehara  et  al.,  2004) 
HIF-1a  (Beasley  et  al.,  2002) 
Transcription  HMGA2  (Miyazawa  et  al.,  2004) 
BRG1/BRM  (Reisman  et  al.,  2003) 
Chemokines  CXCR4  receptor  (Delilbasi  et  al.,  2004) 
CCR7  receptor  (Ding  et  al.,  2003) 
Immortalisation  telomerase  (Liao  et  al.,  2004) 
Others  COX2  (Chang  et  al.,  2004) 
MINT1  &  MINT  31  (Ogi  et  al.,  2002) 
haern  oxygenase  (Yanagawa  et  al.,  2004) 
SCC-related  oncogene  (Estilo  et  al.,  2003) 
Table  2.1  Gene  expression  changes  in  HNSCC  that  have  been  associated 
with  prognosis  compared  with  normal  mucosa 
The  table  includes  some  genes  that  are  referred  to  elsewhere  in  the  text. 66 
immune  surveillance  or  stimulating  angiogenesis  (Lin  et  al.,  2002).  Moreover, 
inhibition  of  COX2  overexpression  may  be  one  of  the  mechanisms  whereby 
retinoids  inhibit  dysplasia  progression  (Subbaramaiah  et  al.,  2002).  Such  data 
has  led  to  great  interest  in  the  utility  of  specific  Cox-2  inhibitors  in 
chemoprevention  (Koki  et  al.,  2002).  However,  it  is  not  certain  that  inhibition  of 
growth  of  oral  cancer  cells  by  'COX-2-selective'  inhibitors  is  entirely  mediated 
by  reduced  prostaglandin  E2  synthesis  as  the  magnitude  of  growth  inhibition 
seen  can  be  unrelated  to  the  COX2  expression  level  (Minter  et  al.,  2003; 
Schroeder  et  al.,  2004).  Disappointingly,  despite  this  strong  preclinical  data,  a 
recent  randomised,  double-blind,  placebo-controlled  trial  of  the  COX  inhibitor, 
ketorolac,  as  an  oral  rinse  found  no  effect  on  response  rates  of  oropharyngeal 
leukoplakia  (Mulshine  et  al.,  2004).  However,  this  conclusion  should  be 
interpreted  cautiously  since  the  study  lacked  any  investigation  of  biological 
endpoints  in  the  target  tissue  to  establish  the  effectiveness  of  the  treatment  on 
COX  activity. 
2.9.2  Gene  expression  profiling 
More  recently,  several  groups  have  compared  the  overall  gene  expression 
profiles  of  HNSCCs  with  normal  oral  mucosa  by  microarray  analysis.  In  most 
cases,  this  has  been  performed  using  fresh  biopsy  material  (EI-Naggar  et  al., 
2002;  Gonzalez  et  al.,  2003;  Mendez  et  al.,  2002;  Sok  et  al.,  2003)  which 
obviously  contains  stromal  and  immune  cells  in  addition  to  epithelial  cells.  In  a 
few  studies,  pure  epithelial  cell  material  was  obtained  by  laser  capture 
microdissection  (Alevizos  et  al.,  2001;  Leethanakul  et  al.,  2003;  Leethanakul  et 
al.,  2000)  or  pure  epithelial  cell  cultures  were  isolated  (Al  Moustafa  et  al.,  2002). 
Both  approaches  have  their  value,  given  recent  work  in  other  models  indicating 
that  gene  expression  changes  occur  in  both  tumour  stromal  and  epithelial 
compartments  of  epithelial  cancers  and  together  facilitate  cancer  development 
(reviewed  in  Mueller  &  Fusenig,  2002;  Park  et  al.,  2000;  TIsty,  2001). 
Such  studies  have  identified  subgroups  of  HNSCCs  with  gene  expression 
profiles  that  correlate  with  prognosis.  One  study  of  25  primary  HNSCCs,  16 
locally  recurrent  HNSCCs  and  13  normal  oral  mucosa  samples  found  a  gene 
expression  signature  associated  with  recurrence  that  included  markers  of 
proliferation,  extracellular  matrix  proteins,  cytokines  and  chemokines,  and 67 
immune  response  (Ginos  et  al.,  2004).  No  attempt  was  made  to  correct  for 
smoking  status  in  this  study  and  so  this  could  account  for  some  of  the 
differences  in  gene  expression  profiles  between  normal  subjects  and  HNSCC 
patients;  however,  the  prognosis  related  differences  in  gene  expression  profiles 
amongst  HNSCCs  are  likely  to  be  unaffected  since  90%  of  the  patients  were 
smokers.  Another  study  of  60  HNSCCs  (58  of  which  were  from  smokers) 
categorized  the  tumours  into  four  groups  associated  with  statistically  significant 
differences  in  recurrence-free  survival.  These  included  a  subtype  with  a 
possible  epidermal  growth  factor  (EGF)  receptor  pathway  signature,  a 
mesenchymal-enriched  subtype,  a  normal  epithelium-like  subtype  and  a 
subtype  with  high  levels  of  antioxidant  enzymes  (Chung  et  al.,  2004). 
Although  not  directly  relevant  to  HNSCC,  one  study  of  24  oesophageal  SCCs 
and  normal  tissues,  found  a  high  rate  of  relapse  to  correlate  with  expression  of 
molecules  associated  with  cell  cycle  regulation,  gene  repair,  apoptosis  and 
chemoradiotherapy  resistance  (Ishibashi  et  al.,  2003).  Smoking-related  changes 
in  this  study  were  controlled  by  comparing  paired  samples  of  normal  and 
malignant  tissues  from  the  same  patient.  In  another  oesophageal  SCC  study, 
the  gene  expression  signature  profile  associated  with  nodal  metastasis  in  a 
training  set  of  36  cases  was  found  to  be  predictive  in  an  independent  validation 
set  of  18  cases  (Tamoto  et  al.,  2004). 
Gene  expression  profiling  offers  one  potential  approach  for  better  diagnostic 
methods  for  analysis  of  dysplasias  in  relation  to  prognosis.  Ha  et  al  found  that 
there  were  many  more  differences  in  gene  expression  between  normal  and 
premalignant  oral  leukoplakias  (mainly  moderate  to  severe  dysplastic  lesions) 
than  between  these  lesions  and  HNSCCs  (Ha  et  al.,  2003).  However,  no 
information  regarding  correlation  with  progression  was  available  in  this  study. 
Although  not  directly  relevant  to  squamous  cancer,  in  another  premalignant 
model,  Barrett's  oesophagus,  screening  of  the  expression  profiles  of  a  panel  of 
23  genes  revealed  that  expression  of  three  genes  (PITX1,  tetraspanin  and 
thymidine  phosphorylase)  could  distinguish  Barrett's  oesophagus  from 
adenocarcinoma  with  an  error  rate  of  28%  in  a  cross  validation  test  (Brabender 
et  al.,  2004). 68 
2.10  Aims  and  rationale  of  approach 
The  work  described  in  this  thesis  builds  on  the  basis  laid  by  the  earlier 
publications  from  the  group  (McGregor  et  al.,  2002;  McGregor  et  al.,  1997; 
Muntoni  et  al.,  2003).  The  existence  of  mortal  and  immortal  dysplastic  and 
carcinoma  cells,  together  with  the  characterisation  of  the  immortal  phenotype  in 
vitro,  has  allowed  us  to  assess  the  importance  of  some  of  the  various 
components  using  functional  studies. 
However,  sole  use  of  cell  culture  technology  to  investigate  HNSCC 
carcinogenesis  has  significant  problems  and  is  often  subject  to  criticism 
(Ramirez  et  al.,  2001).  Thus,  it  is  vital  that  the  expression  pattern  of  these 
surrogate  immortality  markers  is  established  in  vivo.  This  is  vitally  important  as 
potential  molecular  markers,  be  it  for  prediction  of  prognosis  or  as  potential  for 
therapeutic  intervention,  must  also  show  differential  expression  in  the  oral 
tissues. 
Thus,  this  project  aims  to  address  the  expression  of  the  markers  closely 
associated  with  the  immortal  phenotype  (McGregor  et  al.,  2002)  in  vivo.  The 
further  investigation  of  these  cell  cultures  is  also  mandated,  as  it  is  apparent 
that,  at  least  in  terms  of  dysplasia  progression,  immortality  does  not  entirely 
explain  the  presence  of  a  subset  of  lesions  that  are  at  increased  risk  of 
progression  to  SCC.  Thus,  gene  expression  profiling  has  a  large  part  to  play  in 
identification  of  other  markers  of  immortality  and  of  other  important  events  in 
HNSCC  carcinogenesis,  such  as  early/initiating  events,  markers  of  high  risk  of 
dysplasia  progression  to  carcinoma  and  gene  expression  profiles  related  to 
poor  prognosis  and  recurrence/metastasis  in  HNSCC. 
Studies  with  a  relatively  small  group  of  cell  cultures,  all  derived  from  different 
patients,  are  only  likely  to  suggest  hypotheses  for  future  investigation. 
However,  the  aim  is  to  identify  novel  markers  potentially  important  in  these 
important  events  and  determine  their  expression  in  vivo,  especially  for  mortal 
HNSCC  and  high  risk  dysplastic  cell  cultures.  These  markers  may  then  be 
assessed  in  larger  retrospective  and  prospective  studies,  which  will  ultimately 
determine  the  usefulness  of  these  genes  and  particular  patterns  of  gene 
expression  in  improving  patient  care. 69 
Chapter  Three:  Materials  and  methods 
3.1  Cell  culture 
All  cell  culture  work  was  performed  using  strict  aseptic  techniques  inside  a 
laminar  flow  hood  (Class  11  Microbiological  Safety  Cabinets,  Medical  Air 
technology  Ltd.,  Manchester,  UK).  Epithelial  cells  were  incubated  at  370C  in  90 
mm  Falcon  culture  dishes  in  a  dry  atmosphere  containing  5%  (V/V)  C02 
(Heraeus,  Essex,  UK). 
The  derivation,  characterisation  and  maintenance  of  the  primary  human 
keratinocyte  cultures  have  been  described  previously  (Edington  et  al.,  1995; 
McGregor  et  al.,  1997).  All  cells  were  maintained  on  irradiated  Swiss  3T3 
feeders  (60Gy  from  a  Co60  radiation  source).  The  growth  media  used  were 
flavine  adenine  dinucleotide  (FAD)  growth  medium,  composition  1:  3  Ham's 
F12/Dulbecco's  modified  Eagles  medium  (DMEM)  (both  from  Gibco  BRL 
Europe  Life  Technologies,  Paisley,  UK)  supplemented  with  10%  foetal  bovine 
serum  (FBS),  0.4  yg/ml  hydrocortisone  (Sigma-Aldrich,  Poole,  Dorset,  UK),  5 
/jg/ml  insulin  (Gibco  BRL  Europe  Life  Technologies,  Paisley,  UK  ),  5  /ig/ml 
transferrin  (Sigma-Aldrich,  Poole,  Dorset,  UK),  10-10  M  cholera  toxin  (Sigma- 
Aldrich,  Poole,  Dorset,  UK),  1.8  x  10-4  M  adenine  (Sigma-Aldrich,  Poole,  Dorset, 
UK).  For  FAD'  medium,  10  ng/ml  epidermal  growth  factor  (Gibco  BRL  Europe 
Life  Technologies,  Paisley,  UK)  was  added. 
The  irradiated  3T3  feeders  were  removed  by  treatment  with  phosphate  buffered 
saline  (PBS)/0.02%  EDTA  (PE)  for  15-20  seconds  and  vigorous  pipetting  before 
analysis  of  the  keratinocyte  cultures.  Swiss  3T3  cells  were  maintained  in  10C 
medium  (DMEM  plus  10%  donor  calf  serum  (Sigma-Aldrich,  Poole,  Dorset,  UK). 
A  summary  of  the  clinical  and  biological  features  of  the  cell  cultures  used  in  the 
thesis  is  found  in  Table  3.1. 
Oral  fibroblast  cultures  were  derived  from  the  lamina  propria  related  to  one  of 
the  dysplastic  cell  cultures  (1319).  These  were  maintained  in  10C  medium. 
HeLa  cells  were  maintained  in  modified  Dulbecco's  medium  (Beatson 
formulation)  (Gibco  BRL  Europe  Life  Technologies,  Paisley,  UK)  supplemented 
with  10%  foetal  bovine  serum  (Harlan  Sera-Lab,  Crawley  Down,  Sussex,  UK) 70 
culture  age  sex  smoker  site 
histology/ 
stage 
PDL 
NT  NK  M  N  tongue  normal  25 
NB9  53  M  Y  tongue  normal  17 
FNB3  43  M  N  BM  normal  17 
FNB5  38  IF  N  BM  normal  20 
FNB6  33  IF  N  BM  normal  17 
D6  55  M  Y  tongue  moderate  25 
D8  71  M  Y  tongue  mild  9 
D17  61  M  Y  BM  mild/moderate  45 
D25  58  M  Y  FoM  severe  28 
D30  52  M  Y  FoM  mild  30 
D36  35  M  Y  RM  keratosis  only 
D41  55  F  N  Lattongue  mild  3.5 
D47  82  IF  Y  FoM  moderate  20 
D48  62  IF  Y  FoM/VT  mod/severe  25.5 
El  NK  M  NK  tongue  cis  24 
E2  NK  M  NK  alveolus  cis  17 
E4  55  IF  NK  tongue  Ci  41 
E5  NK  M  NK  tongue  severe  31 
D4  51  M  Y  tongue/FoM  cis  immortal 
D9  84  M  N  tongue  mild/moderate  immortal 
D19  53  M  N  lat  tongue  moderate  immortal 
D20  50  M  N  lat  tongue  mild  immortal 
D34  54  IF  Y  tongue  severe  immortal 
D35  68  M  N  lat  tongue  mild/moderate  immortal 
D38  55  F  Y  FoM  cis  immortal 
BICR30  NK  M  Y  larynx  T4N1  MO  17 
BICR37  NK  M  NK  node 
metastasis  J4 
tongue  SCC)  32 
BICR66  55  M  Y  tongue  T2NOMO  37 
BICR80  NK  M  Y  larynx  T4N2MO  62 
BICR3  57  IF  Y  alveolus  T2NOMO  immortal 
BICR7  43  M  Y  tongue  T4N2cMO  crisis 
BICR22  88  M  Y  tongue 
metastasis 
(Tongue  SCC)  immortal 
BICR31  M  NK  tongue  T4N2bMO  immortal 
BICR56  58  IF  Y  tongue  T4N1MO  immortal 
BICR68  74  M  Y  tongue  T4NOMO  im  mortal 
Table  3.1  Basic  clinical  and  biological  features  of  the  primary  keratinocyte 
cultures  used  in  this  thesis 
Site:  BM  =  Buccal  mucosa,  FoM  =  Floor  of  mouth,  VT  =  ventral  tongue, 
lat=lateral,  RM  =  retromolar 
Histology:  Mild/moderate/severe  refers  to  the  grading  of  dysplasia  in  the 
original  biopsy.  CiS  =  carcinoma  in  situ.  Carcinoma  stage  refers  to  TNM 
classification  at  diagnosis. 
PDL  =  population  doublings  in  culture  before  Senescence. 
In  every  case,  NK  =  not  known 71 
and  1mM  glutamine  (Gibco  BRL  Europe  Life  Technologies,  Paisley,  UK).  W138 
cells  (source)  were  maintained  in  modified  Dulbecco's  medium,  supplemented 
with  5%  fetal  bovine  serum  and  1  mM  glutamine. 
To  freeze  cell  stocks  for  storage,  serniconfluent  cultures  were  trypsinized, 
pelleted  and  re-suspended  at  a  concentration  of  approximately  106  cells/ml  in 
chilled  medium  containing  50%  serum  and  10%  (v/v)  dimethylsulfoxide  (DMSO) 
(Fisher  Scientific,  USA).  Suspensions  were  aliquoted  into  1  ml  cryotubes  (Nunc, 
Wiesbaden,  Denmark),  placed  in  a  polystyrene  box  and  frozen,  well  insulated, 
at  -701C  overnight  to  ensure  a  slow  rate  of  cooling  (11C/min).  The  ampoules 
were  then  transferred  to  a  liquid  nitrogen  tank  until  required. 
Frozen  stocks  were  recovered  by  removing  the  ampoules  from  liquid  nitrogen 
and  placing  them  into  a  small,  covered  bucket  of  water  at  37'C.  Once  thawed, 
the  cells  were  added  to  10  ml  of  the  appropriate  pre-warmed  growth  medium, 
centrifuged,  resuspended  in  fresh  growth  medium  and  transferred  to  90  mm 
Falcon  culture  dishes  (Becton  Dickinson,  Franklin  Lakes,  USA). 
All  cultures  were  tested  for  the  presence  of  mycoplasma  infection.  This  was 
assessed  by  Hoechst  33258  staining  (Chen,  1977).  Briefly,  NRK  cells  were 
incubated  for  3-4d  with  medium  that  had  been  in  contact  with  the  keratinocyte 
culture  for  at  least  2d.  These  cells  were  fixed  with  methanol  (3parts)  and  acetic 
acid  (1  part).  The  fixative  was  then  removed  and  5ml  of  Hoescht  33258 
(Sigma-Aldrich,  Poole,  Dorset,  UK)  added  and  left  for  10  mins.  The  stain  was 
then  removed  and  the  cells  washed  with  distilled  water.  The  cells  were  them 
mounted  in  distilled  water  and  visualised  under  a  fluorescence  microscope. 
Extranuclear  DNA  staining  indicated  mycoplasma  infection.  No  infected  cells 
were  identified  during  the  period  of  this  study. 
Organotypic  culture 
After  initial  growth  in  a  90mm  Falcon  culture  dish,  the  keratinocytes  were  grown 
on  a  collagen/fibroblast  gel  and  raised  to  the  air/medium  interface.  This  allowed 
the  development  of  a  stratified  squamous  epithelium.  The  gel  was  mixed  (on 
ice)  using  8  volumes  of  2mg/ml  rat  tail  collagen  solution  (kindly  provided  by  Dr 
M  Edward,  Department  of  Dermatology,  University  of  Glasgow),  with  1  volume 
of  DMEM  (pH  adjusted  to  7.2  with  sterile  1M  NaOH)  and  1  volume  of  FBS.  To 72 
this  gel  mixture  was  added  2.5x1O5  oral  fibroblasts  per  ml  of  gel.  The  gel  was 
mixed  well  and  1.5ml  added  to  each  Millicell-CM  0-4/.  im  cell  culture  insert 
(Millpore  Corporation,  Bedford,  MA,  USA)  in  a  six-well  cell  culture  plate.  This 
was  incubated  at  370C  for  30  min  to  set  the  gel.  Each  gel  was  then  covered 
with  1ml  of  FAD'  medium  and  incubated  overnight  at  370C.  The  next  day  the 
medium  was  removed  and  the  gels  in  the  inserts  plated  with  8xl  05  oral 
keratinocytes  in  250/il  of  FAD+.  FAD+  was  also  added  each  of  the  wells  in  the 
cell  culture  plate,  adjusted  to  touch  the  underside  of  the  semipermeable 
membrane  on  which  the  collagen/fibroblast  gel  rested.  The  medium  was 
changed  every  2d  for  11  d. 
At  the  end  of  this  period,  the  stratified  epithelium  was  either  scraped  into  RNA 
lysis  buffer,  for  subsequent  extraction  of  RNA,  or  placed,  with  the  gel  intact,  into 
neutral  buffered  formalin  for  fixation  prior  to  histological  examination. 73 
3.2  Detection  of  protein  expression 
3.2.1  SDS-PAGE  and  Western  blotting 
To  prepare  whole  cell  protein  extracts  for  immunoblotting,  cells  in  the 
proliferative  phase  of  growth  were  washed  twice  with  ice-cold  PBS  and  then 
scraped  off  in  0.2ml  of  lysis  buffer  (20mM  Hepes,  pH  6.8,5mM  EDTA,  10mM 
EGTA,  5mM  NaF,  0.1/jg/ml  okadaic  acid,  1  mM  DTT,  OAM  KCI,  0.4%  Triton  X- 
100,10%  glycerol,  5/jg/ml  leupeptin,  50/ig/ml  PMSF,  1mM  benzamidine,  5/jg/ml 
aprotinin,  1  mM  sodium  orthovanadate),  incubated  on  ice  for  20  min,  followed  by 
centrifugation  at  13,000  rpm  in  a  microfuge  for  20  min  and  the  lysate 
(supernatant)  recovered.  The  supernatant  was  stored  at  -700C.  Up  to  50/.  Ig  of 
protein  sample  (quantitated  using  the  bicinchonic  acid-copper  (11)  sulphate 
method,  Smith  et  al.,  1985)  was  mixed  with  an  equal  volume  of  2x  loading 
buffer  (187.5  mM  Tris-HCI,  pH  6.8,30%  glycerol,  6.9%  SIDS,  2.1M  9- 
mercaptoethanol,  0.1%  bromophenol  blue),  boiled  for  10  min  before  SDS- 
polyacrylamide  gel  electorphoresis  (SIDS-PAGE). 
Gels  containing  different  concentrations  of  polyacrylamide  (i.  e.  10%,  12%,  and 
15%)  were  used  to  resolve  proteins  according  to  their  molecular  weights.  The 
resolving  gel  was  made  by  adding  the  appropriate  volume  of  30%  (w/v) 
acrylamide:  0.8%  (w/v)  bis-acrylamide  to  a  solution  of  0.45M  Tris,  0.1%  SDSY 
0.08%  TEMED  and  0.1%  (w/v)  APS.  The  stacking  gel  comprised  of  0.125M 
Tris,  pH6.8,0.1%  SIDS,  1.7ml  30%  (w/v)  acrylamide:  0.8%  (w/v)  bys- 
acrylamide,  0.2%  APS  and  0.3%  TEMED.  Proteins  were  analysed  in  parallel 
with  BenchMarkTm  prestained  protein  ladder  (GibcoBRL,  UK)  and 
electrophoresis  was  performed  o/n  prior  to  transfer  onto  nitrocellulose  using  a 
Camlab  semi-dry  blotter  (Camlab,  UK),  following  the  manufacturer's  protocol. 
The  protein  electrophoresis  for  validation  of  the  microarray  GEPs  used  4-12% 
Bis-Tris  Criterion  XT  precast  gels  (Bio-Rad  Laboratories,  Hercules,  CA,  USA). 
The  18  well  format  of  the  gel  allowed  for  analysis  of  a  large  number  of  cultures 
on  one  gel.  A  Bio-Rad  Criterion  wet  blotter  (Bio-Rad  laboratories,  Hercules, 
CA,  USA)  was  used  for  the  transfer  to  nitrocellulose  membrane,  according  to 
the  manufacturer's  instructions. 74 
Western  blots  were  blocked  overnight  at  40C  in  the  presence  of  TBST  (50mM 
Tris  pH  7.5,50mM  NaCl,  1  mM  EDTA,  0.1  %  Tween-20)  containing  5%  non  fat 
dried  milk;  washed  4x  10min  with  TBST  and  then  incubated  with  antibodies 
diluted  in  TBST  containing  5%  non  fat  dried  milk  or  0.1-1%  bovine  serum 
albumin  (according  to  antibody  manufacturer's  instruction)  and  0.1%  sodium 
azide.  The  antibodies  and  their  dilutions  are  shown  in  Table  3.2.  Following 
incubation  with  the  primary  antibody  the  membrane  was  washed  4x  10  minutes 
with  TBST.  This  was  followed  by  incubation  in  20ml  of  a  1:  3000  dilution  of  the 
appropriate  IgG  HRP-linked  antibody  in  blocking  buffer  for  1.5h.  The  secondary 
antibody  solution  was  removed  and  the  membrane  was  washed  3x  10  minutes 
with  TBST.  After  removal  of  excess  surface  liquid,  bound  primary  antibody  was 
detected  using  ECL  chemiluminescent  reagent  (Amersham,  UK)  source 
according  to  manufacturer's  instructions. 
For  loading  controls,  the  membranes  were  reprobed  with  a  polyclonal  antibody 
against  total  p38  MAP  kinase  to  ensure  even  loading  and  transfer  since  it  was 
found  to  be  uniformly  expressed  in  all  keratinocyte  cultures  regardless  of 
proliferative  fate.  The  blots  were  stripped  by  incubation  for  30min  with  1x 
Stripping  buffer  (100mM  2-mercaptoethanol,  2%  SDS,  62.5mM  Tris-HCI  pH6.7) 
at  550C.  The  membrane  was  washed  3  times  with  TBST  prior  to  proceeding  to 
blocking  and  subsequent  antibody  incubation. 
Antigen  Clone  Source  Dilution 
p16  F12  Santa  Cruz  Biotechnology,  Santa 
Cruz,  CA,  USA 
1:  250 
p53  D01  Santa  Cruz  Biotechnology  1:  200 
p38  MAPK  Cell  Signalling  Technology,  USA  1:  1000 
UBE2C  Abcam  Limited,  Cambridge,  UK  1:  500 
Cyclin  B1  GNS1  Neomarkers,  Fremont,  CA,  USA  1:  500 
SMC41-i  state,  Lake  Placid,  NY,  USA  1:  250 
Involucrin  Cancer  Research  UK  monoclonal 
antibody  service 
1:  5000 
S1  0OA9  C-1  9  Santa  Cruz  Biotechnology  1:  100 
lGFBP2  H-75  Santa  Cruz  Biotechnology  1:  200 
Table  3.2  Primary  antibodies  used  for  Western  blotting 75 
3.2.2  Preparation  of  routine  histopathological  sections. 
Tissue  specimens  5,  um  in  thickness  were  cut  using  a  Leica  2035  Microtome 
(Leica,  Heidelberg,  Germany)  and  then  mounted  on  plain  glass  sides.  These 
were  then  oven  dried  for  15  minutes.  The  sections  were  deparaffinized  for  30 
minutes  using  Histoclear  (Fisher  Scientific,  USA)  followed  by  xylene  for  10 
minutes.  Rehydration  was  carried  out  sequentially  in  100%  and  20%  ethyl 
alcohols  (5  minutes,  each  step)  and  finally  water.  The  sections  were  then 
stained  using  haematoxylin  and  eosin  (H&E,  Surgipath,  Peterborough,  UK), 
dehydrated,  mounted  with  a  coverslip  using  Histomount  (Hughes  &  Hughes, 
Wellington,  UK). 
3.2.3  Immunohistochemistry  (IHC) 
For  immunohistochernistry,  fresh  5/im  sections  were  cut  from  the  relevant 
diagnostic  paraffin  blocks  and  mounted  on  silane-coated  slides.  The  sections 
were  rehydrated  as  described  above  and  then  incubated  in  0.3%  H202  for  20 
minutes  followed  by  a5  minute  wash  in  distilled  water.  The  sections  were 
microwaved  in  1.51  of  citrate  buffer  for  4.5  minutes  at  full  power  (once  full 
pressure  had  been  reached).  Immunohistochernistry  was  carried  out  using  the 
Vectastain  ABC  (avid  in-biotin-peroxidase,  Vector  Laboratories,  Burlingame,  CA, 
USA)  kit  for  mouse  or  rabbit  IgG,  as  appropriate,  according  to  manufacturer's 
instructions.  The  washing  buffer  used  at  all  stages  was  PBS  pl-17.6  with  0.1% 
BSA  fraction  V,  as  this  reduces  non-specific  antibody  binding. 
The  p53  lHC  was  performed  on  a  DakoCytomation  Autostainer 
(DakoCytomation  Denmark).  For  all  other  lHC,  the  sections  were  incubated 
with  primary  antibody  overnight  at  40C  in  a  moist  chamber.  The  antibodies  used 
are  shown  in  Table  3.3.  Peroxidase  substrate  DAB  (3,3'-diaminobenzidine)  kit 
(Vector  Laboratories,  Burlingame,  CA,  USA)  was  used  to  visualize  the  primary 
antibody  according  to  manufacturer's  instructions.  Counterstaining  was  carried 
out  using  haematoxylin  and  the  section  dehydrated  with  sequential  treatment 
with  water,  70%  and  100%  ethanol,  and  xylene.  Finally  the  section  was 
mounted  in  Histomount  and  covered  with  a  coverslip. 76 
Antigen  Clone  Source  Dilution 
p16  F12  Santa  Cruz  Biotechnology,  Santa  Cruz, 
CA,  USA 
1:  200 
p5  D01  Santa  Cruz  Biotechnology  1:  300 
Involucrin  Cancer  Research  UK  monoclonal 
antibody  service 
1:  10000 
Cyclin  B1  GNS1  Neomarkers,  Fremont,  CA,  USA  1:  800 
S1  0OA9  C-1  9  Santa  Cruz  Biotechnology  1:  700 
Table  3.3.  Primary  antibodies  used  for  immunohistochemistry 
3.2.4  Histopathological  image  capture 
Routine  H&E  sections  and  immunohistochernistry  were  visualised  using  a  Zeiss 
Axioskop  20  microscope  (Zeiss,  Germany)  with  an  appropriate  light  source  and 
photornicrographs  recorded  using  the  AxioVision  ver.  3.0.6  software  (Zeiss, 
Germany).  The  images  were  cropped  in  Adobe  Photoshop  Elements  (Adobe 
Systems  Incorporated,  San  Jose,  CA,  USA. 
3.3  Laser  capture  microdissection  (LCM) 
Fresh  6/im  sections  were  cut  from  the  relevant  diagnostic  paraffin  blocks  and 
mounted  on  plain  glass  slides,  a  maximum  of  24  hours  before  use.  The 
sections  were  rehydrated  and  briefly  stained  with  haernatoxylin  and  eosin.  The 
slides  were  then  maintained  in  a  dry  environment  under  a  slight  vacuum.  The 
LCM  was  conducted  using  the  Arcturus  Pixcell@  Ile,  according  to  the 
manufacturer's  instructions  (Arcturus  Bioscience,  Mountain  View,  CA,  USA). 
The  Arcturus  LCM  cap  was  located  on  the  apparatus  and  then  placed  on  the 
tissue  section.  The  cells  required  were  identified.  A  pulse  laser  was  then  used 
to  target  these  cells  and  the  cap  removed  with  the  target  cells  adherent  to  the 
cap  (see  Figure  3.1). 77 
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Figure  3.1  Laser  capture  microdissection  for  sampling  of  epithelium  from 
tissue  sections. 
Panels  show  formalin  fixed  tissue  stained  with  Haematoxylin  and  eosin  and 
demonstrate  the  process  of  laser  capture  microdissection  using  the  Arcturus 
Pixcell@  Ile.  The  captured  epithelium  was  subsequently  be  digested  to  release 
the  DNA  for  PCR. 78 
3.4  DNA  extraction  from  archival  tissue 
DNA  was  extracted  from  the  microdissected  material  by  Proteinase  K  digestion, 
as  outlined  by  Going  (Going,  2003).  Briefly,  the  microdissected  tissue  was 
digested  overnight  in  50,  ul  of  proteinase  K  digestion  buffer  at  371C.  The  tube 
was  inverted  to  ensure  that  the  entire  surface  of  the  LCM  cap  was  covered. 
Proteinase  K  was  then  inactivated  by  heating  at  950C  for  10  min.  5/il  of  this 
digest  was  used  in  a  standard  PCR  reaction.  The  DNA  in  the  digest  was 
amplified  using  GAPDH  nested  primers  to  confirm  the  isolation  of  DNA  from  the 
tissue  (Table  3.4). 
3.4.1  p53  sequencing. 
This  was  performed  using  the  proofreading  DNA  polymerase,  Proofstart 
(Qiagen,  Crawley,  UK)  and  primers  outlined  in  Table  3.4.  These  nested  primers 
were  designed  using  the  Prime  program  (GCG  Wisconsin  package,  Accelrys 
Ltd,  Cambridge,  UK).  The  primers  used  amplified  a  short  product  that  covered 
the  mutation  previously  demonstrated  in  the  relevant  culture  (McGregor  et  al., 
2002).  A  small  aliquot  of  cDNA  product  was  assessed  by  5%  acrylamide  gel 
electrophoresis  in  Tris-borate-EDTA  buffer  (TBE),  to  check  for  the  presence  of 
product  of  correct  size  and  the  absence  of  non-specific  products.  The  gel  was 
subsequently  stained  with  ethidium  bromide  (Sigma-Aldrich,  Poole,  Dorset,  UK). 
The  UVIdoc  gel  documentation  system  (Uvitech,  Cambridge,  UK)  was  used  to 
visualise  the  gel. 
Sequencing  of  fragments  in  both  directions  was  performed  according  to  the 
manufacturer's  protocols  (ABI  prism  big  dye  terminator  reaction  kit,  Applied 
Biosystems,  Foster  City,  CA,  USA).  Where  a  mutation  was  found  by  reading  the 
traces  by  eye,  the  result  was  confirmed  using  an  independent  PCR  amplification 
product. 
As  the  standard  sequencing  protocol  was  unsuccessful  for  DNA  from  D9  and 
D20,  the  PCR  products  were  cloned  using  the  TOPO  TA  cloning  kit  (Invitrogen 
Ltd,  Paisley,  UK).  A  non  proofreading  Taq  polymerase  was  used  for  the  PCR 
reaction  to  provide  the  necessary  TA  overhang  for  cloning  into  the  pCR4-TOPO 
constructs.  The  constructs  were  transformed  into  TOP10  competent  E-coli. 
Once  colonies  had  formed,  they  were  picked  and  DNA  minipreps  prepared. 79 
The  DNA  was  then  sequenced  using  T3  and  T7  primers,  as  described  above. 
This  work  was  completed  by  Janis  Fleming. 
Sample  Sequence  Product  Annealing 
size  (bp)  temp  (*C) 
5'-ACTTTCAACTCTGTCTCCTTCC-3' 
5'CCATCGCTATCTGAGCAGC-3'  218  57 
D4  &  D19 
5'-CCCTGCCCTCAACAAGATG-3' 
5'-ACAACCTCCGTCATGTGC-3'  137  56 
5'-GCTTTTGATCCGTCATAAAGTC-3' 
'  144  53  5  -TGGGCATCCTTGAGTTCC-3' 
D9 
5'-ACTTACTTCTCCCCCTCCTC-3' 
'  77  53  5  -CCTCATTCAGCTCTCGGAAC-3' 
5'-AGGTTGGCTCTGACTGTACC-3' 
'  116  54  5  -TGACCTGGAGTCTTCCAGTG-3' 
D20 
5'-GTGTAACAGTTCCTGCATGG-3'  69  52  5'-GAGTCTTCCAGTGTGATGATG-3' 
5'-ATGCCTTCTTGCCTCTTGTC-3'  145  52  5'-CTCACCATGTAGCACTCACC-3' 
GAPDH 
5'-GATTTGGTCGTATTGGGCG-3'  93  51  5'-TGAGGTCAATGAAGGGGTC-3' 
Table  3.4  Nested  oligonucleotide  primers  used  for  p53  sequencing 
These  primers  were  used  for  sequencing  of  culture  and  LCM  tissue  derived 
DNA.  Sample  refers  to  the  tissue  related  to  the  culture  indicated. 80 
3.5  Semi-quantitative  reverse  transcription  polymerase  chain  reaction 
(RT-PCR)  assay. 
RNA  was  extracted  from  the  cultured  cells  using  Qiagen  RNeasy  minikit 
(Qiagen  GmbH,  Hilden,  Germany)  according  to  the  manufacturer's  instructions. 
After  thawing,  the  tissue  samples  were  disrupted  and  homogenised  in  the 
presence  of  the  RNEasy  lysis  buffer  using  Omni-tip  disposable  generator 
probes  in  an  OMNI  TH220  tissue  homogeniser  (Omni  international  Inc  Marietta, 
GA,  USA).  On  column  IDNase  digestion  was  performed  during  the  RNA 
purification,  using  the  RNase-Free  IDNase  Set  (Qiagen  GmbH,  Hilden, 
Germany).  RT-PCR  was  performed  using  the  GeneAmp  RNA  PCR  core 
reagent  kit  (Perkin  Elmer,  Branchberg,  NJ,  USA)  according  to  the 
manufacturer's  protocols. 
The  p16  primers  used  were  p16FP  and  p16RP  (Table  3.5).  These  primers 
were  designed  to  span  the  intron  between  exons  la  and  2,  thus  giving 
specificity  for  p16  and  avoiding  amplification  of  any  contaminating  DNA.  The 
hTERT  primers  used  were  MS1  13  and  MS1  14,  as  described  by  Dome  and  co- 
workers  (Dome  et  al.,  1999).  Primers  used  in  the  detection  of  hTERT  deletion 
splice  variants  (TERT2109  and  TERT2531R)  were  those  previously  published 
by  Yi  and  coworkers  (Yi  et  al.,  2001).  The  hTR  primers  were  those  published 
by  Harada  and  co-workers  (Harada  et  al.,  2001).  The  RARfl2  primers  used 
were  RARfl2FP  and  RARfl2RP  as  described  by  Sirchia  and  coworkers  (Sirchia 
et  al.,  2000).  In  each  experiment,  the  levels  of  GAPDH  mRNA  were  also 
measured  as  an  internal  control.  The  sequences,  product  size  and  optimal 
annealing  temperature  for  each  of  these  oligonucleotide  primer  sets  are  set  out 
in  Table  3.5.  The  reactions  were  carried  out  on  a  PCT200  DNA  engine  (MJ 
Research,  Massachusetts,  USA),  according  to  the  manufacturers  instructions. 
The  cDNA  product  was  assessed  by  5%  acrylamide  gel  electrophoresis  in  TBE 
and  subsequent  staining  of  the  gel  by  addition  of  50/il  of  5mg/ml  ethidium 
bromide  (Sigma-Aldrich,  Poole,  Dorset,  UK),  to  500ml  water  (final  concentration 
0.5/ig/ml).  The  UVIdoc  gel  documentation  system  (Uvitech,  Cambridge,  UK) 
was  used  to  visualise  the  gel.  The  gel  images  were  captured  as  Aiff  files. 81 
product  annealing  Gene  Sequence  (forward/reverse) 
(bp)  temp  (*C) 
5'-TGCCCAACGCACCGAATAG-3' 
p16  176  60 
5'-CACCAGCGTGTCCAGGAAG-3' 
5'-AGAGTGTCTGGAGCAAGTTGC-3' 
hTERT  150  60 
5'-CGTAGTCCATGTTCACAATCG-3' 
hTERT  5'-GCCTGAGCTGTACTTTGTCAA-3' 
various*  64 
(DV)  5'-AGGCTGCAGAGCAGCGTGGAGAGG-3' 
5'-TTTGTCTAACCCTAACTGAGAAG-3' 
hTR  128  62 
5'-TTGCTCTAGAATGAACGGTGGA-3' 
5'GACTGTATGGATGTTCTGTCAG-3' 
RARfl2  256  62 
5'-ATTTGTCCTGGCAGACGAAGCA-3' 
5'-AAGGCTGAGAACGGGAAGCTTGTCATCAAT-3' 
GAPDH  146  60 
5'-AGCCCCAGCCTTCTCCATGGTGGTGAAGAC-3' 
Table  3.5  Oligonucleoticle  primers  used  for  RT-PCR. 
DV  =  deletion  variants.  *  The  size  of  the  products  of  the  hTERT  deletion  variant 
RT-PCR  are  seen  in  Figure  4.7 
The  hTERT  deletion  splice  variants  were  visualised  using  the  Agilent  2100 
Bioanalyzer  (Agilent  technologies,  Germany).  RNA  was  loaded  into  the  RNA 
6000  Nano-chip  in  a  loading  gel  and  with  dye  concentrate  (Agilent  technologies, 
Germany).  The  Bioanalyzer  separates  the  different  sizes  of  RNA  in  the  sample 
by  microcapillary  electrophoresis.  The  different  components  are  detected  by 
laser  induced  fluorescence  of  the  dye  that  intercalates  directly  with  the  RNA. 
The  output  may  be  viewed  as  either  gel-like  images  or  electropherograms 
(Figure  3.2). 82 
3.6  Microarray  RNA  preparation  and  quality  control 
Total  cellular  RNA  was  isolated  from  the  cell  cultures  using  the  Qiagen  RNeasy 
minikit  (Qiagen  GmbH,  Hilden,  Germany)  according  to  the  manufacturer's 
instructions.  The  RNA  was  homogenized  at  the  appropriate  point  in  the  RNeasy 
kit  instructions  using  the  QlAshredder  homogenizer  (Qiagen  GmbH,  Hilden, 
Germany)  according  to  the  manufacturer's  instructions. 
Initially,  the  quality  of  the  RNA  was  assessed  by  spectrophotometry.  Only  RNAs 
with  a  260/280nm  ratio  of  >1.9  were  of  sufficient  quality  to  proceed  to  the 
labelling  stage.  At  the  end  of  the  labelling  and  fragmentation  process,  all  the 
products  were  assessed  using  an  RNA  denaturing  1.1  %  forma  Idehyd  e/aga  rose 
gel  electrophoresis  in  MOPS  buffer.  Later  samples  were  analysed  using  the 
Agilent  2100  Bioanalyzer,  (see  earlier).  Samples  with  28S/18S  ratio  <2.0  were 
rejected  (Figure  3.2).  In  either  analysis,  the  integrity  of  the  initial  RNA  was 
demonstrated  and  the  expected  size  distributions  for  the  cRNA  and  fragmented 
cRNA  were  confirmed. 
3.6.1  Sample  labelling  and  microarray  analysis 
Amplification  and  labelling  of  the  RNA  in  the  pilot  and  main  studies  were 
performed  using  the  Affymetrix  standard  labelling  protocol.  An  outline  of  this 
protocol  is  illustrated  in  Figure  3.3.  Briefly,  15/ig  total  RNA  was  reverse 
transcribed  using  the  Superscript  double  stranded  clDNA  synthesis  kit, 
according  to  manufacturer's  instructions  (Invitrogen  Ltd,  Paisley,  UK)  and 
T7(dT)24  primer  (Helena  Biosciences,  Sunderland,  UK).  The  clDNA  was  purified 
using  buffer  saturated  phenol/chloroform/isoamyl  alcohol  (Ambion  Inc,  Austin 
TX,  USA)  in  Phase  lock  gel  (light)  tubes  (Helena  Biosciences,  Sunderland,  UK). 
In  vitro  transcription  (IVT)  was  performed  using  the  Enzo  Bioarray  high-yield 
transcript-labelling  kit  (Affymetrix,  Santa  Clara,  CA,  USA),  according  to  the 
manufacturer's  instructions.  Subsequent  purification  of  the  cRNA  was  carried 
out  by  the  RNEasy  minikit  RNA  clean-up  protocol  (Qiagen,  GmbH,  Hilden, 
Germany).  If  the  yield  from  IVT  was  <40/ig,  the  reaction  was  repeated,  as  it  was 
assumed  that  there  had  been  a  problem  with  the  IVT  reaction. 83 
A 
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Figure  3.2  Quality  control  measures  for  RNA  for  microarray  analysis 
Total  RNA  was  analysed  on  Agilent  2100  Bioanalyser  using  RNA  nanochips. 
Panel  A  shows  a  "virtual  gel"  trace  of  for  QC  of  array  samples 
L=Iadder 
Lanes  1-3  BICR30a  total  RNA,  labelled  cRNA  and  fragmented  cRNA 
Lanes  4-6  BICR30b  total  RNA,  labelled  cRNA  and  fragmented  cRNA 
Panel  B  shows  traces  for  lanes  1  and  3,  showing  18S  and  28S  peaks.  Samples 
with  28S/18S  ratio  <2.0  were  rejected.  Further  QC  was  conducted  at  the  PICR 
with  test  chips  used  for  certain  samples. 84 
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Labelled  cRNA  targets  derived  from  the  mRNA  (via  cDNA)  of  each  experimental 
sample  are  hybridized  to  nucleic  acid  probes  attached  to  the  solid  support.  By 
monitoring  the  amount  of  label  associated  with  each  oligonucleotide  location,  it 
is  possible  to  infer  the  abundance  of  each  mRNA  species  represented.  Figure 
courtesy  of  Affymetrix. 85 
The  cRNA  was  fragmented  in  buffer  containing  200mM  Tris-acetate,  pH8.1, 
500nM  KOAc  and  150mM  MgOAc  for  35mins  at  940C.  After  visualisation  of  the 
products  and  quality  control  as  described  above,  the  fragmented  cRNA  was 
sent  on  dry  ice  to  the  CRUK  microarray  core  facility  at  the  Paterson  Institute  for 
Cancer  Research  in  Manchester,  UK.  The  cRNA  was  hybridised  to  Affymetrix 
U133A  genechips  for  the  pilot  and  tissue/culture  comparison  experiments  and 
U133A  and  B  gene  chips  for  the  main  study.  The  cRNA  was  processed 
according  to  the  method  outlined  in  the  GeneChip@  Expression  Analysis 
Technical  Manual.  The  hybridisation  cocktail  was  prepared  using  the 
fragmented  target  cRNA,  with  probe  array  controls,  BSA  and  herring  sperm 
DNA.  The  hybridisation  process  was  then  carried  out  in  the  GeneChip 
hybridisation  oven  640  (Affymetrix,  Santa  Clara,  CA,  USA).  Immediately  after 
hybridisation,  the  array  underwent  an  automated  washing  and  staining  protocol 
on  the  GeneChip  fluidics  station  450  (Affymetrix,  Santa  Clara,  CA,  USA).  The 
genechips  were  scanned  using  the  GeneChip  scanner  3000  with  autoloader 
(Affymetrix,  Santa  Clara,  CA,  USA)  and  the  resultant  raw  data  returned  to  BICR 
for  analysis. 86 
3.7  Microarray  data  analysis 
The  first  step  in  data  analysis  was  quality  assessment  of  the  data.  A  number  of 
elements  were  assessed,  two  of  which  are  vitally  important.  Firstly,  the  number 
of  probe  sets  detected  should  be  similar  for  the  arrays.  The  second 
assessment  concerned  the  housekeeping  genes.  The  Signal  375'  ratio  of  the 
GAPDH  and  P-actin  probe  controls  should  ideally  be  1,  but  values  up  to  3  were 
considered  acceptable.  Higher  values  indicate  either poor  quality  starting  RNA 
or  poor  1  st  strand  cDNA  synthesis.  This  occurred  with  only  one  sample,  and 
this  preparation  was  repeated. 
The  data  was  analysed  in  a  standard  fashion  as  outlined  in  Figure  5.1.1.  The 
raw  data  was  Iog2  transformed  and  normalized  using  the  Robust  Multi  Average 
(RMA)  method  of  Irizzary  and  coworkers  (Irizarry  et  al.,  2003),  as  implemented 
in  RMAExpress.  This  is  available  for  download  from  hftp:  //stat- 
www.  berkeley.  edu/users/bolstad/RMAExpress/  RMAExpress.  htmi 
. 
The  data 
was  also  loaded  to  the  Affymetrix  microarray  analysis  suite  (MAS)  6.0.  The 
perfect  match  (PM)  and  mismatch  (MM)  oligonucleotides  were  analyzed  and  the 
"Absent",  "Marginal"  or  "Present"  tags  recorded.  Only  probesets  which  had  6  or 
more  "Present"  flags  for  that  particular  gene  across  the  whole  dataset  of  80 
arrays  were  forwarded  to  further  analysis.  Finally,  after  ascertaining  that  the 
reproducibility  of  the  two  culture  replicates  was  good,  the  mean  of  the  replicates 
was  calculated  and  this  figure  was  used  for  further  analysis  of  the  expression  of 
a  particular  gene  in  a  sample. 
The  expression  data  for  the  normalized,  filtered  genes  were  loaded  in  to 
Bioconductor  in  R  (Gentleman  et  al.,  2004),  TMeV  (http:  //www.  tiqr.  orq/ 
software/tm4/  mev.  html,  TIGR,  Rockville,  MID,  USA),  and  Genespring  6.0 
(Silicon  Genetics,  Redwood  City,  CA,  USA),  after  conversion  to  an  appropriate 
format. 
3.7.1  Statistical  analysis 
Statistical  analysis  was  conducted  in  TMeV  using  SAM  (original  method  by 
Tusher  et  al.,  2001).  Comparison  of  the  various  groups  was  carried  out  using  all 
possible  permutations  and  the  SO  factor  derived  at  the  5th  percentile  (Quon  et 87 
al.,  2001).  This  is  preferable  to  the  original  Tusher  et  al  method  as  this  allowed 
for  tighter  control  of  the  FDR.  Genes  were  considered  significantly  differentially 
expressed  at  FDR  1%  with  fold  change  ýý  2.  Analysis  of  the  data  was 
conducted  in  parallel  by  Keith  Vass  in  BICR,  using  ANOVA,  implemented  in  the 
Bioconductor  package  for  R. 
3.7.2  Annotation 
The  resultant  gene  lists  were  annotated  using  the  Affymetrix  Netaffx  analysis 
center  (hftp:  //www.  affymetrix.  com/analysis/index.  affx),  and  Expression  Analysis 
Systematic  Explorer  (EASE,  hftp:  //apr)sl.  niaid.  nih.  gov/david/,  Hosack  et  al., 
2003).  These  tools  allow  for  functional  annotation  and  linkage  to  multiple 
databases  The  relative  overrepresentation  of  biological  process  and  molecular 
function  Gene  Ontology  terms  (Ashburner  et  al.,  2000)  within  the  gene  lists  was 
assessed  by  Fisher  exact  probability  (p<0.05).  This  algorithm,  which  is  very 
similar  to  a  Chi-square  test,  assesses  the  frequency  of  a  particular  GO  term  in 
the  given  (statistically  significant)  list  relative  to  the  abundance  of  that  term  in  all 
the  annotated  genes  on  the  chip. 88 
Chapter  Four:  Comparison  of  markers  previously  characterised  in 
cultures 
4.1  Introduction 
Our  series  of  primary  cultures  covers  all  stages  of  the  development  of  oral 
cancer  and  provides  a  unique  opportunity  to  study  each  stage  within  a  defined 
system.  It  has  also  given  us  the  ability  to  assess  the  importance  of  particular 
molecular  changes  in  functional  studies  (Muntoni  et  al.,  2003).  However,  the 
relationship  of  the  pattern  of  gene  expression  seen  in  the  cell  cultures  to  that  in 
the  tissue  of  derivation  had  not  been  evaluated.  This  question  was  addressed 
by  in  vivo  analysis  of  the  well-characterised  gene  expression  changes 
associated  with  the  immortal  phenotype,  which  have  been  previously  published 
(McGregor  et  al.,  2002). 
The  in  vivo  material  used  in  these  comparisons  came  from  two  sources: 
1.  Fresh  tissue  frozen  at  the  time  of  establishment  of  the  cultures  and 
subsequently  stored  at  -80*C.  The  amount  of  total  RNA  recovered  from 
the  biopsies  varied  from  1pg  to  19yg.  Total  cellular  RNA  was  extracted 
from  this  tissue  as  RNA  allowed  the  widest  range  of  analyses  of  the 
limited  amount  of  material  using  techniques  and  reagents  available  at  the 
time. 
2.  Paraffin  wax  blocks  of  formalin  fixed  biopsy  tissue.  This  material  was 
used  for  IHC  and  extraction  of  genomic  DNA  after  LCM. 
One  caveat  in  the  comparison  of  the  diagnostic  biopsy  of  origin  and  the  culture 
is  that  it  is  impossible  to  be  certain  of  the  spatial  relation  of  the  portion  of  the 
biopsy  that  gave  rise  to  the  culture  and  the  relevant  wax  embedded  tissue 
block.  This  is  less  of  a  problem  with  the  fresh  tissue  left  after  the  establishment 
of  the  culture.  Since  these  samples  were  so  small,  it  is  reasonable  to  assume 
that  it  was  in  close  proximity  to  the  portion  of  the  lesion  that  gave  rise  to  the 
culture.  This  chapter  assesses  the  agreement  between  the  original  tissue  and 
the  derived  cell  culture  regarding  the  expression  of  p16,  telomerase  (catalytic 
component,  hTERT  and  RNA  template,  hTR),  p53  and  retinoic  acid  receptor 
beta  2  (RAR82)- 89 
Overall  methodological  approach 
The  analysis  of  the  biological  material  from  the  cultures  and  the  tissues  utilised 
techniques  that  are  inherently  semiquantitative  in  nature.  The  RNA  analysis  by 
RT-PCR  required  careful  selection  of  cycle  numbers  and  experimental 
conditions  to  ensure  that  the  reaction  was  limited  to  the  linear  part  of  the  PCR 
reaction  curve.  This  allowed  for  serniquantitative  comparison  of  gene 
expression  in  the  samples.  The  analyses  were  conducted  at  least  three  times 
using  different  amounts  of  RNA  from  the  cultures  and  varying  reaction 
conditions  to  assess  this.  Once  the  conditions  were  optimised,  the  material 
from  the  biopsies  was  analysed  and  this  was  also  repeated  to  ensure  a 
representative  and  repeatable  result  was  obtained.  In  each  case,  GAPDH  was 
amplified  from  the  same  cDNA  to  ensure  an  equal  amount  of  material  had  been 
used  in  each  reaction.  GAPDH  is  useful  in  the  assessment  of  loading  equality, 
as  it  does  not  change,  regardless  of  the  proliferative  fate  of  the  cells.  Most  of 
the  primers  used  came  from  established  methodologies  in  the  literature.  These 
are  acknowledged  in  the  appropriate  section  (see  methods).  The  primers  for 
p16  were  selected  using  the  primer  design  program  Prime,  with  care  taken  to 
ensure  that  the  fragment  amplified  was  part  of  exon  la  of  the  CDKN2a  locus, 
thus  ensuring  p16  specificity. 
Each  Western  blot  was  repeated  at  least  once.  Total  p38  was  used  to  assess 
equality  of  whole  cell  extract  loading.  The  activity  of  this  protein,  a  constituent 
of  the  MAP  kinase  signalling  pathway,  is  primarily  regulated  by  phosphorylation. 
The  expression  of  total  p38  (regardless  of  phosphorylation  state)  is  constant 
regardless  of  the  proliferative  state  and  fate  of  cells  in  culture,  thus  it  is  useful  in 
assessment  of  protein  loading  in  Western  blotting. 
The  IHC  protocol  had  been  developed  by  Ken  Parkinson's  group  in  BICR  (see 
methods).  This  was  optimised  as  appropriate  for  each  different  antibody.  For 
each  tissue  sample  an  unrelated  primary  IgG  control  was  processed  in  parallel. 
This  allowed  for  assessment  of  non-specific  binding  of  antibody.  The  staining 
was  repeated  to  assess  consistency  in  the  intensity  and  extent  of  staining. 
However,  only  sections  that  had  been  stained  in  the  same  run  were  directly 
compared.  No  quantitation  of  staining  was  conducted  and  the  resulting 
assessment  is  descriptive. 90 
4.2  p1l  6 
The  p16  protein,  is  an  inhibitor  of  the  Cyclin  D1/CDK4  complex.  This  complex 
phosphorylates  retinoblastoma  protein  (Rb),  allowing  the  cell  cycle  to  progress. 
Thus,  p16  acts  as  a  cell  cycle  inhibitor.  The  gene  for  p16,  CDKN2A,  also 
encodes  for  p14ARF  and  is  found  at  chromosome  9p2l,  a  common  site  of  LoH 
in  HNSCC  (see  Figure  4.1).  The  level  of  p16  within  the  cell  can  be  reduced  by 
promoter  methylation,  deletion  or  mutation  (Serrano,  1997;  Yoo  et  al.,  2000).  In 
HNSCC,  deletion  of  p16  exon  la  is  common  and  this  also  occurs  in  12%  of 
dysplasias  (Ali  Shahnavaz  et  al.,  2001).  Our  previous  work  has  demonstrated  a 
clear  association  of  loss  of  expression  of  p16  and  immortality  (Loughran  et  al., 
1996;  McGregor  et  al.,  2002;  Munro  et  al.,  1999). 
4.2.1  Expression  of  p16  protein 
Protein  was  extracted  from  a  panel  of  mortal  and  immortal  dysplastic  cultures 
as  previously  described.  The  expression  of  p16  in  the  cultures  was  assessed 
by  Western  blotting  (Figure  4.2).  Expression  of  total  p38  was  measured  to 
assess  the  equality  of  loading  in  the  gels.  In  general,  mortal  dysplastic  cultures 
expressed  p16,  whilst  this  was  lost  in  the  immortal  cultures.  There  were  two 
exceptions  to  the  correlation  of  loss  of  p16  expression  and  the  acquisition  of 
immortality:  D17  and  D38.  D17  has  lost  expression  of  p16  whilst  only  gaining  a 
modest  increase  in  proliferative  lifespan,  whilst  D38  has  retained  p16 
expression  despite  having  gained  the  immortal  phenotype.  This  confirmed  the 
previously  described  pattern  in  the  dysplasia  cultures  (McGregor  et  al.,  2002). 
The  expression  of  p16  in  the  tissues  of  origin  was  assessed  by  lHC  in  5pm 
sections  cut  from  the  original  diagnostic  biopsy  tissue  blocks  (Figure  4.3).  For 
each  tissue  section,  an  IgG  control  was  used  to  assess  non-specific  binding. 
Biopsies  that  gave  rise  to  mortal  cell  cultures  had  nuclear  p16  staining 
throughout  the  viable  layers  of  the  epithelium.  There  was  also  pl  6  expression  in 
the  tissue  that  gave  rise  to  D38,  an  immortal  culture  that  has  retained  p16 
expression.  On  comparison  with  the  Western  blots  of  protein  from  the  cultures, 
the  agreement  was  good;  however,  heterogeneity  was  evident  in  some  of  the 
tissue  samples.  This  was  most  obvious  in  D1  7,  where  there  were  small  areas  of 91 
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Figure  4.1  Genomic  organization  of  the  CDKN2A  and  gene  on  9p2l 
The  CDKN2A  locus  encodes  two  cell  cycle  regulators,  p16  and  ARF(p14), 
which  are  transcribed  from  separate  promoters  located  upstream  (5')  of  unique 
exons  1a  and  1fl  respectively,  a  shared  exon  2,  with  exon  3  present  only  in 
p16.  The  primers  used  for  RT-PCR  are  marked  in  blue.  These  were  designed 
to  span  the  intron  between  exons  la  and  2,  giving  specificity  for  p16  and 
avoiding  amplification  of  any  contaminating  DNA. 
p16  inhibits  the  Cyclin  D-CDK4/6  complex  to  prevent  phosphorylation  of  Rb. 
ARF  inhibits  MDM2  mediated  degradation  of  p53  and  is  induced  by  various 
oncogenic  signals.  ARF  functions  in  overlapping  pathways  and  links  Rb  and 
p53.  The  stabilization  of  p53  mediated  by  ARF  can  lead  to  growth  arrest  via 
p2l,  apoptosis  and  DNA  repair.  This  figure  has  been  adapted  from  Smeds  et  al, 
2002  (Smeds  et  al.,  2002). 
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Figure  4.2  p16  immunostaining  in  mortal  and  immortal  dysplasia  cultures. 
The  panel  shows  Western  blot  of  whole  cell  extract  from  cultured  dysplastic  oral 
keratinocytes  using  p16  antibody  (F12).  Total  p38  was  measured  to  assess 
loading  of  the  samples 
This  result  confirms  that  described  by  earlier  work  in  the  group  (McGregor  et  al., 
2002).  The  mortal  dysplastic  cultures  express  p16,  except  D17  which  has  an 
extended  lifespan.  The  immortal  cultures  have  lost  the  expression  of  p16, 
except  D38  which  is  immortal  and  which  is  furthermore  unusual  in  that  it  has 
also  retained  wild  type  p53. 93 
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Figure  4.3  p16  immunostaining  in  the  tissue  of  origin  of  the  cultures 
The  panels  shows  p16  immunostaining  in  formalin  fixed  biopsy  tissue  from 
which  the  culture  was  derived.  Negative  controls,  using  IgG,  showed  no  non- 
specific  staining.  These  images  are  representative  of  two  experiments.  Cultures 
D30  and  D48  are  mortal  and  p16  expression  is  seen  throughout  the  viable 
layers  of  the  epithelium.  D17  is  also  mortal,  but  has  an  extended  lifespan.  p16 
expression  is  lost  from  large  areas  of  the  biopsy,  but  some  p16  expression  is 
retained  (see  arrow).  D4,  D19,  D34  and  show  loss  of  p16  expression.  However, 
the  heterogeneity  is  the  tissue  from  which  D4  was  derived  is  evident.  D38  is 
atypical,  having  retained  p16  expression  in  the  culture  and  also  in  the  tissue. 
Magnification  x2O,  except  D4  "normal"  AO. 94 
P16  positivity  punctuated  along  the  basement  membrane  (see  arrow  in  Figure 
4-3).  The  tissues  that  yielded  immortal  cell  cultures  showed  complete  loss  of 
pl  6  expression  in  at  least  part  of  the  biopsy.  Tissue  related  to  D4  was  the  most 
heterogeneous  with  areas  of  p16  positivity  present  alongside  areas  devoid  of 
pl  6  expression  (Figure  4.3).  This  tissue  sample  is  an  excision  specimen  and  by 
far  the  largest  piece  of  tissue  examined.  Therefore,  this  may  give  a  realistic 
assessment  of  the  heterogeneity  within  the  lesions  generally. 
4.2.2  Expression  of  p16  mRNA 
The  previously  published  analyses  of  p1  6  in  the  cultures  assessed  the  presence 
or  absence  of  p16  protein  (McGregor  et  al.,  2002).  Analysis  of  p16  transcription 
was  important,  as  it  had  not  been  established  if  the  lack  of  expression  of  protein 
seen  in  the  immortal  dysplastic  cultures  was  also  seen  at  a  transcriptional  level. 
Expression  of  p16  RNA  was  assessed  by  semiquantitative  RT-PCR  of  RNA 
extracted  from  fresh  tissue  and  the  cultures  (Figure  4.4).  In  order  specifically  to 
amplify  p16  transcripts,  primers  were  designed  to  span  the  intron  between 
exons  la  and  2  (Figure  4.1).  GAPDH  mRNA  levels  were  also  measured  to 
ensure  comparable  amounts  of  starting  RNA  were  used.  The  panel  of  samples 
was  smaller,  than  that  seen  in  Figures  4.6,4.8,4.12  as  some  of  the  tissue  RNA 
stocks  were  exhausted.  The  expression  of  p16  transcripts  showed  good 
agreement  between  the  tissues  and  the  cultures,  including  the  atypical  cultures 
D17  and  D38. 
4.2.3  Summary  and  discussion 
There  was  good  agreement  of  the  expression  of  p16  in  tissue  and  cell  culture  at 
mRNA  and  protein  level.  There  was  some  heterogeneity  evident,  particularly  in 
the  larger  tissue  sections.  Such  differential  staining  raises  the  possibility  of  the 
presence  of  "mortal  19  and  "immortal"  keratinocyte  clones  within  the  same  lesion, 
although  the  areas  of  differential  staining  were  quite  distinct.  Whilst  the  method 
of  Reinwald  et  al  facilitates  growth  of  cells  from  all  stages  of  the  development  of 
keratinocyte  neoplasia  (Rheinwald  &  Green,  1975),  the  factors  that  dictate 
which  cells  from  a  biopsy  grow  in  culture  are  unknown.  It  is  possible  that  factors 
such  as  the  doubling  time  of  the  cells,  which  is  related  to  the  time  to  establish  in 95 
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Figure  4.4  Comparison  of  p16  exon  la  expression  in  primary  oral 
keratinocytes  and  their  tissue  of  origin. 
Expression  of  p16  was  demonstrated  by  RT-PCR  in  a  panel  of  mortal  and 
immortal  dysplasia  cultures  for  which  there  was  matched  tissue  RNA  available. 
The  figure  shows  5%  Acrylamide  gel  electrophoresis  of  p16  exon  la  RT-PCR 
products  stained  with  ethidium  bromide.  GAPDH  mRNA  levels  were  also 
measured  as  a  control.  This  data  is  representative  of  two  experiments. 96 
culture,  will  be  important.  However,  since  the  portions  of  the  biopsies  used  to 
establish  the  cultures  were  very  small,  the  amount  of  heterogeneity  therein  may 
not  have  been  significant. 
Previously,  it  has  been  suggested  that  the  high  levels  of  p16  seen  in  cell  culture 
are  due  to  limitations  of  the  culture  system,  and  may  be  a  response  to  the 
stress  of  inadequate  conditions  (Ramirez  et  al.,  2001).  However,  this  current 
work  does  not  support  that  conclusion,  as  high  levels  of  pl  6  were  present  in  the 
tissues  of  origin  and  the  corresponding  culture,  indicating  that  the  p16 
expression  pattern  seen  in  cultures  is  not  merely  the  result  of  inadequate 
culture  conditions 97 
4.3  Telomerase 
Increased  levels  of  telomerase  activity  have  been  described  in  many  cancers, 
including  HNSCC.  Previous  work  within  the  group  has  demonstrated  that 
increased  telomerase  activity  and  levels  of  hTERT  are  associated  with  the 
immortal  phenotype  (McGregor  et  al.,  2002).  The  telomerase  holoenzyme 
consists  of  two  main  components,  a  catalytic  domain  with  telomere-specific 
reverse  transcriptase  activity  (hTERT)  and  an  RNA  template  (hTR).  There  is 
much  controversy  in  the  literature  as  to  the  relative  importance  of  these 
subunits  in  the  regulation  of  telomerase  activity.  Direct  measurement  of 
telomerase  activity  may  be  assessed  using  the  Telomerase  Repeat 
Amplification  Protocol  (TRAP)  assay.  As  this  requires  protein  from  the  cells  or 
tissues,  it  was  not  possible  to  assess  telomerase  activity  in  this  manner. 
4.3.1  hTERT 
Splice  deletions  and  insertions  in  hTERT  transcripts  result  in  a  variety  of 
alternative  forms,  which  may  vary  in  their  activity  (Yi  et  al.,  2000).  These 
various  forms  are  surnmarised  in  Figure  4.5.  Some  of  these  alternatively  spliced 
forms  may  retain  very  little  or  no  telomerase  activity  (Colgin  et  al.,  2000).  The 
insertion  variants  all  insert  a  premature  stop  codon,  resulting  in  a  truncated 
protein.  These  were  not  assessed  in  this  study. 
Initial  experiments  investigated  the  expression  of  all  deletion  and  full  length 
forms  of  hTERT  using  primers  in  a  region  common  to  all  transcripts.  Expression 
was  assessed  by  semi-quantitative  RT-PCR  in  the  tissue  and  cultures  (Figure 
4.6).  Total  cellular  RNA  was  extracted  from  the  cultures  and  fresh  tissue  frozen 
at  the  time  the  cultures  were  established.  The  PCR  primers  used  avoided 
regions  of  splice  deletion  (Dome  et  al.,  1999).  GAPDH  mRNA  levels  were  also 
measured  to  ensure  comparable  amounts  of  starting  RNA  were  used.  As 
previously  described,  hTERT  expression  in  the  mortal  cultures  was  very  low  or 
absent,  with  higher  expression  evident  in  the  immortal  cultures.  A  small  amount 
of  hTERT  expression  was  noted  in  D17.  However,  whilst  the  pattern  of  hTERT 
expression  showed  good  agreement  for  the  tissues  related  to  the  immortal 
samples,  expression  of  hTERT  was  also  seen  in  the  tissue  of  origin  of  two  of 
the  mortal  samples,  D41  and  D48. 98 
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Figure  4.5  Genomic  organisation  of  the  hTERT  gene 
The  figure  shows  the  domains  and  variants  of  human  telomerase  catalytic 
subunit  hTERT  gene.  Six  alternate  splicing  sites  are  present  (green  arrows  = 
insertions  1-4  and  yellow  arrows  =  deletions  a  and  fl).  All  four  insertion  variants 
generate  premature  stop  codons.  Adapted  from  Yi  et  al  (2001)  (Yi  et  al.,  2001). 
The  primers  used  for  serniquanitative  RT-PCR  are  marked  in  blue  (Dome  et  al., 
1999).  The  primer  set  spans  nucleotides  1789-1971  and  does  not  amplify  the 
region  of  either  of  the  deletion  variants  of  hTERT  gene.  It  spans  intron  4  to 
avoid  analysis  of  contaminating  genomic  DNA.  The  primers  used  for  analysis  of 
the  deletion  splice  variants  are  those  described  in  Yi  et  al,  (2001)  and  span 
nucleotides  2109-2531  (marked  in  red)  (Yi  et  al.,  2001). 
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Figure  4.6  Comparison  of  hTERT  RNA  expression  in  primary  oral 
keratinocytes  and  their  tissue  of  origin. 
Expression  of  hTERT  was  demonstrated  by  RT-PCR  in  a  panel  of  mortal  and 
immortal  dysplasia  cultures  for  which  there  was  matched  tissue  RNA  available. 
The  figure  shows  5%  Acrylamide  gel  electrophoresis  RT-PCR  products  stained 
with  ethidium  bromide.  GAPDH  mRNA  was  also  amplified  as  a  control.  This 
data  is  representative  of  three  experiments.  Note  that  the  tissue  related  to  D17 
does  show  hTERT  expression  albeit  at  a  very  low  level. 100 
The  reasons  for  hTERT  expression  in  D41  and  D48  tissues  are  not  clear.  As 
the  tissue  was  not  microdissected  in  this  experiment,  this  may  represent  tissue 
heterogeneity  within  the  area  of  dysplasia.  Alternatively,  the  possibility  of 
contamination  from  cells  in  the  lamina  propria  cannot  be  discounted,  as  high 
levels  of  telomerase  activity  have  been  reported  in  activated  lymphocytes 
(Hiyama  et  al.,  1995).  However,  the  H&E  stained  tissue  sections  related  to  D41 
and  D48  did  not  reveal  a  prominent  lymphoctyic  infiltrate  in  the  upper  lamina 
propria.  Additionally,  as  there  is  little  evidence  of  contamination  from  other  cell 
types  in  relation  to  p16  expression,  contamination  is  an  unlikely  cause.  Work  to 
be  described  later  shows  that  these  two  cultures  have  a  gene  expression  profile 
more  like  normal  cultures  than  the  other  mortal  dysplastic  cultures.  Additionally, 
these  are  the  only  mortal  dysplastic  cultures  derived  from  the  tissues  of  patients 
who  were  non-smokers.  Due  to  the  varying  activity  of  the  deletion  variants,  the 
possibility  that  the  expression  of  hTERT  in  these  tissue  samples  may  not  relate 
to  telomerase  activity  had  to  be  assessed  in  some  manner. 
4.3.2  hTERT  splice  variants 
As  there  was  no  possibility  of  direct  assessment  of  telomerase  activity  using  the 
TRAP  assay,  the  deletion  variants  of  hTERT  were  assessed.  Admittedly,  this 
only  allows  for  inference  of  the  likelihood  of  the  hTERT  expression  in  the  tissues 
resulting  in  telomerase  activity  and  the  assessment  is  semiquantitative.  RNAs 
isolated  from  HeLa  and  W138  cells  were  used  as  positive  and  negative  controls 
respectively.  The  data  show  that  whilst  in  all  cases  the  dominant  form  present 
was  the,  8  deletion  (-,  8),  full-length  hTERT  transcript  was  also  present,  the  only 
exception  being  D17  tissue  (Figure  4.7).  The  predominance  of  the  fl  splice- 
deletion  form  is  in  agreement  with  the  work  of  other  groups  (Yi  et  al.,  2000). 
Thus,  the  hTERT  expression  demonstrated  in  the  initial  analysis  of  D41  and 
D48  was  not  solely  due  to  the  expression  of  an  inactive  splice  variant. 
However,  the  uniform  pattern  seen  in  the  tissues  is  not  surprising,  as  there  is  no 
evidence  in  the  literature  for  regulation  of  hTERT  activity  by  alternative  splicing 
in  keratinocyte  neoplasia  in  vivo. 101 
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Figure  4.7  Agilent  2100  Bloanalyser  "virtual  gel"  of  hTERT  mRNA  deletion 
splice  variants 
The  primers  used  were  designed  to  detect  the  deletion  splice  variants  of 
hTERT.  The  figure  shows  semiquantitative  RT-PCR  products  analysed  using  a 
RNA  6000  nanochip  on  an  Agilent  Bioanalyser.  The  output  can  be  visualised 
as  a  virtual  gel.  This  demonstrated  the  presence  of  all  four  deletion  splice 
variants  of  hTERT.  HeLa  and  W138  cells  were  used  as  positive  and  negative 
controls  respectively. 
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4.3.3  hTR 
The  expression  of  the  telomerase  RNA  template  (hTR)  was  assessed  by 
serniquantitative  RT-PCR  in  the  tissue  and  cultures  (Figure  4.8).  Tissue  RNA 
was  extracted  from  fresh  tissue  frozen  at  the  time  the  cultures  were  established. 
GAPIDH  mRNA  levels  were  also  measured  to  ensure  comparable  amounts  of 
starting  RNA  were  used.  This  analysis  demonstrated  that  there  was  very  little 
variation  in  hTR  levels  in  the  cultures,  whether  mortal  or  immortal,  as  has  been 
described  previously  (McGregor  et  al.,  2002).  The  exception  to  this  was  D41.  In 
the  tissues,  hTR  expression  was  detected  in  most  samples,  but  there  was 
greater  variation,  with  the  highest  levels  present  in  two  out  of  four  dysplastic 
biopsies  that  gave  rise  to  immortal  cultures.  The  it  mortal"  tissues  showing  the 
highest  hTR  expression  (D30  and  D36)  were  not  those  that  showed  hTERT 
expression  (D41  and  D48). 
In  cell  culture,  it  has  been  demonstrated  that  telomerase  activity  is  related  to 
hTERT  expression  and  that  in  alterations  of  telomerase  activity  hTERT  reduces, 
whilst  hTR  remains  constant  (Shin  et  al.,  2003).  However,  in  vivo  studies  have 
shown  hTR  to  be  upregulated  in  some  solid  tumours.  Our  in  vivo  data  supports 
these  observations,  as  hTR  was  most  highly  expressed  in  two  of  the  immortal 
dysplasias.  However,  the  effect  was  not  as  clear  as  for  hTERT. 103 
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Figure  4.8  Comparison  of  telomerase  template  component  (hTR)  RNA 
expression  in  primary  oral  keratinocytes  and  their  tissue  of  origin. 
Expression  of  hTR  was  demonstrated  by  RT-PCR  in  a  panel  of  mortal  and 
immortal  dysplasia  culture  for  which  there  was  matched  tissue  RNA  available. 
The  figure  shows  5%  Acrylamide  gel  electrophoresis  RT-PCR  products  stained 
with  ethidium  bromide.  GAPDH  mRNA  levels  were  also  measured  as  a  control. 
This  data  is  representative  of  two  experiments. 104 
4.3.4  Discussion 
The  expression  of  hTERT  in  the  immortal  cultures  reflected  that  seen  in  the 
tissues  of  origin.  This  suggests  that  the  normal  repression  of  hTERT 
expression  had  been  lost  in  the  subset  of  dysplastic  tissues  that  gave  rise  to 
immortal  cultures  and  this  was  maintained  in  culture.  In  contrast,  the  subgroup 
of  dysplastic  tissues  that  gave  rise  to  mortal  cultures  generally  showed  no 
hTERT  expression  both  in  vivo  and  in  culture.  Why  a  minority  of  dysplastic 
lesions  express  hTERT  in  vivo,  but  not  in  culture  is  not  entirely  clear.  This  may 
be  due  to  the  persistence  of,  for  example,  the  putative  telomerase  repressor  on 
chromosome  3p.  This  is  a  common  site  of  LoH  in  immortal  cultures  and  in 
HNSCC  in  vivo  (Partridge  et  al.,  1994). 
The  reason(s)  for  the  loss  of  hTERT  expression  in  the  mortal  cultures  are  not 
clear.  Other  workers  have  shown  that  normal  oral  cells  in  culture  lose 
measurable  telomerase  activity  by  passage  5  (Fujimoto  et  al.,  2003).  Kunimura 
and  co-workers  suggested  that  this  relates  to  the  rapid  loss  of  a  telomerase- 
positive  cell  subpopulation  in  culture  (Kunimura  et  al.,  1998).  This  work 
suggests  that  the  apparent  loss  of  hTERT  expression  on  establishment  of 
normal  cell  cultures  may  be  due  to  dilution  of  the  telomerase  positive  cells  in  a 
heterogeneous  cell  population.  This  hypothesis  has  not  been  rigorously 
demonstrated.  Use  of  organotypic  culture  systems  has  also  clearly 
demonstrated  that  telomerase  activity  reduces  once  cells  are  committed  to 
terminal  differentiation  (Cerezo  et  al.,  2003).  However,  as  the  monolayer  culture 
system  does  not  allow  cells  to  differentiate  to  any  degree,  reduction  of  hTERT 
expression  related  to  differentiation  is  an  unlikely  and  in  any  case  paradoxical, 
explanation  for  the  phenomenon  seen  in  our  cultures. 
Telomerase  activity  in  normal  cells  in  primary  culture  has  also  been  related  to 
the  cell  cycle  (Kunimura  et  al.,  1998).  Telomerase  increases  in  S  phase  and  is 
dramatically  reduced  after  S  phase.  In  contrast,  in  immortalized  cell  lines 
telomerase  activity  remains  constant  with  respect  to  the  cell  cycle,  indicating 
that  telomerase  activity  is  deregulated  in  immortal  cells  (Holt  et  al.,  1997).  This 
may  explain  the  good  agreement  of  immortal  cultures  with  tissues  in  our  panel. 
Thus,  whilst  mortal  oral  keratinocytes  may  express  hTERT  in  vivo,  it  is  possible 
that  only  a  small  fraction  of  the  mortal  cells  in  vitro  may  be  in  S  phase  and 105 
indeed  some  cells,  even  at  low  passage,  may  be  exhibiting  features  of 
senescence.  The  observation  that  telomerase  activity  and  hTERT  expression 
reduces  as  cultured  normal  oral  keratinocytes  approach  senescence  has  been 
attributed  to  methylation  of  the  hTERT  promoter  as  expression  of  hTERT  was 
re-established  by  application  of  5'Aza-2'-deoxycytidine  (Shin  et  al.,  2003). 
The  expression  of  hTR  in  vivo  varies,  with  generally  higher  levels  in  the  tissues 
that  gave  rise  to  the  immortal  cultures.  This  implies  that  the  regulation  of  hTR 
expression  may  be  different  in  culture  from  the  in  vivo  situation.  However, 
without  direct  measurement  of  telomerase  activity,  it  is  difficult  to  be  sure  of  the 
relative  importance  of  these  subunits  in  vivo. 106 
4.4  P53 
Mutation  of  p53  has  a  well  established  role  in  the  development  of  many 
cancers,  including  HNSCC.  Cells  lacking  wild  type  p53  do  not  show  G1  arrest  in 
response  to  DNA  damage  and  this  leads  to  the  accumulation  of  genetic 
abnormalities  and  also  harbour  defects  in  apoptosis.  Earlier  work  in  the  group 
has  demonstrated  that  p53  mutation  is  associated  with  the  acquisition  of 
immortality  (McGregor  et  al.,  2002). 
4.4.1  p53  protein 
p53  protein  expression  was  measured  in  the  cell  cultures  using  Western  blotting 
(Figure  4.9,  lower  panel).  Expression  of  total  p38  was  measured  to  assess  the 
equality  of  loading  in  the  gel.  The  pattern  of  protein  expression  confirms  that 
previously  described  (McGregor  et  al.,  2002).  In  general,  the  expression  in  the 
mortal  cultures  was  low,  with  the  exception  of  D1  7,  which  had  an  elevated  level 
of  p53  (shown  to  be  wild  type  McGregor  et  al.,  2002).  Table  4.1  shows  that  the 
protein  level  seen  in  the  immortal  cultures  relates  well  to  the  previously 
published  mutations  in  p53  (McGregor  et  al.,  2002).  The  highest  levels  were 
seen  in  D19  and  D34,  both  of  which  have  homozygous  mutations,  whereas  the 
protein  level  in  D4,  which  had  a  heterozygous  mutation,  was  lower.  The 
frameshift  mutation  identified  in  D35  resulted  in  a  truncated  protein,  which  was 
not  detected  in  the  Western  blot.  The  level  in  D38,  which  has  wild  type  p53, 
was  similar  to  that  seen  in  the  mortal  cultures. 
The  expression  of  p53  protein  in  the  tissues  was  assessed  by  1HC  (Figure  4.9, 
top  panel).  This  showed  that,  excepting  D17,  the  tissues  that  gave  rise  to 
mortal  cultures  demonstrated  low  intensity  of  staining  which  was  restricted  to 
the  basal  and  immediately  suprabasal  layers  of  the  epithelium.  In  contrast,  the 
expression  of  p53  in  the  tissues  which  gave  rise  to  immortal  cultures  was  higher 
in  intensity  and  extended  beyond  the  immediately  suprabasal  cells  into  the 
more  superficial  layers  of  the  epithelium.  This  must  be  interpreted  with  some 
caution,  as  basal  cell  hyperplasia  (BCH)  is  a  common  feature  seen  in  reactive 
and  preneoplastic  changes  in  oral  epithelium.  The  spatial  effect  seen  may 
merely  be  a  function  of  an  increased  basal  compartment  in  these  tissues. 107 
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Figure  4.9  p53  (DO-1)  immunostaining  in  primary  oral  keratinocyte 
cultures  and  their  tissue  of  origin. 
Upper  panel  shows  p53  immunostaining  in  formalin  fixed  biopsy  tissue  from 
which  the  culture  was  derived.  EL  refers  to  the  extended  lifespan  of  D17. 
Negative  controls  (not  shown),  using  IgG  showed  no  staining. 
Lower  panel  shows  Western  blot  of  whole  cell  extract  from  cultured  dysplastic 
oral  keratinocytes  using  p53  antibody  (DO1).  p38  was  also  measured  to  assess 
loading  of  the  samples.  The  mutation  in  D35  resulted  in  a  truncated  protein  and 
is  shown  here  as  absent.  Magnification  x2O. 
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However,  BCH  is  also  present  in  many  of  the  tissues  that  gave  rise  to  mortal 
cultures  and  the  p53  staining  in  the  tissues  is  still  restricted  to  the  basal 
compartment. 
The  expression  of  p53  protein  in  the  tissues  related  to  D1  7  and  D38  showed  an 
intermediate  pattern  of  staining  which  does  not  fit  either  of  the  patterns 
mentioned  above.  This  may  reflect  heterogeneity  within  the  tissue  or  the  loss  of 
p53  functions  by  the  presence  of  defects  at  other  point(s)  within  p53  regulated 
pathways,  but  without  the  increase  in  staining  seen  in  a  mutated  and  stabilised 
p53.  The  p53  protein  results  are  summarised  in  Table  4.1. 109 
cultures  biopsy 
dysplasia  growth  p53  gene  status  protein  WB  protein  lHC 
D17  mortal  wild  type  mod  intermediate 
D30  mortal  wild  type  low  basal 
D36  mortal  wild  type  low  basal 
D41  mortal  wild  type  low  basal 
D47  mortal  wild  type  low  basal 
D4  immortal  mutation,  exon  5,  stop  mod  upper  layer 
codon 
D19  immortal  mis-match  mutation,  high  upper  layer 
exon  5 
D34  immortal  mis-match  mutation,  high  upper  layer 
exon  4 
D35  immortal 
frame-shift  mutation,  absent  none  specific 
exon  6 
D38  immortal  wild  type  mod  intermediate 
Table  4.1  A  comparison  of  the  in  vitro  gene  status  of  p53  with  p53  protein 
expression  in  vitro  and  in  vivo. 
The  cell  culture  p53  mutation  data  is  from  McGregor,  Muntoni  et  al  (2002) 
(McGregor  et  al.,  2002).  Protein  expression  in  the  cultures  was  assessed  by 
Western  blot  (WB)  as  shown  in  Figure  4.9. 
Protein  expression  in  the  tissues  was  assessed  by  immunostaining  of  formalin- 
fixed  biopsy  tissue  (IHC),  as  shown  in  Figure  4.9. 110 
4.4.2  p53  expression  in  organotypic  culture 
In  order  to  assess  the  effect  of  reconstituting  a  stratified  squamous  epithelium 
on  the  expression  pattern  of  p53,  an  organotypic  culture  system  was  developed. 
This  used  fibroblasts  derived  from  an  oral  premalignant  lesion  (which  also  gave 
rise  to  the  keratinocyte  culture  D19)  set  in  a  collagen  gel  matrix.  The  epithelial 
cells  (2  mortal  cultures  and  2  immortal  cultures),  placed  on  collagen  gels  at  the 
air  interface,  were  fed  from  below.  This  resulted  in  the  formation  of  a  stratified 
squamous  epithelium  over  about  11  days  (Figure  4.10).  Immunohistochemistry 
revealed  that  the  organotypic  cultures  maintained  the  difference  in  their 
expression  of  p53  seen  in  monolayer  culture,  although  it  was  not  as  clear  as  in 
the  original  tissues  (Figure  4.10,  compared  with  Figure  4.9).  This  demonstrated 
that  the  alterations  in  p53  expression  were  an  intrinsic  feature  of  the  cells,  as 
reconstitution  of  a  stratified  epithelium  in  organotypic  culture  showed  a  similar 
pattern  of  expression  of  p53  to  that  in  the  original  biopsy. 
4.4.3  p53  gene  status 
Sequencing  of  specific  sections  of  the  p53  gene  was  carried  out  in  order  to 
assess  the  genetic  relationship  between  the  immortal  cultures  and  the  biopsies. 
As  p53  mutations  had  been  previously  described  in  the  immortal  cultures  in 
vitro,  sequencing  of  material  from  the  in  vivo  samples  was  only  conducted  in 
these  areas  (McGregor  et  al.,  2002).  Initially  clDNA  derived  from  total  cellular 
RNA  by  RT-PCR  was  sequenced.  This  demonstrated  that  the  same  mutation 
was  present  in  the  tissue  related  to  D19,  but  was  heterozygous  (Table  4.2). 
The  requisite  mutation  could  not  be  demonstrated  in  D4.  However,  the  mutation 
in  D4  resulted  in  a  stop  codon  and  this  may  be  removed  by  nonsense  mediated 
mRNA  decay  (reviewed  in  Culbertson,  1999).  There  was  insufficient  RNA  to 
gain  satisfactory  results  from  D34  and  D35. 
DNA  was  extracted  from  laser  capture  microdissected  (LCM)  tissue  from 
formalin  fixed  sections  of  the  original  biopsies  (Figure  3.1).  This  allowed  for 
sampling  of  phenotypically  different  areas  of  epithelium.  The  heterozygous 
mutation  found  in  D4  in  culture  was  present  in  the  dysplastic  area  of  the  tissue 
section,  but  was  absent  from  "normal"  adjacent  epithelium  (Table  4.2). ill 
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Figure  4.10  Formalin-fixed  tissue  derived  from  organotypic  cultures  of 
clysplastic  oral  keratinocytes  D19  (immortal)  and  D30  (mortal). 
Left  panels  formalin-fixed  tissue  stained  with  haematoxylin  &  eosin. 
Magnification  x2O 
Right  panels  show  p53  protein  expression  (immunostaining  using  antibody  DO- 
1  with  haematoxylin  counterstain).  Comparison  with  corresponding  panels  in 
Figure  16  shows  that  p53  expression  in  D30  extends  more  superficially  in 
organotypic  culture  than  in  the  tissue.  However,  on  comparison  with  D19,  a 
clear  difference  in  expression  pattern  was  maintained.  Magnification  x40 ,w 
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sample  mutation  zYgosity 
Same  mutation 
as  culture? 
D  19  biopsy  RNA  NT  488  C>A  heterozygous  yes* 
D4  biopsy  RNA  not  detected  N/A  N/A 
D19  biopsy  DNA  NT  488  C>A  heterozygous  yes 
D4  biopsy  DNA 
dysplastic 
NT  489  C>A  heterozygous  yes 
D4  biopsy  DNA 
non-dysplastic 
not  detected  N/A  N/A 
D9  biopsy  DNA  NT  1009  C>T  heterozygous  yes 
,  D20  biopsy  DNA  NT  743  G>A  heterozygous  yes 
Table  4.2  Comparison  of  p53  mutations  in  vitro  and  in  vivo  in  D4,  D19,  D9 
and  D20. 
The  mutations  were  initially  detected  in  cell  culture  (McGregor  et  al.,  2002). 
Primers  were  designed  to  detect  the  specific  mutation  found  in  the  culture  and 
sequencing  was  performed  on  cDNA  derived  from 
"  total  cellular  RNA  (from  frozen  tissue)  -  by  RT-PCR 
"  DNA  (from  laser  capture  microdissection)  -  by  PCR. 
*Note:  The  fact  that  the  mutation  in  the  biopsy  is  heterozygous  may  indicate 
some  level  of  stromal  or  normal  epithelial  contamination  or  heterogeneity  within 
the  sample. 113 
The  mutation  found  in  D19  in  culture  was  also  seen  in  the  tissue,  but  was 
heterozygous.  This  may  indicate  some  level  of  stromal/normal  epithelial 
contamination  or  heterogeneity  within  the  sample.  The  mutations  previously 
seen  in  D9  and  D20  were  also  present  in  the  original  biopsy  tissue.  Analysis  of 
D34  and  D35  is  ongoing. 
4.4.4  Summary  and  discussion 
This  analysis  demonstrates  that  the  differences  in  p53  expression  seen  in  the 
culture  were  present  in  the  tissue  of  origin.  Whilst  others  have  demonstrated 
that  suprabasal  p53  expression  in  dysplastic  oral  epithelium  is  associated  with 
an  increased  risk  of  progression  to  carcinoma  (Cruz  et  al.,  2002;  Cruz  et  al., 
1998),  this  data  is  novel  in  that  it  relates  the  alterations  in  the  intensity  and 
spatial  distribution  of  p53  staining  to  p53  mutation  and  immortality  in  cell  culture. 
As  the  mutations  seen  in  the  cultures  were  also  demonstrated  in  the  tissues 
from  which  they  were  derived,  this  demonstrated  a  clear  genetic  relationship 
between  the  immortal  cells  in  culture  and  their  tissues  of  origin. 114 
4.5  Retinoic  acid  receptor  beta  (RAR-fl) 
Retinoids  can  regulate  gene  expression  and  thus  modulate  differentiation  and 
growth  in  cells  (Lotan,  1996)  and  there  has  been  much  interest  in  the  effects 
that  deregulation  of  this  system  may  have  in  carcinogenesis.  Much  interest  has 
been  expressed  in  their  potential  use  in  the  treatment  of  dysplastic  lesions; 
however,  this  modality  has  proven  to  be  disappointing.  Downregulation  of  RAR- 
,8 
has  been  reported  in  many  cancers,  including  HNSCC  (Lotan  et  al.,  1995). 
We  have  previously  described  constitutive  expression  of  RAR-fl  in  our  mortal 
dysplastic  cultures  with  complete  loss  of  expression  in  our  immortal  dysplastic 
cultures  (McGregor  et  al.,  1997). 
Multiple  isoforms  of  RAR--fl  have  been  described.  Among  the  four  known  RAR-fl 
isoforms,  RAR-,  fl2  is  thought  to  be  the  key  tumour  suppressor  in  humans  (Lotan 
et  al.,  1995;  Toulouse  et  al.,  2000),  but  the  possibility  remains  that  RAR-fll  is 
also  involved.  The  expression  pattern  of  RAR-fll  suggests  it  is  a  fetal  isoform 
(Toulouse  et  al.,  1996),  but  no  direct  tests  of  the  effect  of  the  latter  on  tumour 
cell  phenotype  have  been  published.  It  is  very  similar  to  RAR-fl3  which  is  not 
found  in  human  cells.  The  fourth  isoform,  a  truncated  version  of  RAR,  82  named 
RARfl4,  is  associated  with  turnorigenicity  in  humans  and  mice,  so  it  is  unlikely  to 
have  a  tumour  suppressor  activity  (Berard  et  al.,  1994;  Hayashi  et  al.,  2003) 
The  structure  of  isoforms  RARfl2  and  RARfl4  is  shown  in  Figure  4.11. 
Unfortunately,  the  commercially  available  RARfl  primary  antibodies  appear 
neither  specific  nor  reproducible  in  lHC  or  Western  blot.  Therefore,  there  is  no 
data  on  the  expression  of  RARfl  protein  in  the  cultures  or  the  tissues. 
4.5.1  RNA 
The  expression  of  RAR-fl2was  assessed  by  semi-quantitative  RT-PCR  in  the 
tissue  and  cultures  (Figure  4.12).  Tissue  RNA  was  extracted  from  fresh  tissue 
frozen  at  the  time  the  cultures  were  established.  GAPDH  mRNA  levels  were 
also  measured  to  ensure  comparable  amounts  of  starting  RNA  were  used.  The 
pattern  of  expression  in  the  cultures  agrees  with  the  pattern  previously 
described  by  Northern  blotting  i.  e.  constitutive  expression  in  mortal  cultures  with 
no  expression  in  immortal  cultures,  except  D38  (McGregor  et  al.,  1997). 
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Figure  4.11  Diagram  of  RARfl2  and  RARfl4  transcripts  and  RARfl2  protein 
functional  domains 
The  most  recent  annotation  of  the  RARfl  locus  and  various  isoforms  is  outlined 
in  Ensembl  transcript  ID  ENST00000330688  (hftp:  //www.  ensembl.  orq).  Much  of 
the  literature  refers  to  the  mRNA  sequence  of  RARfl  as  exons  5-12.  This 
diagram  adopts  the  numbering  sequence  assigned  in  the  Ensembl  annotation 
(exons  1-8). 
RARfll  (and  RAR,  83)  differ  from  RARfl2  in  their  5'UTR  and  A  coding  region. 
RARfl4  is  generated  by  alternative  splicing  in  exon  1  (Zelent  et  al.,  1991).  The 
RAR,  82-specific  primers  used  were  those  published  by  Sirchia  et  al  (Sirchia  et 
al.,  2000).  The  positions  shown  by  the  red  arrows. 
The  figure  is  adapted  from  Chen  et  al,  2002  (Chen  et  al.,  2002). 116 
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Figure  4.12  Comparison  of  retinoic  acid  receptor,  82  (RAU2)  expression 
demonstrated  by  RT-PCR  in  a  panel  of  cultures  derived  from  dysplastic 
oral  epithelium  and  their  tissue  of  origin. 
Expression  of  RARP2  was  demonstrated  by  RT-PCR  in  a  panel  of  mortal  and 
immortal  dysplasia  cultures  for  which  there  was  matched  tissue  RNA  available. 
The  figure  shows  5%  Acrylamide  gel  electrophoresis  of  RT-PCR  products 
stained  with  ethidium  bromide.  GAPDH  mRNA  levels  were  also  measured  as  a 
control.  This  data  is  representative  of  two  experiments. 
Tissue  expression  of  RARP2  matched  expression  in  the  mortal  cell  cultures  to 
some  degree,  but  the  immortal  cell  cultures  did  not  match  at  all. 117 
whilst  RAR-fl2was  not  expressed  in  the  immortal  cultures,  it  was  expressed  in 
three  out  of  four  dysplastic  biopsies  related  to  these  cultures. 
Mesenchymal  contamination  is  a  possible  explanation,  as  fibroblast  cultures 
express  high  levels  of  RAR-fl  in  the  presence  of  retinoic  acid  (Crowe  et  al., 
1991).  However,  this  observation  has  not  been  confirmed  in  vivo,  and  as  this 
effect  should  have  been  seen  in  the  II  mortal"  tissues,  such  an  explanation  is 
unlikely.  Alternatively,  heterogeneity  in  gene  expression  resulting  from  the 
presence  of  mortal  and  immortal  subpopulations  in  the  tissues  may  be 
responsible.  This  explanation  assumes  that,  whilst  mortal  and  immortal  cells 
were  present  in  the  tissue,  the  immortal  cells  preferentially  grew  in  culture. 
However,  the  lack  of  heterogeneity  of  p16  and  p53  staining,  particularly  in 
tissues  related  to  D19  and  D35  mitigates  against  this  conclusion.  A  more  likely 
explanation  lies  in  the  now  well  established  relation  of  RAR-j8  expression  to 
squamous  cell  differentiation  (Lotan,  1996).  Therefore,  the  discrepancy  in  the 
tissues  of  origin  may  be  explained  by  changes  in  RAR-j8  expression  associated 
with  terminal  differentiation  in  the  tissues.  Such  changes  may  not  be  apparent 
in  monolayer  culture  of  immortal  cells. 
4.5.2  RAR#2  expression  in  organotypic  culture 
In  order  to  assess  the  influence  of  differentiation  on  the  RAR-fl2  expression  in 
the  immortal  cell  cultures,  an  organotypic  culture  system  was  utilised.  The 
expression  of  RAR7,82  in  the  stratified  squamous  epithelium  formed  over  a 
period  of  11  days  was  assessed  by  serniquantitative  RT-PCR  of  total  cellular 
RNA  (Figure  4.13).  GAPIDH  mRNA  levels  were  also  measured  to  ensure 
comparable  amounts  of  starting  RNA  were  used.  The  differences  in  expression 
of  RAR7,82  between  mortal  and  immortal  dysplasias  in  monolayer  culture  were 
also  seen  in  organotypic  culture,  indicating  that  a  change  in  the  activation  of  the 
terminal  differentiation  pathway  did  not  result  in  the  re-expression  of  RAR-fl2in 
immortal  cells.  Thus,  a  difference  in  differentiation  state  was  not  the  sole 
reason  for  the  poor  agreement  of  the  immortal  culture  findings  with  their  tissue 
of  origin. 
However,  the  organotypic  culture  system  does  not  fully  reconstitute  in  vivo 
conditions.  Many  other  cell  types  are  present  within  the  lamina  propria  that  may 118 
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The  figure  shows  that  growth  of  these  primary  cultures  in  a  system  which  allows 
differentiation  to  occur  did  not  result  in  a  change  in  the  expression  of  RARP2  in 
the  mortal  or  immortal  cultures. 119 
contribute  to  variations  in  the  oxidative  state.  In  addition,  the  serum  used  in  the 
feeding  medium  contains  an  undefined  level  of  retinoids.  It  may  be  interesting 
to  repeat  the  experiment  with  varying  concentrations  of  retinoids,  in  order  to 
recreate  a  physiological  retinoid  gradient  across  the  epithelium. 
4.5.3  Discussion 
The  agreement  of  RAR-fl  expression  in  the  cultures  and  tissues  was  poor, 
particularly  in  the  tissues  that  gave  rise  to  immortal  cultures.  The  reasons  for 
this  are  unclear.  As  the  pathways  and  interactions  related  to  the  role  of 
differentiation  and  tumour  microenvironment  in  the  development  of  HNSCC  are 
undoubtedly  important,  it  is  a  disadvantage  that  these  cannot  be  examined  in 
monolayer  cultures.  Despite  this  caveat,  organotypic  culture  showed  that 
induction  of  differentiation  did  not  result  in  the  expression  of  RAR-fl  in  the 
cultures.  The  reasons  for  this  are  not  clear 
These  results  have  implications  for  the  extrapolation  of  in  vitro  gene  expression 
data  to  the  in  vivo  state.  Validation  of  the  markers  related  to  the  pathways 
described  above  (and  perhaps  others)  must  be  conducted  with  care,  bearing  in 
mind  the  possibility  that  the  in  vivo  correlation  of  the  expression  of  such  genes 
with  that  in  the  monolayer  culture  may  be  poor. 120 
Chapter  Five:  Microarray  study 
5.1  Introduction 
Analysis  of  the  global  gene  expression  profile  of  the  cell  cultures,  both  mortal 
and  immortal  was  conducted  using  the  Affymetrix  U133A  and  U133B 
genechips.  This  allowed  further  analysis  of  the  differences  in  gene  expression 
seen  on  comparison  of  cultured  mortal  and  immortal  dysplastic  oral 
keratinocytes.  This  data  was  further  augmented  by  analysis  of  normal  oral 
keratinocyte  cultures  and  those  from  carcinomas,  both  primary  tumours  and 
metastases,  a  full  list  of  which  is  seen  in  Table  3.1.  The  range  of  samples 
analysed  allowed  for  fuller  characterisation  of  events  at  various  stages  of  the 
development  of  oral  squamous  cell  carcinoma.  These  results  refer  primarily  to 
the  differences  associated  with  keratinocyte  immortality. 
All  preparatory  work  for  the  microarray  analysis  was  carried  out  at  the  BICR. 
This  included  culture  of  the  cells,  harvest  and  isolation  of  RNA,  and  the  various 
stages  of  analysis  and  labelling  to  produce  the  labelled,  fragmented  cRNA 
ready  for  hybridisation  to  the  genechip  arrays.  The  fragmented  cRNA  was  sent 
to  the  Microarray  Core  facility  at  the  Paterson  Institute  for  Cancer  Research, 
where  the  hybridisations  and  scanning  were  carried  out.  The  RNA  was  only 
processed  if  the  stringent  quality  controls  set  by  the  PICR  were  met  (see 
materials  and  methods).  A  test  array  was  used  for  at  least  one  sample  in  every 
batch  sent.  The  raw  data  was  returned  to  the  BICR  for  subsequent  analysis. 
5.1.1  Transformation  and  normalisation 
All  of  the  raw  microarray  data  was  analysed  as  shown  in  Figure  5.1.  The  matrix 
was  log2  transformed  to  improve  the  data  distribution.  This  allows  easier 
assessment  of  the  degree  to  which  different  genes  alter  their  transcription.  The 
data  was  normalized  using  the  Robust  Multichip  Average  (RMA)  method 
(I  riza  rry  et  al.,  2003)  implemented  in  RMAExpress  http:  //stat- 
www.  berkeley-edu/users/bolstad/RMAExpress/RMAExpress.  htmi. 121 
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Figure  5.1  Schematic  flow  diagram  of  microarray  data  analysis 
This  diagram  shows  the  standardised  process  which  was  developed  for  data 
analysis  for  all  samples  in  the  main  study.  The  entire  group  of  filtered  genes  are 
hereafter  referred  to  as  "all  present  genes". 122 
RMA  performs  the  following  operations: 
e  Probe-specific  background  correction  to  compensate  for  non-specific 
binding  using  perfect  match  (PM  )  values  alone  (mismatch  (MM)  values 
are  not  utilised). 
Probe-level  multichip  quantile  normalization  to  unify  PM  distributions 
across  all  chips 
Robust  probeset  summary  of  the  log  normalized  probe  level  data  by 
median  polishing,  resulting  in  a  single  value  for  the  probe  set. 
As  RMA  is  based  on  rank  normalisation,  the  distribution  in  each  sample 
becomes  the  same.  This  results  in  a  compression  of  the  dynamic  range  of  the 
data.  This  may  be  limiting  in  terms  of  the  statistical  analysis  of  the  data,  but  may 
be  an  advantage  when  using  clustering  algorithms. 
5.1.2  Filtering 
In  order  to  filter  the  data  and  remove  probe  sets  that  were  not  contributing 
meaningfully  to  further  analysis,  the  data  was  analysed  using  Affymetrix 
Microarray  Analysis  Suite  (MAS)  6.0.  This  utilises  both  the  PM  and  MM  data 
from  the  array  and  on  this  basis  assigns  a  present  (P),  marginal  (M)  or  absent 
(A)  flag  to  each  probe  set  in  a  particular  sample.  These  flags  were  used  to  filter 
the  data,  as  only  probesets  which  were  judged  "present"  in  6  or  more  samples 
were  used  in  further  analysis.  In  the  main  study,  this  reduced  the  number  of 
probesets  forwarded  to  further  analysis  from  44930  to  23562. 
5.1.3  Data  clustering 
Hierarchical  cluster  analysis  was  used  to  arrange  genes  according  to  similarity 
in  pattern  of  gene  expression.  This  uses  standard  statistical  algorithms  and  the 
output  is  displayed  graphically,  conveying  the  clustering  and  the  underlying 
expression  data.  Clustering  methods  can  be  divided  into  two  classes, 
supervised  and  unsupervised.  In  supervised  clustering,  vectors  are  classified 
with  respect  to  known  reference  points.  In  unsupervised  clustering,  no 
predefined  references  are  used  (as  in  hierarchical  clustering).  Eisen  recently 
reviewed  various  methods  (Eisen  et  al.,  1998). 123 
Hierarchical  clustering  is  widely  used  to  find  patterns  in  multidimensional 
datasets,  especially  for  microarray  data.  The  object  of  this  algorithm  is  to 
compute  a  cluster  dendrogram  that  assembles  all  gene  expression  elements 
into  a  single  tree.  The  dendrogram  produced  is  a  binary  tree  in  which  each  data 
point  corresponds  to  terminal  nodes  and  distance  from  the  root  to  a  subtree 
indicates  the  similarity  of  subtrees  -  highly  similar  nodes  or  subtrees  have 
joining  points  that  are  farther  from  the  root.  It  must  be  remembered  that  at  the 
highest  levels  of  the  hierarchy  the  branches  are  very  dependent  on  the  lower 
links,  thus  they  are  less  reliable.  Almost  all  hierarchical  agglomerative 
algorithms  are  safe  when  the  interest  is  placed  on  the  small,  low  levels  of  the 
hierarchy,  but  they  become  unsafe  at  high  levels.  The  groups  of  genes  derived 
from  the  cluster  analysis  showed  great  similarity  to  clinical  and  biological 
knowledge  of  the  cultures  in  terms  of  type  (normal,  dysplastic  or  carcinoma)  and 
replicative  fate  (mortal  or  immortal). 
5.1.4  Statistical  analysis 
Statistical  differences  in  gene  expression  were  assessed  using  the  Statistical 
Analysis  of  Microarray  (SAM)  algorithm  (Tusher  et  al.,  2001).  The  multiple 
hypotheses  tested  on  analysis  of  microarray  data  mandates  control  of  the  type  I 
error  rate  (false  positives).  In  SAM  this  is  defined  as  the  False  Discovery  Rate 
(FDR).  SAM  identifies  genes  with  statistically  significant  changes  in  expression 
by  assimilating  a  set  of  gene-specific  t  tests.  Each  gene  is  assigned  a  score 
(delta,  A)  based  on  its  change  in  gene  expression  relative  to  the  standard 
deviation  of  repeated  measurements  for  that  gene  (permutations).  Genes  with 
scores  greater  than  a  threshold,  A,  are  deemed  significant.  The  threshold  can 
be  adjusted  to  identify  smaller  or  larger  sets  of  genes.  The  percentage  of  such 
genes  identified  by  chance  is  the  FDR. 124 
5.2  Pilot  study 
The  pilot  study  assessed  several  important  variables  that  may  impinge  on  the 
gene  expression  profile.  The  3T3  feeders  are  required  for  many  of  these  cells 
to  survive,  but  removal  of  the  feeders  may  have  differential  effects  depending 
on  cell  type,  as  some  of  the  carcinomas  will  grow  in  the  absence  of  an  irradiated 
3T3  feeder  layer.  In  addition,  there  was  concern  that  an  immediate  stress 
response  may  alter  the  GEP,  as  the  feeders  were  being  removed  using 
PBS/EDTA.  Assessment  of  the  effects  of  serum  replenishment  on  the  gene 
expression  profile  and  of  two  different  operators  growing  the  cells,  preparing 
and  labelling  the  RNA,  was  also  required. 
As  it  was  unclear  whether  the  method  of  preparation  of  the  cells  would  have  an 
effect  on  the  gene  expression  profile,  or  affect  the  normal  and  SCC  cultures 
differently,  different  protocols  for  the  removal  of  the  feeder  cells  were  assessed: 
A.  Removal  of  irradiated  3T3  feeders  24  hours  prior  to  RNA  extraction.  The 
cells  were  fed  for  the  intervening  period.  This  allowed  for  much  quicker 
extraction  of  RNA  after  removal  of  the  medium,  but  cells  may  respond 
differently  without  feeders  present. 
B.  Removal  of  the  feeders  immediately  followed  by  RNA  extraction.  This 
minimised  variation  in  culture  conditions,  but  increased  the  possibility  of 
an  immediate  stress  response. 
The  cluster  dendrogram  in  Figure  5.2  shows  a  clear  difference  between  the 
gene  expression  profiles  of  the  normal  culture  (FNB5)  and  carcinoma  (BICR  56) 
as  assessed  by  hybridisation  to  the  Affymetrix  U133A  genechip.  It  also 
demonstrated  that  the  agreement  of  the  technical  replicates  was  good,  despite 
that  fact  that  the  labelling  of  the  replicates  was  carried  out  by  two  different 
operators  (the  author  and  Janis  Fleming).  On  this  basis,  the  subsequent  main 
microarray  study  used  duplicate  technical  replicates.  The  good  reproducibility 
of  the  GEP  of  the  technical  replicates  in  the  pilot  study  was  also  seen 
throughout  the  main  study  (data  not  shown).  The  differences  in  the  GEP  seen 
due  to  alternative  timings  of  feeder  removal  in  prep  method  were  greater  than 
between  different  operators  using  the  same  protocol  (Figure  5.2). 125 
In  order  to  establish  whether  any  3T3  feeders  remained  on  the  plate  and  were 
differentially  contributing  to  the  GEP,  cRNA  prepared  from  irradiated  3T3 
feeders  was  analysed  on  an  Affymetrix  U1  33A  genechip  and  is  also  seen  in  the 
dendrogram  in  Figure  5.2.  This  shows  that  the  gene  expression  profile  of  the 
irradiated  3T3s  was  very  different  from  the  keratinocytes,  regardless  of  how 
they  were  prepared.  The  20  highest  expressed  genes  in  the  3T3s  are  shown  in 
Table  5.1,  in  comparison  with  the  levels  seen  in  FN135  and  BICR  56  (by  both 
methods  of  3T3  removal).  Very  few  genes  were  more  highly  expressed  in  the 
irradiated  3T3  feeders  than  in  the  keratinocyte  cultures.  Furthermore,  only  one 
of  these  genes  (GNAS)  showed  any  differential  expression  between  the  two 
methods  of  3T3  removal. 
Application  of  SAM  to  the  two  timings  of  3T3  removal  yielded  a  list  of 
consistently  differentially  expressed  genes  seen  in  Figure  5.3  (FDR  =  1%,  fold 
change  ýt2).  This  list  includes  genes  involved  in  cell-to-cell  communication, 
such  as  interleukin  8,  several  interleukin  receptors  and  also  genes  involved  in 
adhesion,  such  as  cadherin  11  and  integrin  alpha  2.  Many  of  these  genes  have 
a  role  in  communication  between  the  fibroblasts  and  the  keratinocytes,  which 
may  indicate  a  role  in  aiding  the  survival  of  the  cultures. 
Using  2-factor  ANOVA,  a  small  group  of  genes  was  identified  in  which  the 
different  methods  had  a  differential  effect  on  the  cultures.  This  showed  that  the 
effect  on  the  normal  cultures  of  early  removal  of  3T3s  was  greater  than  in  the 
carcinoma  culture,  as  the  method  A  normal  samples  cluster  differently  to  the 
method  B  normal  samples  (p<0.001).  The  group  of  genes  differentially  affected 
by  the  early  removal  of  the  3T3s  is  shown  in  Figure  5.4.  However,  the  group  of 
genes  is  small  and  the  fold  changes  of  the  genes  involved  were  not  large,  so 
the  differential  effect  is  subtle. 126 
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Figure  5.2  Hierarchical  cluster  of  the  GEPs  of  cultures  used  in  the  of 
microarray  pilot  study. 
The  cluster  was  constructed  using  the  normalised  gene  expression  data  for  all 
genes  and  the  euclidean  distance  measure  with  complete  linkage.  The  pilot 
study  included  9  Affymetrix  U133A  genechips,  including  one  irradiated  3T3 
sample.  Three  variables  were  assessed. 
1.  Two  operators  (KH/JF)  grew  parallel  cultures  of  each  sample. 
2.  Two  methods  of  3T3  feeder  removal: 
A.  removal  of  3T3  and  re-feeding  with  medium  24  hours  prior  to  RNA 
extraction. 
B.  removal  of  3T3s  immediately  prior  to  RNA  extraction. 
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3.  Two  samples:  one  normal  (FNB5)  and  one  carcinoma  (BICR56). 127 
FNB5  FNB5  BICR56  BICR56 
Gene  A  B  A  B  3T3 
GNAS  complex  locus  893  340  1111  360  9617 
eukaryotic  translation 
elongation  factor  1  7221  6888  7706  7105  7393 
alpha  1 
tubulin  alpha  6  7337  7084  7574  7605  7211 
tubulin,  alpha, 
ubiquitous 
7411  6925  7925  7974  6546 
ribosomal  protein  S10  5530  4880  6383  6059  6515 
ribosomal  protein  S2  7029  6650  7921  7262  6342 
ubiquitin  C  6539  6548  6953  6974  5934 
cofilin  1  (non-muscle)  4816  5028  4692  4464  5404 
ribosomal  protein  S27  2645  2470  2925  2641  5313 
ribosomal  protein  S10  4713  3951  5119  5136  . 5240 
poly(A)  binding  protein 
1  2847  2466  4013  3706  5052 
tumor  protein, 
translational  ly-  4390  4394  4411 
1 
4204  5016 
controlled  1 
eukaryotic  translation  3166  2824  1068  593  4977  initiation  factor  5A 
nuclease  sensitive 
element  binding  protein  3019  2557  3630  3739  4829 
11  1  1  1  1 
ribosomal  protein  S12  1  4659  1  4545  1  4839  1  4520  1  4646 
Table  5.1  Assessment  of  contamination  of  keratinocyte  cultures  with 
possible  3T3  genes. 
This  table  outlines  a  comparison  of  the  15  most  highly  expressed  genes  in 
irradiated  3T3  feeders,  with  the  expression  of  these  genes  seen  in  BICR56  and 
FN135,  by  both  timings  of  3T3  removal,  A  and  B.  The  figures  shown  are  the 
mean  values  for  the  technical  replicates. 
Apart  from  one  gene  (GNAS)  there  was  no  systematic  difference  in  the 
expression  of  these  genes  in  the  keratinocyte  cultures.  This  indicated  that 
differential  3T3  contamination  was  unlikely  to  be  contributing  to  the  GEP  of  the 
keratinocyte  cultures. 128 
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Figure  5.3  Graphical  representation  of  genes  significantly  differentially 
expressed  between  methods  A  and  B. 
The  figure  shows  the  expression  of  those  genes  with  red  representing 
overexpression  and  green  underexpression  relative  to  the  median  expression  of 
the  gene  across  the  dataset.  Genes  and  samples  have  been  hierarchically 
clustered  using  euclidean  metric  and  complete  linkage. 
Genes  were  selected  using  SAM  (FDR  1%  and  fold  change  : ý-2).  The  official 
gene  symbol  is  shown  on  the  right.  The  genes  selected  are  a  group  of  genes 
whose  pattern  of  expression  is  related  solely  to  the  timing  of  the  removal  of  3T3 
feeders.  These  genes  are  primarily  related  to  cell  to  cell  communication  (16/28 
by  Gene  Ontology)  and  adhesion  (7/28  by  Gene  Ontology). 
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Figure  5.4  Graphical  representation  of  genes  significantly  differentially 
expressed  by  sample  type  and  by  method. 
The  genes  shown  were  selected  by  2  factor  ANOVA  (p<0.001).  Genes  and 
samples  have  been  hierarchically  clustered  using  euclidean  metric  and 
complete  linkage. 
This  demonstrates  that  a  small  number  of  genes  show  a  pattern  of  expression 
which  changes  only  in  the  normal  cultures  upon  differing  timing  of  feeder 
removal.  Thus,  the  early  (24  hour)  removal  of  the  3T3  feeders  has  a  small,  but 
significant  differential  effect  on  the  normal  cells,  but  not  the  carcinomas.  The 
genes  perform  various  functions  such  as  metabolism  (12/21  by  gene  ontology), 
and  cell  growth  and  maintenance  (5/21).  The  changes  were  not  marked,  but  the 
list  does  include  one  potential  marker  of  immortality  (UPK1  B,  see  Table  5.5). 130 
5.2.1  Discussion 
The  pilot  study  demonstrated  that  there  was  little  difference  in  GEP  of  the  RNA 
isolated  and  prepared  by  the  two  operators.  The  larger  differences  in  GEP 
resulting  from  different  preparation  methods  clearly  indicated  a  need  for  strict 
standardization  of  technique.  There  was  no  evidence  that  contamination  from 
irradiated  3T3  feeders  contributed  significantly  (either  consistently  or 
differentially)  to  the  observed  keratinocyte  GEP.  The  different  timing  of  removal 
affected  expression  of  a  small  number  of  genes  in  the  normal  culture,  with  little 
effect  on  the  carcinoma  culture. 
Such  analysis  demonstrated  the  need  for  strict  standardization  of  the  culture 
and  preparation  protocols.  The  standard  protocol  for  the  preparation  of  all  RNA 
used  in  the  main  microarray  study  was  removal  of  3T3  feeders  immediately 
before  RNA  extraction.  This  was  preferred  because  it  avoided  the  differential 
effects  on  gene  expression  in  the  cultures  that  are  more  dependent  on  the  3T3 
feeder  layer  for  survival.  Such  standardization  also  aligned  the  methodologies 
of  cell  culture  and  preparation  of  the  cells  for  extraction  of  protein  for  the 
validation  steps  later  and  allowed  for  direct  comparison  with  the  earlier 
published  data  that  had  been  gained  from  cells  grown  using  this  protocol. 131 
5.3  Main  study 
The  main  microarray  study  utilised  Affymetrix  U133A  and  B  genechips.  Gene 
expression  profiles  were  gained  from  cell  cultures  derived  from  all  stages  of 
SCCHN  development  -  normal,  dysplastic,  primary  carcinomas  and 
metastases.  This  included  a  number  of  cultures  (both  mortal  and  immortal) 
derived  from  biopsies  where  the  patient  subsequently  developed  a  carcinoma  at 
the  same  site.  The  clinical  and  biological  details  of  all  cultures  used  in  the  study 
are  in  Table  3.1.  The  cells  were  grown  to  a  standardized  protocol  (see  pilot 
study)  and  harvested  at  approximately  60%  confluence. 
5.3.1  Comparison  of  normal  cultures  with  all  carcinomas  cultures 
A  cluster  dendrogram  of  the  normal  cultures  and  all  of  the  carcinomas,  both 
mortal  and  immortal,  is  shown  in  Figure  5.5.  The  cluster  was  constructed  using 
the  mean  value  of  gene  expression  in  the  two  technical  replicates  since  the 
agreement  between  the  GEPs  of  the  two  technical  replicates  was  good  (see 
pilot  study  and  Figure  5.2).  The  dendrogram  demonstrated  a  clear  difference  in 
the  gene  expression  profile  of  mortal  and  immortal  carcinomas.  The  normal 
group  displayed  the  least  heterogeneity,  with  the  mortal  carcinomas  closely 
related  to  the  normal  cultures,  but  forming  a  distinct  group.  The  immortal 
cultures  clustered  together,  again  demonstrating  some  heterogeneity.  The 
culture  in  crisis,  BICR7,  was  related  to,  but  distinct  from,  the  immortal 
carcinoma  cultures. 
Application  of  SAM  to  compare  the  mortal  and  immortal  carcinoma  groups 
yielded  a  list  of  1251  genes  expression  differences  significant  at  a  FDR  of  1% 
and  fold  change  ýt2  (Table  5.2).  In  contrast,  comparison  of  the  normal  with  the 
mortal  and  immortal  carcinomas  gave  lists  of  gene  expression  differences  of 
472  and  716  genes  respectively  (using  the  same  parameters).  Surprisingly,  the 
overlap  between  the  latter  two  lists  of  gene  expression  changes  was  only  11 
genes,  indicating  that  the  mortal  and  immortal  carcinoma  cells  may  have  arisen 
via  divergent  pathways.  However,  such  seeming  large  numbers  of  differences 
in  gene  expression  may  also  occur  in  relation,  for  example,  to  a  change  in 
activity  of  a  single  transcription  factor  or  additional  chromosomal  material 
gained  by  passage  through  crisis. 132 
NT 
NB9 
FNB5 
FNB6 
FNB3 
BICR80 
BICR30 
BICR66 
BICR37 
BICR7 
BICR68 
BICR3 
BICR56 
BICR22 
BICR31 
normal 
mortal  carcinoma 
carcinoma  -  crisis 
immortal  carcinoma 
Figure  5.5  Hierarchical  cluster  based  on  the  gene  expression  profile  of 
normal  and  carcinoma  keratinocyte  cultures. 
The  cluster  was  calculated  using  the  mean  of  two  technical  replicates  for  each 
cell  culture,  all  present  genes,  and  using  the  euclidean  distance  measure  with 
complete  linkage.  The  similarity/difference  between  two  samples  is  based  on 
the  total  distance  travelled  on  the  horizontal  plane. 
The  normal  samples  cluster  together,  with  the  mortal  carcinomas  most  closely 
associated.  The  immortal  carcinomas  are  quite  different  in  terms  of  GEP. 
BICR7  (in  crisis)  does  not  cluster  closely  with  any  of  the  samples 133 
Further  analysis  using  more  stringent  criteria  (1%  FDR  and  a  fold  change  of  > 
5)  reduced  the  list  from  1251  to  155  differences,  as  shown  in  Figure  5.6.  These 
genes  clearly  distinguished  not  only  the  mortal  and  immortal  carcinomas,  but 
also  the  mortal  and  immortal  dysplastic  cultures,  although  some  heterogeneity 
was  present,  particularly  among  the  mortal  samples  (Figure  5.6).  In  general,  the 
genes  fall  into  two  groups  -  those  more  highly  expressed  in  mortal  carcinomas 
and  those  in  immortal  carcinomas.  The  pattern  of  gene  expression  within  the 
mortal  samples  showed  that,  for  many  of  the  genes,  there  was  also  a  difference 
between  the  normal  and  mortal  carcinomas.  Thus,  genes  underexpressed  in  the 
normal  cultures  showed  a  further  reduction  in  expression  in  the  mortal 
carcinomas  and  vice-versa.  This  phenomenon  further  illustrated  the  possibility 
of  divergence  in  the  pathways  to  immortal  and  mortal  carcinomas. 
5.3.2  Comparison  of  normal  and  dysplastic  cell  cultures 
Figure  5.7  shows  the  cluster  dendrogram  for  comparison  of  the  GEPs  of  normal 
cultures  and  all  the  dysplastic  cultures,  both  mortal  and  immortal.  The  main 
difference  in  gene  expression  was  related  to  the  acquisition  of  the  immortal 
phenotype.  Compared  with  the  carcinomas,  there  was  a  greater  level  of 
heterogeneity  in  relation  to  the  dysplastic  cell  cultures,  particularly  amongst  the 
mortal  samples.  Two  samples  (D41  and  D48)  consistently  clustered  with  the 
normal  samples.  These  were  the  only  mortal  dysplastic  cultures  derived  from 
non-smokers,  whilst  the  others  were  derived  from  smokers.  One  mortal  sample 
(D17)  clusters  with  the  immortal  samples.  Whilst  this  culture  senesces,  it  only 
does  so  after  an  extended  lifespan.  In  addition,  it  demonstrates  some  of  the 
features  associated  with  immortal  cells,  namely  loss  of  p16  and  RAR-fl.  Clearly 
in  addition  to  these  changes,  it  had  an  overall  GEP  similar  to  the  immortal 
cultures  (see  comments  later).  Within  the  immortal  samples,  D35  was 
somewhat  different  in  pattern  of  gene  expression.  This  patient  subsequently 
developed  a  carcinoma  at  the  same  site  within  six  months  of  the  initial  biopsy. 
Thus,  it  is  possible  that  invasive  SCC  was  present  in  another  part  of  the  lesion 
at  the  time  of  initial  assessment.  The  GEP  of  the  other  immortal  cultures  from 
patients  who  developed  a  carcinoma  at  the  same  site  (D19  and  D20)  did  not 
cluster  consistently  with  the  carcinomas. 134 
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Figure  5.6  Graphical  representation  of  genes  significantly  differentially 
expressed  between  mortal  and  immortal  carcinoma  samples. 
Genes  were  selected  using  SAM  (FDR  :!!  ý  1  %)  and  ýt  5  fold  difference  in 
expression  between  mortal  and  immortal  carcinomas,  giving  a  total  of  155 
genes.  The  figure  shows  the  expression  of  these  genes  in  all  samples  (normal, 
dysplasia  and  carcinoma).  Red  represents  relative  overexpression  and  green 
relative  underexpression  as  shown  in  the  visual  scale.  Genes  have  been 
hierarchically  clustered  using  euclidean  metric  and  complete  linkage.  This 
demonstrates  that  some  of  the  genes  which  differentiate  mortal  and  immortal 
carcinomas  also  differentiate  mortal  and  immortal  dysplastic  cell  cultures. 
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Figure  5.7  Hierarchical  cluster  based  on  the  GEP  of  dysplastic  and 
normal  keratinocyte  cultures. 
The  cluster  was  calculated  using  the  mean  of  the  two  technical  replicates  for 
each  cell  culture,  all  present  genes,  and  using  the  euclidean  distance  measure 
with  complete  linkage. 
The  normal  cultures  cluster  together  along  with  D41  and  D48.  The  other  mortal 
dysplastic  cultures  cluster  together  except  D17  (marked  with  a  star)  which 
clusters  with  the  immortal  cell  cultures. 136 
5.3.3  Cluster  analysis  of  all  samples 
Figures  5.8  and  5.9  show  cluster  dendrograms  constructed  using  all  the 
samples  in  the  study.  The  matrix  has  been  clustered  using  two  different 
distance  measures,  euclidean  distance  (Figure  5.8)  and  cosine  correlation 
(Figure  5.9).  Euclidean  distance  is  the  most  common  method  employed  to 
measure  differences  between  the  points  in  n-dimensional  space  that  represent 
gene  expression  values.  It  clusters  based  on  absolute  values  of  gene 
expression.  However,  a  more  appropriate  metric  for  clustering  of  microarray 
data  may  be  the  cosine  correlation,  related  to  the  angle  between  the  vectors, 
since  it  allows  comparison  of  trends  in  change  of  gene  expression  amongst 
samples  rather  than  their  absolute  values  (Causton  et  al.,  2003). 
There  were  few  differences  in  gene  expression  relationships  identified  by  the 
different  distance  metrics,  but  some  interesting  points  emerge.  The  euclidean 
metric  placed  immortal  dysplastic  cultures  D4  and  D38  with  the  mortal  cultures, 
in  close  association  with  D17.  However,  the  cosine  correlation  metric  placed 
D17  with  the  immortal  cultures  closely  associated  with  D38  and  BICR7  (a 
carcinoma  in  19  crisis").  This  indicates  that  the  patterns  of  gene  expression  in  D1  7 
and  D38  had  some  common  features  to  that  seen  in  immortality  and  crisis, 
whilst  in  terms  of  overall  gene  expression  levels  it  was  more  like  the  mortal 
cultures.  There  was  also  evidence  that  D4  changed  in  early  pass  culture,  losing 
expression  of  RAR-fl  (McGregor  et  al.,  1997).  This  may  indicate  that  D4 
progressed  through  crisis  shortly  after  establishment  in  culture  and  may  account 
for  a  similar  effect  in  relation  to  its  position  in  the  different  cluster  dendrograms. 
However,  on  comparison  with  the  dendrogram  in  Figure  5.7,  it  is  clear  that 
these  effects  were  subtle,  as  D4,  D17  and  D38  clustered  with  the  immortal 
samples,  despite  the  use  of  the  euclidean  distance  metric.  The  pattern  in  Figure 
5.9  also  indicates  that  the  gene  expression  patterns  associated  with  crisis  (as 
seen  in  BICR7)  may  have  been  present  to  some  degree  in  D17  and  D38.  The 
euclidean  metric  clustered  the  mortal  carcinomas  close  together,  whereas  with 
the  cosine  correlation,  there  was  greater  heterogeneity,  particularly  in  the  mortal 
carcinomas. 
The  main  difference  in  GEP  seen  in  both  clusters  was  associated  with  the 
acquisition  of  immortality.  In  addition  to  this,  some  consistent  subgroups  were 
identified  within  the  mortal  and  immortal  groups. 137 
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Figure  5.8  Hierarchical  cluster  based  on  the  GEP  of  all  samples  using 
euclidean  distance. 
The  cluster  is  based  on  the  mean  values  of  technical  replicates,  using  all 
present  genes.  Distance  metric  =  euclidean,  with  complete  linkage.  The 
euclidean  distance  metric  uses  absolute  values  of  gene  expression  to  calculate 
the  cluster  dendrogram. 138 
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Figure  5.9  Hierarchical  cluster  based  on  the  GEP  of  all  samples  using 
cosine  correlation 
The  cluster  is  based  on  the  mean  values  of  technical  replicates,  using  all 
present  genes.  distance  metric  =  cosine  correlation  linkage  =  complete.  The 
cosine  correlation  metric  groups  samples  according  to  trends/pattern  of 
expression  rather  than  absolute  value. 139 
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5.3.4  Dysplasia  progression 
The  patients  whose  biopsies  gave  rise  to  D  19,  D20,  D35  (immortal),  and  E2,  E4 
and  E5  (mortal)  all  subsequently  developed  SCCHN.  The  carcinomas 
associated  with  D19,  D20  and  D35  arose  at  the  same  intra-oral  site  as  the 
original  dysplastic  biopsy,  whereas  the  clinical  details  of  the  carcinomas  related 
to  E2,  E4  and  E5  are  less  clear.  Microarray  analysis  did  not  allow  us  to  identify 
clear  groupings  of  the  dysplastic  cultures  derived  from  lesions  that  subsequently 
progressed  to  carcinoma.  However,  D35  consistently  clustered  with  certain 
immortal  carcinomas,  but  there  was  no  consistent  relationship  of  D19  and  D20 
to  the  carcinomas  (Figures  5.8  and  5.9).  As  a  group,  the  erythroplakia  cultures 
(Ell,  E2,  E4  and  E5)  did  not  show  a  consistent  pattern  of  relationship  to  the 
carcinoma  cultures,  however  El  and  E2  were  closely  associated  with  mortal 
carcinoma  cultures,  regardless  of  the  distance  metric  used  to  construct  the 
cluster  dendrogram  (Figures  5.8  and  5.9).  However,  as  the  clusters  were  based 
on  the  entire  gene  expression  profile,  this  does  not  rule  out  the  possibility  that  a 
"high  risk  signature"  of  gene  expression  in  the  dysplastic  cultures  that  clinically 
progressed  to  carcinoma  may  be  hidden  in  a  subset  of  the  data.  Paul  Drake,  a 
Clinical  Research  Fellow  in  the  group,  is  conducting  further  analysis  of  the  data 
with  the  aim  of  identification  of  such  a  gene  expression  signature. 
5.3.5  Identification  of  the  genes  associated  with  the  immortal  phenotype 
Based  on  the  groups  derived  from  the  cluster  analysis  and  from  clinical  and 
biological  knowledge,  various  groups  of  the  cultures  were  selected  for  analysis 
by  SAM.  Statistical  analysis  was  also  performed  using  ANOVA,  with  good 
agreement  of  the  list  of  genes  selected  by  the  two  methods  (Figure  5.10).  The 140 
number  of  statistically  significant  differences  in  gene  expression  between  the 
groups  selected  is  shown  in  Table  5.2  (upper  and  lower).  The  FDR  of  1%  was 
selected  as  this  was  deemed  to  give  a  working  list  of  a  manageable  size,  whilst 
maintaining  a  high  level  of  stringency.  In  addition,  the  fold  change  cut  off  was 
set  at  ýt2  for  practical  reasons  including  limiting  the  size  of  the  gene  lists  and 
allowing  for  some  possibility  of  validation  of  the  differences  identified  by 
independent  methods.  D17  was  excluded  from  the  mortal  dysplastic  group 
since,  as  indicated  previously,  this  appears  to  have  an  overall  GEP  very  similar 
to  the  immortal  dysplastic  samples  (Figures  5.8  and  5.9). 
The  method  for  selection  of  the  genes  associated  with  immortality  is  shown  in 
Figure  5.11.  This  selected  consistent  differences  in  gene  expression  that  are 
associated  with  the  immortal  phenotype,  whether  at  the  dysplasia  or  carcinoma 
stages.  This  required  comparison  of  the  normal  cultures  with  the  immortal 
dysplastic  culture  and  the  immortal  carcinomas  (comparisons  1  and  2). 
Additionally,  these  differences  in  gene  expression  had  to  be  present  on 
comparison  of  the  mortal  and  immortal  dysplastic  cultures  (comparison  3).  Initial 
criteria  also  excluded  genes  that  differed  on  comparison  of  the  normal  cultures 
and  mortal  carcinomas.  On  close  inspection  of  the  expression  pattern  of  these 
genes  this  was  seen  to  be  inappropriate  as  the  differences  noted  in  many  of 
these  genes  were  paradoxical  to  the  differences  associated  with  immortality. 
Thus,  these  genes  were  retained  in  the  list.  Examples  of  genes  retained 
include  cdc20  and  AF1Q  in  Figures  5.13  and  5.14. 
This  analysis  yielded  a  list  of  55  Affymetrix  probesets,  representing  49  different 
genes  (Figure  5.12).  Of  these  genes,  27  were  expressed  at  a  higher  level  in 
immortal  samples  and  22  genes  were  expressed  at  a  lower  level  in  immortal 
samples  than  mortal.  The  mean  expression  level  for  the  different  biological 
groups  (with  standard  error)  is  shown  in  Figures  5.12  and  5.13.  This 
demonstrates  the  variability  within  the  groups,  even  though  the  statistical 
stringency  in  the  initial  SAM  analysis/ANOVA  was  high.  Certain  genes  have 
extremely  large  standard  errors,  particularly  within  the  mortal  carcinoma  group 
in  Figure  5.13.  As  it  was  less  likely  that  these  genes  would  be  good  markers  of 
the  immortal  phenotype,  none  of  these  markers  was  selected  for  the 
subsequent  validation  steps. 141 
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Figure  5.10  Comparison  of  the  size  and  agreement  of  gene  lists  obtained 
by  SAM  and  ANOVA 
This  Venn  diagram  illustrates  the  agreement  between  ANOVA  (p<0.01)  and 
SAM  (FDR  1%)  in  the  comparison  of  normal  v  immortal  carcinoma  (in  both 
cases  fold  change  >2  fold).  In  this  instance,  the  ANOVA  list  is  almost 
completely  a  subset  of  the  SAM  list. 142 
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Table  5.2  (upper  and  lower)  Number  of  statistically  significant  differences 
in  gene  expression  in  comparison  of  all  groups. 
The  numbers  of  gene  expression  differences  were  generated  using  SAM  at 
FDR1%  and  fold  changes  L-2.  MD  =  mortal  dysplasia,  MDT  =  mortal  dysplasia 
which  progressed  to  carcinoma,  MC  =  mortal  carcinoma,  ID  =  immortal 
dysplasia,  IDT  =  immortal  dysplasia  which  progressed  to  carcinoma,  IC  = 
immortal  carcinoma.  The  allMD-D17  v  all  ID  could  not  be  completed  due  to  a 
lack  of  sufficient  computing  power  at  BICR. 
D17  was  left  out  of  these  analyses  since,  as  previously  indicated,  this  appears 
to  have  a  GEP  very  close  to  the  immortal  dysplasias  overall  (Figures  5.8  and 
5.9  and  comments  in  the  text). 
The  largest  number  of  significant  differences  in  gene  expression  were  found  on 
comparison  of  mortal  carcinomas  and  immortal  dysplasias  which  progressed  to 
carcinoma  . 143 
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Figure  5.11  Venn  diagram  illustrating  the  method  of  identification  of 
genes  associated  with  immortality 
Gene  lists  derived  from  the  statistical  analysis  of  comparisons  of  various  groups 
were  loaded  into  Genespring@.  Only  genes  which  showed  consistent 
differences  in  the  normal-immortal  dysplasia  and  normal-immortal  carcinoma 
comparisons  and  were  also  present  in  a  comparison  of  mortal-immortal 
dysplasias  were  selected.  The  55  probe  sets  identified  relate  to  49  individual 
genes  (Figure  5.12). 
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Figure  5.12  Graphical  representation  of  expression  of  55  candidates. 
The  55  probe  sets  were  derived  as  shown  in  Figure  5.11.  The  diagram  shows 
the  genes  and  samples  clustered  using  the  euclidean  distance  metric  and 
complete  linkage.  Red  indicates  relative  overexpression,  and  green  relative 
underexpression  -  see  visual  scale. 
The  genes  divided  into  two  clear  groups  with  reciprocal  patterns  related  to  the 
immortal  phenotype.  The  samples  clustered  very  similarly  to  that  seen  in  earlier 
figures,  however  NT  (marked)  no  longer  clusters  with  the  other  normal  samples. 
All  of  the  immortal  dysplasia  cultures  that  progressed  to  carcinoma  (D19,  D20 
and  D35)  were  closely  associated  with  immortal  carcinoma  cultures. 
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Figure  5.13  Affymetrix  U133A  genechip  expression  levels  of  27  genes 
overexpressed  in  immortal  samples. 
Genes  were  selected  as  outlined  in  Figure  5.11.  Expression  level  is  the 
normalised  mean  Affymetrix  expression  level  for  each  group  with  the  standard 
error  of  the  mean  also  shown.  In  addition  to  demonstrating  overexpression  in 
the  immortal  samples,  many  of  these  genes  showed  a  reduction  of  expression 
on  comparison  of  the  normal  and  mortal  samples. 146 
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Figure  5.14  Affymetrix  U133A  genechip  expression  levels  of  22  genes 
underexpressed  in  immortal  samples. 
Genes  were  selected  as  outlined  in  Figure  5.11.  Expression  level  is  the 
normalised  mean  Affymetrix  expression  level  for  each  group  with  the  standard 
error  of  the  mean  also  shown.  Whilst  these  genes  demonstrate  consistent 
underexpression  in  the  immortal  samples,  the  standard  errors,  particularly  in  the 
mortal  samples  were  often  large,  indicative  of  the  heterogeneity  within  these 
samples. 147 
5.3.5.1  Functional  and  gene  ontology  annotation. 
The  genes  identified  are  shown  in  Tables  5.3  and  5.4,  together  with  a  brief 
description  of  their  function.  Some  of  these  genes  are  related  to  p53,  either  as 
directly  p53  responsive  genes  or  indirectly  through  unknown  intermediates. 
These  genes  include  GOS2,  ALDH1A3  and  DDA3. 
Classification  of  the  genes  using  the  gene  ontology  (GO)  is  a  useful  method  of 
classifying  the  genes  related  to  biological  process,  molecular  function  or  cellular 
component  (Ashburner  et  al.,  2000).  However,  the  GO  is  not  complete  and 
many  genes,  particularly  those  whose  function  has  not  been  fully  investigated, 
do  not  have  a  GO  annotation.  This  may  introduce  a  certain  amount  of  bias  into 
the  spread  of  gene  ontology  term  seen.  Statistical  analysis  of  the  relative 
overrepresentation  of  particular  gene  ontology  terms  using  Fisher  exact 
probability  revealed  several  groups  of  genes  that  were  over  represented  in  the 
subset  of  genes  associated  with  immortality  (Tables  5.5  and  5.6).  Many  of  the 
genes  more  highly  expressed  in  immortal  cells  are  associated  with  cell 
proliferation,  but  there  are  other  genes  whose  biological  function  does  not  relate 
to  this,  for  example  HMMR,  and  GlP2.  The  genes  that  were  more  highly 
expressed  in  the  mortal  cells  are  a  much  more  varied  group.  Many  of  these  are 
associated  with  metabolism  of  various  substrates  (including  alcohol,  retinoids, 
lipids  and  proteins),  whilst  others  are  associated  with  the  inflammatory  response 
(e.  g.  CXCI-6). 
It  is  possible  that  the  preponderance  of  genes  related  to  the  cell  cycle  amongst 
the  genes  overexpressed  in  the  immortal  cultures  may  be  misleading.  This  may 
partly  be  due  a  greater  growth  fraction  or  higher  proliferative  rate  than  mortal 
cultures,  as  the  doubling  time  is  shorter  for  immortal  cultures  than  for  mortal 
cultures  (data  not  shown).  Alternatively,  the  mortal  cultures  may  contain  a 
senescent  subpopulation  even  though  the  cultures  were  used  at  the  earliest 
passage  possible.  However,  there  are  many  other  genes  in  these  lists  that 
have  not  been  linked  to  the  cell  cycle  and  these  may  prove  to  be  proliferation 
independent  markers  of  the  immortal  phenotype.  However,  the  cells  that  are 
immortal  may  have  consistent  changes  within  the  regulatory  mechanisms  of  the 
cell  cycle  and  as  such,  these  genes  may  be  important  and  should  be  assessed 148 
Symbol  Gene  Name  Alias  Genbank  Biological  function 
acidic  nuclear  phosphor-  function  unclear,  inhibits  protein  phosphatase 
ANP32E  protein  32  family,  member  E  LANP-L  NM  030920  2A 
abnormal  spindle-like, 
ASPM  microcephaly  associated  NM  018123  microtubule-based  process 
regulation  of  cell  cycle  -  G2/M 
CCNB1  Cyclin  131  NM  031966  transition/mitosis,  complexes  with  cdc2 
mitosis,  protein  amino  acid  phosphorylation, 
CDC2  cell  division  cycle  2  CDK1  NM  001786  start  control  point  of  mitotic  cell  cycle 
cell  division  cycle  20  regulation  of  cell  cycle,  ubiquitin-dependent 
CDC20  homologue  p55CDC  NM  001255  protein  catabolism 
DNA  replication  and  chromosome  cycle, 
CENPF  centromere  protein  F  mitosin  NM  016343  regulation  of  mitosis,  chromosome  separation 
differential  display,  activated  CKS1  B, 
DDA3 
_ 
by  p53  CDC28  NM  001826  regulation  of  CDK  activity,  cytokinesis 
DLG7  discs,  large  homolog  7  HURP  NM  014750  cell-cell  signalling 
FLJ30525  hypothetical  protein  NM  144584  function  unknown 
interferon  alpha-inducible 
G1  P2  protein  IF115  NM  005101  cell-cell  signalling,  immune  response 
GTF21RD2  GTF21RD2  AY312853  transcription  factor 
chromosome  condensation 
HCAP-G  protein  G  CAP-G  NM  022346  mitotic  chromosome  condensation 
hyaluronan-mediated  motility 
HMMR  receptor  RHAMM  NM  012485  cell  motility 
cDNA  for  differentially 
HSJO01348  expressed  C016  gene  NM  017527  function  unknown 
invasive  growth  microtubule-based  process, 
IF144  interferon-induced  protein  44  MTAP44  NM006417  response  to  viruses 
KIAA0186  hypothetical  protein  NM  021067 
mitotic  arrest  deficient-like  1  HSMAD2  mitotic  chromosome  segregation,  mitotic 
MAD21_1  (yeast)  MAD2  NM  002358  spindle  checkpoint 
cytokinesis,  meiosis,  protein  amino  acid 
NEK2  NIMA-related  kinase  2  NLK1  NM  002497  phosphorylation,  regulation  of  mitosis 
RA-regulated  nuclear  matrix- 
RAMP  associated  protein  L2DTL  NM  016448  function  unknown 
SIP  Siah-interacting  protein  CACYBP  NM  014412  centromere/kinetochore  complex  maturation 
structural  maintenance  of  chromosome  organization,  condensation,  and 
SMC4L1  chromosomes  4-like  1  CAP-C  NM  005496  segregation,  transport 
STK6  serine/threonine  kinase  6  ALK  NM  003158  mitosis,  protein  amino  acid  phosphorylation 
TOP2A  topoisomerase  11  alpha  NM  001067  DNA  topological  change 
TPX2,  microtubule- 
TPX2  associated  protein  homolog  NM  012112  mitosis 
ESK,  mitotic  spindle  assembly  and  checkpoint, 
MPS1  L1,  positive  regulation  of  cell  proliferation,  protein 
TTK  TTK  protein  kinase  PYT  NM  003318  amino  acid  phosphorylation 
Cyclin  catabolism,  mitosis,  regulation  of  cell 
ubiquitin-conjugating  enzyme  proliferation,  regulation  of  DNA  repair, 
UBE2C  E2C  ubch1O  NM  007019  ubiquitin-dependent  protein  catabolism 
ZIC2  Zic  family  member  2  HPE5  NM  007129  brain  development 
Table  5.3  Functional  annotation  of  27  genes  overexpressed  in  immortal 
cell  cultures. 
The  biological  function  noted  is  that  designated  by  the  gene  ontology  and  is  a 
composite  from  all  three  of  the  annotation  networks  of  the  gene  ontology. 149 
Symbol  Gene  Name  Alias  Genbank  Biological  functions 
ABCAl  ATP-binding  cassette,  sub-  CERP  NM_005502  cholesterol  metabolism, 
family  A,  member  1  phagoc  osis,  protein  targeting 
ADAMTS1  a  disintegrin-like  and  METH1  NM006988  integrin-mediated  signalling  pathway, 
metalloprotease  with  negative  regulation  of  cell 
thrombospondin  type  1  proliferation,  proteolysis  and 
motif,  1  peptidolysis 
AFlq  ALL1  -fused  gene  from  NM006818  cell  growth  and  maintenance 
chromosome  lq 
ALDHlA3  aldehyde  dehydrogenase  1  ALDH6  NM000693  alcohol  and  lipid  metabolism 
family,  member  A3 
ALDH4Al  aldehyde  dehydrogenase  4  ALDH4  NM003748  proline  biosynthesis/catabo  I ism 
family,  member  Al 
CXCL6  chemokine  (C-X-C  motif)  GCP-2  NM002993  chemotaxis,  cell-cell  signalling, 
ligand  6  inflammatory  response,  signal 
transduction 
GOS2  putative  lymphocyte  GO/Gl  NM015714  regulation  of  cell  cycle 
switch  gene 
GPX3  glutathione  peroxidase  3  NM002084  response  to  lipid  hydroperoxide 
IGFBP2  insulin-like  growth  factor  IBP2  NM000597  regulation  of  cell  growth 
binding  protein  2 
IVIL  involucrin  NM005547  differentiation 
KLK7  kallikrein  7  NM005046  epidermal  differentiation,  proteolysis 
and  peptidolysis 
KRT23  keratin  23  HAIM  NM015515  cytoskeleton  organization  and 
biogenesis 
LCN2  lipocalin  2  (oncogene  24p3)  NGAL  NM005564  transport 
LOC91947  signal  transduction,  sensory 
perception 
PLAT  plasminogen  activator,  T-PA  NM_000930  blood  coagulation,  protein 
tissue  modification,  proteolysis  and 
peptidolysis 
RHCG  Rhesus  blood  group,  C  RHGK  NM016321  transport 
glycoprotein 
Sl0OA9  S100  calcium  binding  CAGB;  NM_002965  cell-cell  signalling,  inflammatory 
protein  A9  MIF  response 
sloop  S100  calcium  binding  NM_005980  calcium  binding,  motility 
protein  P 
SERPINBII  serine  proteinase  inhibitor,  MNEI;  Pl  NM_030666  regulation  of  proteolysis  and 
clade  B  (member  1  2  peptidolysis 
SLC6Al4  solute  carder  family  6  ATB(O+)  NM007231  amino  acid  metabolism, 
member  14  neurotransmitter  transport 
SPRR3  small  proline-rich  protein  3  NM005416  cornfied  envelope.  differentiation 
UPM  B  uroplakin  1B  NM006952  urothelial  differentiation 
Table  5.4  Functional  annotation  of  22  genes  underexpressed  in  immortal 
cell  cultures. 
The  biological  function  noted  is  that  designated  by  the  gene  ontology  and  is  a 
composite  from  all  three  of  the  annotation  networks  of  the  gene  ontology. 150 
GO  biological  process 
group 
I  No.  of 
genes 
I  Fisher  exact 
probability,  p 
I  examples 
cell  proliferation 
cell  cycle  15  3.7x10-14  MAD21-1 
,  cdc20 
mitosis  11  5.5xl  0-17  STK6,  CAPG, 
G2/M  transition  2  0.004  DDA3,  CyclinB1 
G1  1  0.03  Cdc2 
metabolism 
protein  modification  5  0.03  STK6,  NIMA 
ubiquitin-dependent 
protein  catabolism 
2  0.02  UBE2C,  cdc20 
DNA  metabolism 
regulation  of  DNA 
repair 
1  0.01  UBE2C 
DNA  topological 
change 
1  0.01  TOP2A 
cytoskeleton 
organization 
3  0.02 
I 
ASPM,  IF144 
I 
Table  5.5  Classification  of  genes  upregulated  at  immortality  by  GO 
biological  process. 
The  analysis  demonstrates  several  significantly  over  represented  groups  of 
genes,  as  assessed  by  Fisher  exact  probability.  Only  groups  over  represented 
with  p<0.05  were  considered  significant.  Groups  are  presented  as  a  primary 
term  (shaded  pale  blue)  with  "child"  terms  underneath.  The  primary  term  may 
not  itself  be  significantly  over  represented.  A  particular  gene  with  multiple 
functions  may  belong  to  more  than  one  group. 151 
GO  biological  No.  of  Fisher  exact 
process  group  genes 
I 
probability,  p  examples 
metabolism 
I 
alcohol  metabolism  2  0  04  ALDH1A3 
.  ALDI-14 
amino  acid  2  0  03  SLC6A14 
metabolism  . 
protein  catabolism  4  0.02  KLK7,  PLAT 
immune  response 
inflammatory  2  0  03  CXCL6 
response  .  S10OA9 
Table  5.6  Classification  of  genes  down-regulated  at  immortality  by  GO 
biological  process. 
The  analysis  demonstrates  several  significantly  over  represented  groups  of 
genes,  as  assessed  by  Fisher  exact  probability  Groups  are  presented  as  a 
primary  term  (shaded  pale  blue)  with  associated  child  terms  underneath  (if 
appropriate).  The  primary  term  may  not  itself  be  significantly  over  represented. 
The  analysis  demonstrates  several  significantly  over  represented  groups  of 
genes,  as  assessed  by  Fisher  exact  probability.  Only  groups  over  represented 
with  p<0.05  were  considered  significant. 152 
in  the  validation  steps.  The  above  provisos  must  be  noted,  particularly  when 
validating  these  markers  in  vivo. 
5.3.6  Discussion 
The  pilot  study  was  vital  in  aiding  our  understanding  of  the  effects  that  subtle 
changes  in  experimental  protocol  could  have  on  the  gene  expression  profile.  It 
confirmed  that  strict  standardization  of  the  protocol  was  required.  The  pilot 
study  also  demonstrated  the  differential  effect  that  the  removal  of  irradiated  3T3 
feeders  may  have  on  the  GEP,  particularly  on  the  normal  cultures. 
Microarray  analysis  of  samples  from  all  stages  of  the  development  of  HNSCC 
revealed  that  the  main  differences  in  gene  expression  were  associated  with  the 
immortal  phenotype.  Within  the  main  division  of  the  samples  into  mortal  and 
immortal,  many  of  the  samples  clustered  according  to  their  clinical  groups. 
Exceptions  to  this  included  the  consistent  clustering  of  D41  and  D48  with  the 
normal  samples.  It  was  noted  earlier  that  these  patients  were  non-smokers  and 
that  the  tissues  from  which  these  cultures  were  derived  expressed  hTERT  at  a 
high  level.  This  may  indicate  that  these  cultures  are  fundamentally  different 
from  the  other  mortal  dysplastic  cultures.  Comparison  with  the  expression  of 
hTERT  in  the  tissues  related  to  the  normal  samples  may  shed  some  light  on 
this.  However,  no  tissue  from  the  normal  biopsies  was  retained  (either  frozen  or 
formalin  fixed),  so  this  analysis  is  not  possible. 
The  microarray  analysis  allowed  for  the  generation  of  a  list  of  novel  candidate 
genes  associated  with  the  immortal  phenotype.  Many  of  the  genes  that  were 
overexpressed  in  the  immortal  cultures  are  related  to  control  of  the  cell  cycle. 
All  these  genes  require  to  be  validated  to  confirm  the  accuracy  of  microarray 
data  and  assess  if  the  differences  seen  at  the  level  of  transcript  are  also  seen 
after  translation. 153 
Chapter  Six:  Validation  of  microarray  results 
6.1  Expression  of  well  characterised  markers 
Initial  validation  was  restricted  to  the  well-characterised  markers  in  the  cultures 
such  as  hTERT,  RAR-fl,  and  p16.  The  expression  of  these  markers  is  outlined 
in  Figure 
6.1.1  hTERT 
The  upper  panel  of  Figure  6.1  shows  the  expression  of  hTERT  as  detected  by 
the  Affymetrix  U133A  genechip.  Only  one  of  the  two  hTERT  probe  sets  on  the 
U133A  genechip  passed  the  filtering  level  set  in  the  initial  analysis  (i.  e.  ý!  6P). 
One  culture,  which  had  hTERT  ectopically  expressed  by  retroviral  vector  (D17 
EST)  was  added  to  this  graph  as  a  positive  control.  This  demonstrates  that  the 
Affymetrix  U133A  probe  set  207199at  does  detect  hTERT,  but  only  when 
present  at  a  high  level,  such  as  follows  ectopic  expression.  Otherwise,  there  is 
little  discernable  difference  in  the  expression  of  hTERT  in  the  mortal  and 
immortal  samples.  There  is  no  correlation  between  this  result  and  that  found  by 
quantitative  RT-PCR  (McGregor  et  al.,  2002).  This  indicates  that  the  probe  set  is 
not  sensitive  enough  to  measure  accurately  the  expression  of  hTERT  in  these 
keratinocyte  cultures. 
6.1.2  RAR-fl 
The  lower  panel  of  Figure  6.1  shows  the  expression  of  RAR-,  8  as  detected  by 
the  only  one  of  three  probe  sets  that  passed  the  initial  filtering  criteria.  This 
demonstrates  a  good  agreement  with  the  previously  published  Northern  blot 
data  (McGregor  et  al.,  1997).  The  level  of  expression  is  low  in  D41  and  D48, 
but  this  is  appropriate  considering  their  similarity  to  the  normal  cultures  that  has 
been  demonstrated  by  the  GEP.  Unfortunately  Northern  blot  analysis  of  RARfl 
expression  in  these  samples  has  not  been  conducted. 154 
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Figure  6.1  Expression  of  "known"  markers  on  Affymetrix  U133A  genechip 
Panel  A  shows  expression  of  hTERT  as  measured  by  oligo-nucleotide  probe  set 
207199 
- 
at.  D17  with  ectopically  expressed  hTERT  (D17EST)  and  the  empty 
vector  control  (D1  7NEO)  were  included  as  controls. 
Panel  B  shows  expression  of  RARfl  as  measured  by  oligonucleoticle  probe  set 
205080 
- 
at.  The  other  RARfl  probe  set  is  not  informative  and  was  not  passed 
as  "present"  in  the  initial  filtering  of  the  data. 
Two  of  the  three  p16  probe  sets  were  designated  as  present  in  the  initial 
filtering.  However,  the  oligonucleoticle  probe  sets  for  the  measurement  of  p16 
on  the  U1  33A  genechip  were  not  informative. 155 
6.1.3  PI  6 
Blast  analysis  of  the  probe  sets  for  p16  revealed  that  the  probe  sets  which 
Affymetrix  state  measure  p16  expression  are  located  in  exon  2  of  the  CDKN2a 
locus.  Selection  of  probe  sets  in  this  location  does  not  allow  for  differentiation 
of  the  expression  of  p16  and  p14  (ARF)  and  thus  the  data  generated  is  not 
informative. 
6.1.4  p53 
The  complex  regulation  of  p53  levels  by  modulation  of  p53  degradation  means 
that  expression  of  p53  mRNA  does  not  necessarily  relate  to  the  protein  level  or 
the  function  of  the  protein.  Thus,  it  is  more  informative  to  look  at  the  expression 
of  various  p53  target  genes.  The  Affymetrix  gene  expression  for  a  selection  of 
these  is  shown  in  Table  6.1.  Many  of  these  genes  changed  in  a  predictable 
manner  related  to  the  loss  of  p53  in  the  immortal  cultures.  However,  others 
showed  no  change  at  all. 
6.1.5  Discussion 
The  microarray  expression  of  these  well-characterised  genes  agrees  well 
expression  as  assessed  by  other  methods  (see  chapter  4).  However,  this 
analysis  has  highlighted  the  limitations  of  microarray  analysis  with  regard  to 
sensitivity,  specificity  and  accurate  design  and  annotation  of  the  probe  sets.  It 
is  also  not  possible  to  comment  meaningfully  on  proteins  for  which  expression 
level  or  activity  is  controlled  mainly  by  post-translational  events. 156 
GENE  Normal  MD  mc  ID  Ic 
p2lWAF1  836  ±  34  803  ±  37  1183  472  393  ±  38  197  154 
Cyclin  G2 
296  ±  30  261±  15  438  ±  81  166  ±  28  110  ±  17 
Ribonucleotide 
reductase  MI  322  ±  34  332  ±  21  156  ±  12  580  ±  86  596  ±  48 
Ribonucleotide  691  1130  1105 
reductase  M2  130  703  ±  93  102  ±  27  210  101 
GADD45  901  ±  634  ±  44  1231  ±  490  ±  90  485  ±  78  119  132 
tp531P3  490  ±  607  ±  35  1044  ±  351  ±  79  176  ±  30  104  93 
PERP  2109  1676  2230  ±  1655  1147 
185  133  106  217  96 
Table  6.1  Mean  Affymetrix  expression  level  of  selected  known  p53  target 
genes  in  various  groups  of  samples. 
The  numbers  shown  in  the  table  are  normalised  and  represent  the  mean  for  the 
various  groups  with  standard  error  of  the  mean  also  shown.  MID  =  mortal 
dysplasia,  MC  =  mortal  carcinoma,  ID  =  immortal  dysplasia  and  IC  =  immortal 
carcinoma.  No  significant  differences  in  expression  of  other  p53  target  genes, 
such  as  PUMA,  MDM2,  BAX,  PIDD,  FAS,  were  seen. 157 
6.2  Validation  of  novel  candidate  markers  of  immortality  in  vitro  by 
western  blotting 
The  candidate  markers  of  immortality  were  validated  by  Western  blotting. 
Ultimately,  this  was  preferred  to  validation  at  mRNA  level  by  quantitative  RT- 
PCR  as  only  markers  that  show  differences  at  protein  level  can  be  considered 
to  harbour  gene  expression  changes  that  may  alter  the  phenotype  of  the  cell. 
Even  so,  many  functional  changes  are  post-translational  and  are  unlikely  to  be 
identified  by  Western  blotting.  Additionally,  the  expression  of  some  genes  may 
be  regulated  by  alterations  in  the  pattern  of  degradation  of  the  encoded 
proteins.  The  use  of  Western  blotting  restricted  the  validation  process  to  those 
genes  for  which  antibodies  were  commercially  available.  The  Western  blots, 
together  with  the  Affymetrix  expression  data,  for  a  selection  of  these  validated 
are  seen  in  Figures  6.2  (genes  more  highly  expressed  in  immortal  cells)  and 
7.2.2  (genes  more  highly  expressed  in  mortal  cells). 
In  general,  the  protein  expression  of  genes  which  were  more  highly  expressed 
in  immortal  cultures  ,  agreed  with  the  Affymetrix  expression  level.  There  was 
very  little  expression  of  these  genes  in  the  mortal  cultures  (Figure  7.2.1).  The 
expression  levels  in  the  atypical  mortal  culture  D17  were  very  similar  to  that 
seen  in  the  immortal  samples.  This  is  in  keeping  with  earlier  comments  on  the 
pattern  of  gene  expression  in  this  culture. 
The  heterogeneity  within  the  mortal  samples,  which  was  alluded  to  earlier,  was 
evident  in  those  in  the  genes  that  were  overexpressed  in  the  mortal  cultures 
(Figure  6.3).  Additionally,  low  levels  of  expression  of  proteins  encoded  by  these 
genes  in  the  immortal  cultures,  as  predicted  by  the  Affymetrix  expression  level, 
were  not  uniformly  seen.  This  seems  to  be  particularly  true  for  D9  and  D34 
(bearing  in  mind  that  D38  is  also  atypical).  The  Western  blots  indicated  that  few 
of  the  markers  showed  an  "all-or-nothing"  loss  or  gain  of  the  expression  of  the 
particular  gene,  as  was  the  case  with  p16. 158 
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Figure  6.2  Validation  of  selected  genes  which  were  overexpressed  in 
immortal  samples. 
Western  blots  of  whole  cell  extract  from  a  panel  of  normal,  dysplastic  and 
carcinoma  keratinocyte  cultures.  The  Y-axis  refers  to  the  normalised  Affymetrix 
expression  level  for  the  mean  of  the  technical  replicates.  Bars  in  the  graphs 
coloured  green  represent  normal  samples,  red  bars  mortal 
dysplasia/carcinomas  and  blue  bars  immortal  dysplasias/carcinomas.  The 
expression  of  these  proteins  matches  the  RNA  transcript  level  as  assessed  by 
microarray.  The  expression  of  some  of  these  genes  in  D17  is  similar  to  that 
seen  the  in  immortal  dysplastic  cultures.  This  work  was  completed  by  the  author 
and  Dr  J  Thurlow. 159 
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Figure  6.3  Validation  of  selected  genes  which  were  underexpressed  in 
immortal  samples. 
Western  blots  of  whole  cell  extract  from  a  panel  of  normal,  dysplastic  and 
carcinoma  keratinocyte  cultures.  The  Y-axis  refers  to  the  normalised  Affymetrix 
expression  level  for  the  mean  of  the  technical  replicates.  Bars  in  the  graphs 
coloured  green  represent  normal  samples,  red  ones  mortal 
dysplasia/carcinomas  and  blue  immortal  dysplasias/carcinomas.  The  pattern  of 
protein  expression  matched  the  RNA  transcript  level  only  to  some  degree.  In 
particular,  some  of  the  immortal  cultures  (ID9  and  D34)  expressed  more  protein 
than  the  RNA  analysis  would  indicate.  This  work  was  completed  by  the  author 
and  Dr  J  Thurlow. 160 
6.2.1  Discussion 
Validation  of  a  panel  of  markers  showed  good  agreement  in  the  RNA 
expression  level  and  expression  of  protein  in  vitro.  This  confirms  the  accuracy 
of  the  microarray  expression  data.  The  heterogeneity  seen  in  figures  6.2  and 
6.3  indicates  that  in  the  case  of  some  of  the  markers,  post  transcriptional  or 
post  translational  modifications  may  have  modulated  the  levels  of  protein 
detected. 161 
6.3  Validation  of  candidate  markers  of  immortality  in  vivo  by  lHC 
The  expression  of  some  of  the  markers  validated  in  western  blot  was  also 
assessed  in  the  original  tissue  sections  by  lHC  in  10  of  the  carcinomas:  four 
[I  mortal",  five  "immortal"  and  one  in  "crisis".  A  selection  of  the  markers  validated 
in  the  carcinomas  is  shown  in  Figures  6.4  and  6.5.  p53  was  added  to  the  panel 
as  the  p53  status  of  the  culture  had  been  fully  investigated,  with  p53  mutation 
and  alteration  in  expression  showing  clear  association  with  immortality  (Burns  et 
al.,  1993).  The  carcinomas  were  utilised  in  preference  to  the  dysplasia  tissues, 
as  the  difference  in  expression  level  of  the  novel  immortality  markers,  as 
measured  by  the  arrays,  was  maximal  in  comparison  of  mortal  and  immortal 
carcinoma  cultures.  Assessment  of  the  expression  of  these  proteins  in  vivo  is 
subject  to  very  similar  caveats  to  those  outlined  for  validation  by  western 
blotting,  in  addition  to  the  subjective  nature  of  assessing  expression  of  proteins 
by  lHC. 
The  tissues  from  which  the  immortal  carcinomas  were  derived  showed  relatively 
uniform  staining  of  the  markers  of  immortality  particularly  at  the  advancing  edge 
of  the  tumour  (Figure  6.5).  In  most  cases,  the  tissues  showed  fairly  uniform  p53 
expression,  together  with  strong  Cyclin  131  expression,  especially  at  the 
invading  edge  of  the  HNSSC  nests.  In  contrast,  these  HNSCC  nests  showed 
only  a  small  proportion  of  cells  expressing  S10OA9  or  involucrin.  There  was, 
however,  a  measure  of  heterogeneity  in  all  of  these  tumours.  This  was  most 
pronounced  in  BICR56,  which  showed  areas  of  well  differentiated  nests  of 
tumour,  which  centrally  showed  a  mortal  staining  pattern.  However,  the 
expression  of  the  characteristically  immortal  markers  was  clearly  present  in  the 
basal  layer  of  these  nests,  indicating  that  they  were  not  mortal  in  character,  but 
immortal  with  retained  ability  to  differentiate.  In  general,  the  more  poorly 
differentiated  the  tumour,  the  more  uniform  the  immortal  staining  pattern. 
BICR7,  which  has  an  overall  GEP  very  similar  to  that  of  the  immortal 
carcinomas  showed  a  characteristically  immortal  staining  pattern  (Figure  6.5). 
The  tumours  that  gave  rise  to  mortal  carcinoma  cultures  were  much  more 
heterogeneous,  with  varying  proportions  of  characteristic  mortal  and  immortal 
staining  patterns  (Figure  6.4).  Thus,  some  areas  showed  staining 162 
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Figure  6.4  Validation  of  selected  candidate  immortality  genes  by 
immunohistochernistry  in  tumours  which  gave  rise  to  mortal  cultures. 
The  panels  show  p53,  Cyclin  B1,  Involucrin  and  S10OA9  immunostaining  in 
formalin-fixed  biopsy  tissue  from  which  the  cultures  were  derived.  Negative 
controls  (not  shown),  using  IgG  showed  no  staining.  The  panels  indicate  the 
level  of  heterogeneity  present  in  the  tumours  which  gave  rise  to  the  mortal 
carcinoma  cultures.  One  tumour,  BICR25,  showed  a  uniform  mortal  staining 
pattern.  This  work  was  conducted  on  adjacent  sections  where  possible  and 
completed  by  the  author,  Dr  J  Thurlow  and  Ms  J  Fleming. c 
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Figure  6.5  Validation  of  selected  candidate  immortality  genes  by 
immunohistochernistry  in  tumours  which  gave  rise  to  immortal  cultures 
and  in  BICR7  (crisis). 
The  panels  show  p53,  Cyclin  131,  Involucrin  and  S10OA9  immunostaining  in 
formalin-fixed  biopsy  tissue  from  which  the  cultures.  was  derived.  Negative 
controls  (not  shown),  using  IgG  showed  no  non-specific  staining.  Whilst  the 
pattern  of  staining  of  the  markers  of  immortality  was  relatively  consistent,  there 
was  still  some  level  of  heterogeneity,  most  evident  in  BICR56.  The  pattern  of 
expression  in  BICR7  (in  crisis  in  vitro)  was  similar  to  that  of  the  other  immortal 
tumours.  This  work  was  conducted  on  adjacent  sections  where  possible  and 
was  completed  by  the  author,  Dr  J  Thurlow  and  Ms  J  Fleming. 164 
patterns  very  similar  to  that  found  in  most  of  the  immortal  carcinomas  (see 
above),  whilst  others  showed  staining  more  characteristic  of  the  mortal  cells  in 
vitro  (very  little  p53  and  Cyclin  B1  staining,  and  high  expression  of  involucrin 
and  S10OA9).  One  tumour,  BICR  25,  was  composed  almost  entirely  of  nests  of 
cells  with  a  mortal  phenotype. 
6.3.1  Discussion 
These  lHC  data  indicate  that  the  in  vitro  mortal  and  immortal  phenotypes  exist 
in  HNSCCs  in  vivo.  Also,  it  is  clear  that  both  may  exist  within  the  same  tumour. 
Thus,  the  extensive  gene  expression  differences  associated  with  immortality  in 
vitro  also  contribute  to  HNSCC  heterogeneity  in  vivo.  These  findings  have  clear 
implications  as  to  identification  of  the  source  cells  within  the  tumours  that  grew 
in  our  cultures,  as  the  immortal  cells  appear  to  be  less  differentiated,  whilst  the 
cells  with  a  characteristic  mortal  phenotype  are  more  differentiated.  The  factors 
that  dictate  which  type  of  cell  grows  from  a  mixed  cell  population  are  not  known. 165 
Chapter  Seven:  General  Discussion 
7.1  The  culture  model 
Whilst  this  study  has  largely  centered  round  the  use  of  microarray  technology 
for  the  assessment  of  the  GEPs  of  the  various  cell  cultures,  the  ultimate  clinical 
usefulness  of  the  data  is  dependent  upon  the  ability  of  the  cell  culture  model  to 
replicate  the  pattern  of  gene  expression  seen  in  vivo.  The  initial  experiments 
outlined  in  this  thesis  indicated  that  the  limited  panel  of  molecular  changes 
previously  reported  as  having  association  with  immortality  (McGregor  et  al., 
2002)  was  present  to  a  large  degree  in  the  tissue  from  which  the  cultures  were 
derived.  In  particular,  this  was  true  for  changes  in  expression  and  activity  of 
those  genes  that  control  the  cell  cycle  and  are  involved  in  the  replicative 
barriers  of  senescence  and  crisis.  Generally,  this  is  in  keeping  with  the  original 
observations  of  Rheinwald  and  coworkers,  who  indicated  that  serial  cultivation 
with  irradiated  3T3  fibroblasts,  gave  rise  to  a  genetically  stable  cell  population 
that  corresponded  well  to  the  tissue  of  origin  (Rheinwald  &  Beckett,  1981).  The 
subsequent  demonstration  of  good  in  vivolin  vitro  correspondence  of  the  novel 
markers  of  immortality  further  supports  the  culture  system  as  a  reasonable 
model  of  HNSCC  development  in  vivo.  This  not  only  included  proliferation 
markers  but  also  markers  of  differentiation  and  motility,  such  as  involucrin  and 
S1  OOA9. 
The  poor  correlation  of  the  expression  of  RAR-fl  in  the  cultures  and  tissue 
serves  to  indicate  that  the  3T3  culture  system  does  not  fully  replicate  the  in  vivo 
state.  The  observation  that  RAR-,  8  was  expressed  in  the  immortal  tissues 
requires  explanation.  It  is  likely  that  all  of  the  dysplastic  lesions,  whether  giving 
rise  mortal  or  immortal  cultures,  allowed  terminal  differentiation  to  occur,  but  in 
the  immortal  cultures  control  of  differentiation  might  have  been  either  defective 
or  occurring  in  a  smaller  proportion  of  cells.  Additionally,  the  monolayer  culture 
method  does  not  allow  the  cells  to  establish  an  interaction  with  fibroblasts  and 
other  stromal  cells.  Such  interactions  have  been  shown  to  be  of  great 
importance  in  the  development  of  neoplastic  lesions  as  stromal  cells  have  been 
shown  to  exert  a  significant  effect  on  the  gene  expression  profile  of  the 
neoplastic  population  (TIsty,  2001;  TIsty  &  Hein,  2001).  The  further  use  of 
organotypic  models,  either  as  described  earlier  (Figure  4.10)  or  use  of  the  more 166 
sophisticated  model  recently  described  (Andriani  et  al.,  2004)  may  improve  this, 
but  faithful  reconstitution  of  the  in  vivo  state  may  not  be  possible  in  vitro,  due  to 
its  complexity. 
To  further  explore  the  relationship  between  the  cultures  and  tissues,  a  fuller 
exploration  of  the  gene  expression  patterns  in  some  of  the  matched  tissue  and 
culture  samples  has  now  been  conducted  using  microarray  analysis,  as  funding 
for  this  has  become  available  since  the  completion  of  the  laboratory  work  for 
this  thesis.  Analysis  of  the  data  may  give  further  insight  into  the  changes  in 
gene  expression  on  establishment  in  culture. 
In  terms  of  the  pattern  of  gene  expression  related  to  proliferation  and  growth, 
the  good  agreement  of  in  vivo  and  in  vitro  gene  expression  and  the  continued 
clear  separation  of  the  mortal  and  immortal  samples  laid  a  basis  upon  which  the 
microarray  study  could  proceed.  There  was  a  reasonable  expectation  that  at 
least  some  of  the  changes  in  gene  expression  in  culture  would  be  identified  in 
the  tissue  of  origin.  The  identification  of  the  atypical  gene  expression  profiles  of 
D17  and  D38  in  their  related  tissues  was  further  evidence  of  the 
appropriateness  of  this  tissue  culture  model,  as  is  the  extensive  heterogeneity 
in  gene  expression  in  D4.  This  was  initially  a  mortal  culture,  from  which 
emerged  an  immortal  cell  line  (McGregor  et  al.,  1997). 
The  in  vivo  validation  of  the  novel  markers  of  immortality  utilised 
immunohistochernistry,  which  allowed  the  variability  of  expression  of  the 
markers  to  be  assessed.  Heterogeneity  in  gene  expression  was  noted  in  all  the 
carcinomas,  but  particularly  in  the  turnours  that  gave  rise  to  mortal  cultures.  A 
possible  alternative  method  of  in  vivo  validation  would  have  been  microarray 
analysis  of  the  original  tumours.  As  there  was  no  fresh  frozen  tissue  from  the 
original  turnours,  the  only  material  available  was  formalin  fixed.  Whilst  the 
advances  in  microarray  technology  now  allow  microarray  analysis  of  RNA 
extracted  from  formalin  fixed  material,  the  interpretation  of  such  data  is  difficult. 
In  many  ways,  immunohistochernistry  is  superior  to  this,  as  it  allows 
assessment  of  the  final  product  i.  e.  the  protein,  together  with  visualisation  of 
any  variability  in  expression  within  the  tumour.  In  the  context  of  microarray 
analysis,  this  could  only  be  achieved  by  the  examination  of  morphologically 
different  areas  within  the  tumour,  each  captured  by  LCM.  The  variation  in 167 
staining  seen  in  the  primary  tumours  in  this  study  indicated  that  "bulk"  analysis 
of  tumours  might  obscure  important  patterns  of  heterogeneity  of  gene 
expression  within  the  tumour.  Microarray  analysis  of  HNSCC  in  many  other 
publications  is  often  based  on  the  bulk  analysis  of  tumours  (Cromer  et  al.,  2004; 
Kuriakose  et  al.,  2004;  Lemaire  et  al.,  2003;  Roepman  et  al.,  2005). 
7.2  The  gene  expression  profiles 
The  most  striking  differences  in  the  GEPs  were  the  large  number  of  differences 
upon  comparison  of  the  mortal  and  immortal  carcinomas  and  also  comparison 
of  the  mortal  and  immortal  high  risk  dysplasia  cultures  (Table  5.2,  upper  and 
lower).  The  large  number  and  pattern  of  these  differences  indicated  that  there 
may  be  two  separate,  perhaps  divergent,  pathways  to  the  development  of  the 
mortal  and  immortal  carcinomas,  with  intermediates  much  in  keeping  with  the 
clinical  history  of  the  individual  dysplastic  lesion.  Thus,  it  may  be  possible  to 
identify  low  and  high  risk  dysplastic  lesions,  with  the  high  risk  lesions  having  a 
very  similar  GEP  to  the  SCC  cultures.  This  was  borne  out  by  the  relatively 
small  number  of  differences  when  comparing  the  mortal  and  immortal  dysplasia 
cultures  with  their  respective  carcinomas.  However,  the  hierarchical  clustering 
did  not  allow  for  the  clear  identification  of  these  various  groups  in  terms  of  their 
GEP.  There  were  very  few  consistent  differences  in  gene  expression  on 
comparison  of  the  high  risk  immortal  dysplastic  lesions  and  the  immortal 
carcinomas.  This  indicates  that  these  cells  had  gained  additional  changes  in 
their  GEP  that  were  not  present  in  the  low  risk  immortal  dysplastic  cultures. 
The  fact  that  they  clustered  very  closely  with  the  immortal  carcinomas  indicated 
that  they  may  have  gained  almost  all  of  the  immortal  carcinoma  related  changes 
in  gene  expression,  but  had  not  yet  acquired  that  ability  to  invade  (Figures  5.8 
and  5.9).  In  this  respect,  this  is  very  similar  to  the  findings  of  Ha  and  coworkers 
(Ha  et  al.,  2002b),  who  found  that  most  moderate/seve  rely  dysplastic  lesions 
had  a  GEP  very  similar  to  HNSCCs. 
Due  to  certain  limitations  of  hierarchical  clustering  in  its  ability  to  demonstrate 
the  differences  in  the  GEP  of  the  various  groups  we  have  recently  employed 
more  sophisticated  clustering  techniques,  such  as  spectral  clustering  (Kluger  et 
al.,  2003)  in  collaboration  with  Dr  G  KaIna  and  Dr  D  Higham  in  the  Department 
of  Mathematics  at  the  University  of  Strathclyde.  This  method  of  clustering  is 168 
based  on  singular  value  decomposition  (SVD)  which  may  be  used  to  assign  one 
or  more  numerical  values  to  each  gene  and  each  sample.  Spectral  clustering 
has  been  demonstrated  as  a  useful  tool  for  analyzing  microarray  data  from  well 
characterized  cancer  types,  for  example,  it  correctly  identifies  known  subtypes 
of  leukemia,  lymphoma,  breast  cancer  and  brain  cancer  (Higham  et  al.,  2005; 
Kluger  et  al.,  2003),  which  has  proved  difficult  with  other  methods.  Application 
of  spectral  clustering  to  the  data  allows  for  a  clearer  separation  of  the  different 
groups  of  cultures  and  this  can  be  demonstrated  on  several  different 
dimensions,  not  merely  the  2D  relationship  which  is  dictated  by  the  use  of 
hierarchical  clustering  algorithms  (for  example,  Figure  5.8).  The  delineation  of 
groups  of  cultures  relates  to  the  known  clinical  features  the  lesions  (Figure  7.1). 
The  main  groups  of  samples,  based  on  both  clinical  and  gene  expression 
pattern,  are  shown  in  Figure  7.2.  The  number  of  gene  expression  differences 
for  selected  comparisons  is  also  shown  in  this  diagram  and  the  pair-wise 
comparisons  suggest  that  two  pathways  for  the  development  of  HNSCC  exist- 
a  mortal  pathway  and  an  immortal  pathway.  These  can  be  observed  in  distinct 
patterns  of  gene  expression.  The  number  of  changes  in  gene  expression  within 
each  arm  of  the  diagram  was  small  when  compared  to  the  difference  in  gene 
expression  between  the  mortal  and  immortal  cultures.  However,  the 
interpretation  of  such  a  diagram  must  be  treated  with  caution,  as  the  cultures 
were  derived  from  different  individuals  and  not  sequential  biopsies  taken  during 
HNSCC  development  in  a  single  patient.  The  demonstration  of  similar  gene 
expression  changes  occurring  in  the  development  of  an  HNSCC  within  a 
dysplastic  lesion  from  the  same  patient  would  allow  such  lineage  relationships 
to  be  more  surely  established. 169 
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Figure  7.1  Analysis  of  the  gene  expression  profiles  by  spectral  clustering 
Analysis  of  the  GEPs  of  dysplasias  by  spectral  clustering  in  relation  to  primary 
HNSCCs,  SCC  recurrences,  metastases  and  normal  mucosa.  See  discussion 
text  for  an  explanation  of  the  basis  of  spectral  clustering.  The  diagram  shows 
the  components  of  vectors  V2  and  V3  for  each  sample  as  the  horizontal  and 
vertical  coordinates,  respectively.  Samples  that  were  close  in  this  two- 
dimensional  ordering  can  be  viewed  as  similar  in  GEP.  This  method 
demonstrates  an  enhanced  separation  of  the  cultures  utilising  the  different 
vector  components.  This  data  is  reproduced  courtesy  of  Dr  G  KaIna  and  Dr  D 
Higham,  Department  of  Mathematics,  University  of  Strathclyde. 
N=  normal,  MD  =  mortal  dysplasia,  MDT  =  mortal  dysplasia  which  progressed 
to  SCC  MC  mortal  carcinoma,  ID  =  immortal  dysplasia,  IDT  =  immortal 
dysplasia  which  progressed  to  carcinoma,  IC  =  immortal  carcinoma,  M 
metastases  (mortal  or  immortal),  R=  recurrence  (all  immortal). 170 
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Figure  7.2  Possible  pathways  of  oral  cancer  progression  based  on 
similarities  in  gene  expression  between  normal  oral  mucosa,  clysplasias 
and  SCCs 
Relationships  of  dysplasias  to  carcinomas  revealed  by  gene  expression 
profiling.  The  model  demonstrates  how  the  two  types  of  HNSCC  may  be 
derived  from  intermediate  dysplasias.  Solid  lines  indicate  likely  routes  of 
progression  via  mortal  and  immortal  pathways,  based  on  modest  differences  in 
gene  expression  between  low  and  high  risk  dysplasias  and  SCCs.  Dashed  or 
dotted  lines  indicate  possible  alternative  pathways;  those  indicated  by  dotted 
lines  would  involve  much  bigger  gene  expression  changes.  The  numbers 
represent  the  number  of  statistically  significant  difference  in  gene  expression, 
as  also  shown  in  Table  5.2  (upper  and  lower). 171 
The  possibility  of  two  pathways  in  the  development  of  HNSCC  raises  interesting 
questions  in  relation  to  the  gene  expression  pattern  of  the  two  carcinomas.  The 
classical  markers  of  invasion  and  metastasis  were  predominantly  found  in  the 
mortal  carcinoma  cultures  and  were  absent  from  the  immortal  cultures.  These 
included  elevated  expression  of  MMPs,  collagens  and  laminins,  CEACAM1, 
certain  integrins  and  components  of  the  urokinase  plasminogen  activator 
pathway.  Alterations  in  the  TGF-,  8  pathways  were  also  present  in  the  mortal 
cultures.  It  would  seem  likely  then  that  these  carcinomas  invade  using  the 
mesenchymal  method,  either  as  individual  cells  or  collectively  and  this  might 
have  involved  EMT  (See  Figure  2.1  and  Friedl  &  Wolf,  2003).  As  the  immortal 
cultures  downregulate  the  expression  of  these  genes,  it  is  less  clear  how  the 
immortal  HNSCCs  became  invasive. 
The  alternative  method  of  amoeboid  movement  does  not  require  the  alterations 
in  proteolytic  enzymes  and  intercellular  attachments  characteristically 
associated  with  cancer  invasion  and  metastasis  (see  chapter  2).  The 
overexpression  of  RHAMM  (Dr  J  Thurlow,  personal  communication),  an 
alternative  hyaluronan  receptor,  might  be  indicative  of  changes  that  allowed 
cells  to  move  in  this  way.  RHAMM  has  been  identified  as  a  cell  surface 
receptor  involved  in  cell  motility,  but  recent  work  suggests  that  it  is  more  likely  to 
act  as  an  intracellular  hyaluronan-binding  protein  interacting  with  both 
microtubules  and  actin  filaments  (Assmann  et  al.,  1999).  Investigation  in  other 
cancers  has  found  overexpression  of  RHAMM  at  the  invasive  edge  of  lobular 
breast  cancer  and  demonstrated  a  relationship  between  RHAMM  expression 
and  risk  of  nodal  metastases  in  breast  cancer  and  with  clinical  aggressiveness 
in  pancreatic  cancer  (Abetamann  et  al.,  1996;  Wang  et  al.,  1998).  Thus, 
RHAMM  over  expression  in  immortal  HNSCCs  could  be  responsible  for  the 
invasiveness  of  immortal  HNSCCs. 
Amoeboid  migration  has  also  been  related  to  increased  signalling  via 
Rho/ROCK  (Croft  et  al.,  2004;  Sahai  &  Marshall,  2003).  Although  our  immortal 
HNSCCs  did  not  show  significant  changes  in  expression  of  Rho  family 
members,  my  colleague  Dr  J  Thurlow  has  recently  shown  that  they  did  over 
express  ECT2,  a  Rho  GEF  (Miki  et  al.,  1993).  ECT2  has  been  implicated  in 
cytokinesis  and  in  the  activation  of  Cdc42  in  mitosis  (Oceguera-Yanez  et  al., 
2005),  but  it  also  interacts  with  the  polarity  protein  complex,  Par6/Par3/PKCý 172 
and  localises  at  sites  of  cell-cell  contact  as  well  as  in  the  nucleus  (Liu  et  al., 
2004).  ECT2  also  interacts  with  the  Kelch-like  protein,  KLEIP,  which  co- 
localises  with  actin  at  cell-cell  contact  sites  (Hara  et  al.,  2004).  Thus,  ECT2 
could  also  play  a  role  in  immortal  HNSCC  motility.  Further  work  is  required  to 
test  these  alternative  hypotheses  and  to  explain  immortal  HNSCC  motility. 
7.3  Gene  expression  profile  and  prognosis 
Such  profound  differences  in  the  GEPs  of  the  mortal  and  immortal  carcinomas 
might  also  have  clinical  importance.  It  was  noted  in  the  Chapter  2  that  the 
ability  to  establish  as  a  cell  line  in  culture  has  been  related  to  poor  prognosis 
and  lymph  node  metastases  (Shimada  et  al.,  2003).  Although  univariate 
analysis  of  immortality  in  culture  showed  correlation  with  nodal  status,  p53 
pathway  defects  (elevated  p53  or  MDM2  expression),  p2l  WAR  and  p27  KIP1 
expression  and  reduced  FHIT  expression,  in  multivariate  analysis,  p53  pathway 
defects  were  the  main  independent  predictors  of  cell  line  establishment  and  of 
propensity  to  lymph  node  metastasis.  This  is  compatible  with  the  GEP  seen  in 
our  immortal  cells  and  suggested  that  acquisition  of  immortality  was  associated 
with  future  propensity  of  primary  SCCs  to  metastasise  to  lymph  nodes. 
The  link  between  immortality  in  cell  culture  and  poor  prognosis  is  borne  out  to 
some  extent  by  our  follow-up  data.  The  small  number  of  patients,  the  extensive 
co-morbidities  in  these  patients  and  incomplete  follow-up  information  -  the 
clinical  case  notes  for  some  of  the  patients  have  been  lost  or  destroyed  -  places 
severe  limitations  upon  this  analysis.  Another  factor  was  stage  at  presentation, 
as  those  tumours  that  gave  rise  to  immortal  cultures  tended  to  be  more 
advanced.  Of  primary  HNSCCs  that  gave  rise  to  immortal  cultures,  five  of 
seven  were  T4,  whereas  only  three  of  eight  primary  mortal  HNSCCs  had  a 
tumour  of  this  size.  In  terms  of  the  presence  of  nodal  metastases,  five  of  seven 
immortal  turnours  were  node  positive,  whilst  only  three  of  eight  mortal  tumours 
had  nodal  metastases  at  diagnosis.  Despite  these  caveats,  none  of  the  patients 
whose  tumour  gave  rise  to  a  mortal  carcinoma  has  died  in  circumstances 
directly  attributable  to  their  HNSCC  diagnosis.  However,  at  least  five  of  the 
patients  who  produced  an  immortal  culture  died  from  causes  attributable  to  their 
HNSCC  diagnosis,  often  after  a  protracted  clinical  course. 173 
7.3.1  Other  microarray  studies 
Interpretation  of  the  results  of  microarray  studies  in  the  published  scientific 
literature  is  greatly  hindered  by  the  variety  of  study  designs  and  methodologies 
employed.  In  some  studies,  statistical  analysis  of  the  data  is  not  ideal,  as 
correction  for  multiple  hypothesis  testing  has  not  been  performed  (Al  Moustafa 
et  al.,  2002;  Ha  et  al.,  2003).  In  others,  where  appropriate  corrections  were 
made,  the  list  of  genes  was  very  small,  even  allowing  for  a  large  FDR  (Nagata 
et  al.,  2003).  Interestingly  (and  perhaps  not  surprisingly  in  view  of  this), 
comparison  of  the  GEPs  of  some  of  the  early  gene  expression  studies 
has  produced  agreement  of  around  7%  in  the  lists  of  genes  proposed  as 
important  in  the  development  of  HNSCC  (see 
hftp:  //www.  upstate.  edu/microb/shillite/Microarray  Oral  Cancer  Genes.  HTM). 
Many  recently  published  in  vivo  gene  expression  profiling  studies  have  utilised 
various  classification  methods  to  subdivide  HNSCCs  into  groups  with  GEPs  that 
may  be  linked  to  different  prognoses.  Generally,  these  in  vivo  studies  measure 
gene  expression  differences  in  the  whole  tumour  cell  population,  not  just  the 
malignant  epithelial  component,  as  in  our  study.  Whilst  some  studies  have 
utilised  LCM  technology  to  select  a  pure  epithelial  tumour  sample  for  analysis, 
none  has  attempted  to  select  and  analyse  morphologically  different  areas,  or  to 
sample  areas  with  differing  patterns  of  differentiation.  The  merits  of  such  bulk 
analysis  of  tumours  are  debatable,  as  the  tumour  heterogeneity  alluded  to 
above  cannot  be  assessed.  The  presence  of  other  types  of  cell  in  the  sample 
analysed  can  vary  extensively,  particularly  as  the  intensity  of  the  immune 
response  to  the  tumour  differs  between  patients.  One  study  has  demonstrated 
that  this  can  have  a  marked  effect  on  the  overall  GEP,  particularly  with  relation 
to  immune  system-related  markers  (Ginos  et  al.,  2004).  Others  argue, 
however,  that  it  does  not  matter  if  some  of  the  markers  are  stromal  or 
immunoregulatory  elements  (Roepman  et  al.,  2005).  That  argument  can  only 
be  valid  if  the  sole  aim  is  a  clinically  relevant  set  of  molecular  predictors  - 
analysis  of  the  GEP  in  terms  of  cellular  and  molecular  biology  of  the  tumours  is 
compromised  by  inability  to  distinguish  the  relative  contribution  of  the  various 
cellular  elements. 
The  study  of  25  primary  HNSCCs,  16  locally  recurrent  HNSCCs  and  13  normal 
oral  mucosa  samples  by  Ginos  and  coworkers  found  a  gene  expression 174 
signature  correlating  with  local  recurrence  (Ginos  et  al.,  2004).  This  included 
proteins  involved  in  extracellular  matrix  interactions,  such  as  certain  laminins 
and  integrins,  proteins  implicated  in  EMT,  (such  as  SNA12),  and  the  MET 
oncoprotein.  With  the  exception  of  MET,  this  molecular  signature  of  recurrent 
disease  strongly  resembles  the  GEP  of  our  mortal  SCCs.  A  different  study  of 
60  HNSCCs  categorized  the  tumours  into  two  main  groups,  one  of  which  could 
be  further  subdivided  (Chung  et  al.,  2004).  The  main  group,  which  was  not 
further  subdivided,  was  associated  with  increased  local  recurrence  and 
displayed  a  gene  expression  signature  which  was  both  consistent  with  that 
demonstrated  by  Ginos  and  coworkers  and  resembled  that  of  our  mortal  SCCs: 
e.  g.  LAMA3,  B3  and  C2,  P-cadherin,  desmocollin  2,  keratin  14,  kallikrein  10, 
SKALP  and  TGF-fl. 
Three  recent  in  vivo  studies  have  reported  HNSCC  GEPs  associated  with  high 
risk  of  lymph  node  metastasis  (Chung  et  al.,  2004;  Cromer  et  al.,  2004) 
Roepman  et  al,  2005).  The  studies  reported  by  Chung  et  al.  and  Cromer  et  al. 
also  suggest  that  the  gene  expression  changes  associated  with  lymph  node 
metastasis  are  different  from  those  associated  with  local  recurrence  of 
HNSCCs.  Despite  the  long  lists  of  genes  generated  by  these  studies,  there 
appears  to  be  no  overlap  between  the  published  profiles  of  high  risk  of 
metastasis  of  HNSCC.  This  may  partly  be  explained  by  the  use  of  different 
microarray  platforms  and  variations  in  the  design  of  the  studies  including  the 
use  of  different  reference  samples.  However,  there  is  greater  overlap  between 
the  GEPs  predictive  of  lymph  node  metastasis  in  Chung  et  al  and  Cromer  et  al 
with  our  immortal  HNSCC  signature  than  with  our  mortal  HNSCC  signature.  In 
contrast,  the  metastasis  associated  GEP  identified  by  Roepman  and  coworkers 
which  was  based  on  82  heterogeneous  HNSCCs  does  not  seem  to  have  any 
particular  bias  in  relation  to  our  HNSCC  immortality  markers  (Roepman  et  al., 
2005). 
The  study  by  Chung  and  coworkers  identified  a  gene  expression  signature  of 
primary  HNSCCs  that  predicted  future  lymph  node  metastasis  with  80% 
accuracy  (Chung  et  al.,  2004).  The  lymph  node  positive  signature  included 
known  proliferation  associated  genes  and  many  other  genes  that  were  more 
highly  expressed  in  our  immortal  SCCs,  for  example  ECT2,  UBE2C  and  STK6. 
The  lymph  node  positive  predictor  signature  derived  by  Cromer  et  al.  based  on 175 
34  hypopharyngeal  HNSCCs  also  shows  greater  similarity  with  our  immortal 
SCC  gene  expression  profile  than  our  mortal  signature,  whereas  the  lymph 
node  negative  signature  resembles  our  mortal  SCC  profile  much  more  closely 
(Cromer  et  al.,  2004).  Overall,  these  various  in  vivolin  vitro  comparisons  and 
the  observations  of  Shimada  and  coworkers  cited  above  (Shimada  et  al.,  2003), 
suggest  that  the  HNSCCs  that  only  recur  locally  may  have  a  GEP  similar  to  our 
mortal  SCCs;  whereas  HNSCCs  that  metastasise  to  lymph  nodes  tend  to  have 
an  immortal  phenotype. 
It  is  clear  that,  despite  the  efforts  in  standardization  (including  MIAME)  the 
variation  between  microarray  studies  is  still  large.  At  present,  it  is difficult  to  see 
clinical  utility  of  such  data  if  these  disparate  studies,  purporting  to  assess  the 
same  biological  event,  arrive  at  completely  exclusive  lists  of  genes  (Chung  et 
al.,  2004;  Cromer  et  al.,  2004;  Roepman  et  al.,  2005).  As  the  number  of 
suggested  useful  markers  grows,  it  is  not  going  to  be  possible  to  test  all  of  the 
candidate  genes  in  properly  constituted  clinical  studies.  Perhaps  a  more 
rigorous  validation  of  the  markers  in  such  studies  is  required,  for  example  by 
immunohistochernistry  in  the  original  tumours.  Obviously,  this  also  has  its 
limitations. 
7.4  The  possible  origins  of  HNSCC 
The  establishment  of  cultures  from  HNSCCs  with  different  replicative 
characteristics  and  the  distinctive  gene  expression  patterns  seen  in  our  analysis 
may  reflect  differences  in  origin.  Two  theories  have  been  proposed  regarding 
the  derivation  of  such  neoplastic  cells.  The  selection  hypothesis  proposes  that 
squamous  neoplasia  arises  from  pre-existing  telomerase  proficient  stem  cells 
(Owens  &  Watt,  2003).  Stem  cells  are  responsible  for  the  continual 
replacement  of  cells  within  a  tissue  and  in  squamous  epithelium  under  steady 
state  conditions,  it  is  likely  that  these  cells  are  relatively  quiescent  and  do  not 
express  telomerase.  In  contrast,  the  remainder  of  the  cells  in  the  proliferative 
compartment  of  squamous  epithelia  do  express  telomerase  at  a  low  level,  but 
this  is  rapidly  lost  upon  establishment  in  cell  culture,  as  was  demonstrated  in 
Figure  4.6.  However,  when  stem  cells  enter  the  cell  cycle,  it  is  likely  that  they 
too  will  express  telomerase.  These  cells  are  obvious  candidates  for  the  origin 
of  squamous  neoplasia,  as  they  are  present  within  the  tissue  over  a  long  period 176 
and  as  such  would  have  the  opportunity  to  accumulate  the  required  number  of 
mutations  for  the  establishment  of  neoplastic  disease.  As  they  are  telomerase 
proficient  in  vivo,  they  should  possess  long  telomeres  and  be  genetically  stable. 
In  some  respects,  the  mortal  HNSCC  phenotype  bears  such  features.  These 
cells  lack  telomerase  activity  when  cultured  in  vitro,  have  WT  p53  and  are 
relatively  genetically  stable.  Tumours  bearing  these  features  have  been  shown 
to  have  a  better  prognosis  in  vivo.  However,  comparison  with  the  microarray 
analysis  of  epithelial  stem  cells  by  Blanpain  and  coworkers,  shows  there  is  no 
consistent  relationship  of  a  suggested  stem  cell  gene  expression  pattern  to  any 
of  our  groups  of  keratinocytes  (Blanpain  et  al.,  2004).  Admittedly,  the  stem  cells 
in  this  study  were  from  hair  follicle,  and  as  such,  analysis  of  stem  cells  from  oral 
mucosa  must  be  compared  with  our  data  before  the  hypothesis  is  dismissed. 
Additionally,  the  fact  that  the  mortal  tumours  in  our  study  appear  to  be  more 
highly  differentiated  than  the  immortal  tumours  may  also  mitigate  against  this 
hypothesis.  Recent  telomere  length  studies  indicate  that,  in  general,  the 
immortal  cultures  have  short  telomeres  whilst  the  telomere  length  of  mortal 
cancers  is  more  variable  (data  not  shown).  This  may  indicate  that  both  arose 
from  telomerase  deficient  cells.  Therefore,  mortal  HNSCC  may  simply  be 
tumours  that  for  stochastic  reasons  have  not  completed  a  sufficient  number  of 
cell  divisions  to  precipitate  senescence  and  telomeric  dysfunction,  and  as  such 
have  retained  the  ability  to  differentiate. 
An  alternative  viewpoint  suggests  that  epithelial  neoplasms  may  arise  from 
differentiated,  telomerase  negative  cells.  The  observation  that  keratinocytes 
lacking  stem  cell  properties  can  be  immortalised  by  adenovirus  EIIA  supports 
this  (Barrandon  et  al.,  1989).  Such  telomerase  deficient  cells  should 
demonstrate  shorter  telomeres  with  telomeric  fusions,  deregulated  telomerase 
and  mutation  of  p53,  together  with  appreciable  genomic  instability.  These  cells 
would  be  expected  to  demonstrate  aneuploidy,  extensive  LoH  and  unbalanced 
chromosomal  translocations.  The  immortal  HNSCCs  (and  dysplasias)  display 
these  characteristics.  If  this  is  so,  the  telomerase  deregulation  hypothesis 
predicts  that  cells  which  have  bypassed  senescence,  but  not  crisis,  should  also 
be  identifiable  in  developing  lesions.  One  of  our  cell  cultures,  BICR7,  displayed 
the  features  of  crisis  in  vitro  and  in  vivo  analysis  of  HNSCC  tumours  has 
demonstrated  several  of  these  features  (Gordon  et  al.,  2003).  Similar  findings 177 
have  also  been  reported  in  other  cancer  models.  In  our  study,  these  cells  had 
also  lost  molecular  markers  of  terminal  differentiation. 
The  presence  of  intermediate  features  in  vivo  (D1  7,  D38)  and  in  vitro  (Gordon  et 
al.,  2003)  raises  the  possibility  that  conversion  of  mortal  tumours  to  immortal 
may  be  possible.  However,  the  data  presented  here  indicates  that  such  an 
effect  requires  extensive  changes  in  gene  expression.  The  observation  that 
most  of  the  turnours  show  heterogeneity  of  expression  of  mortal  and  immortal 
markers,  may  reflect  such  interconversion.  The  variation  was  present  in  all  of 
the  tumours  which  gave  rise  to  the  mortal  cell  cultures.  Thus,  in  the  carcinomas 
which  had  a  uniformly  immortal  phenotype  in  vivo,  the  development  of 
immortality  may  have  been  an  early  effect,  perhaps  at  the  dysplasia  stage.  The 
existence  of  atypical  transitional  forms  of  dysplasia  cell  culture  (D1  7  and  D38)  is 
evidence  which  supports  this.  Alternatively,  these  tumours  may  have  been  at  a 
more  advanced  stage  of  conversion  from  a  predominantly  mortal  HNSCC 
phenotype  to  a  predominantly  immortal  one. 
The  turnours  which  gave  rise  to  the  mortal  carcinoma  cultures  have  been  shown 
to  be  very  heterogeneous,  containing  areas  with  both  the  mortal  and  the 
immortal  HNSCC  phenotype  (Figure  6.4).  This  may  indicate  that  invasion 
predated  the  development  of  immortal  clones  within  the  tumour.  As  the 
immortal  phenotype  has  been  associated  with  poor  prognosis,  this  presents  a 
plausible  explanation  for  the  better  prognosis  if  turnours  have  a  population  of 
mortal  cells  at  the  time  of  diagnosis  i.  e.  late  development  of  the  immortal  cell 
population.  However,  this  advantage  may  be  time-limited  if  the  tumour 
undergoes  conversion  from  a  mortal  to  an  immortal  phenotype.  Thus,  there  is 
no  implication  that  the  mortal  HNSCCs  are  indolent  lesions,  as  it  is  likely  that 
given  time  they  too  will  spread  and  kill  the  patient. 
The  establishment  of  both  a  retrospective  and  prospective  analysis  of  dysplastic 
lesions  may  help  in  answering  these  questions.  Both  of  these  studies  have 
received  ethical  approval  from  the  relevant  LRECs  in  Glasgow  (KH  in 
retrospective  study  as  co-investigator,  prospective  study  as  main  investigator). 
The  retrospective  study  will  utilise  the  issue  archives  in  the  Department  of  Oral 
pathology  at  Glasgow  Dental  Hospital  and  School.  The  pathology  database 
contains  27  patients  with  a  biopsy-confirmed  dysplastic  lesion  who  have 178 
subsequently  developed  a  SCC  at  the  same  site.  The  prospective  study, 
designed  to  collect  a  patient's  first  diagnosed  dysplastic  lesion,  has  been 
recruiting  for  two  years.  Whilst  the  recruitment  rate  has  been  disappointing, 
around  50  biopsies  have  been  stored,  with  the  availability  of  both  fresh  and 
formalin  fixed  material. 
7.5  Consistent  changes  unrelated  to  proliferative  capacity 
There  are  surprisingly  few  consistent  gene  expression  changes  common  to  all 
HNSCC  cultures,  regardless  of  proliferative  fate.  Genes  such  as  this  may  be 
good  candidates  for  therapeutic  intervention,  as  they  are  altered  in  the 
carcinoma  cultures.  Gene  such  as  Creatine  kinase  B,  SIX  and  FOXQ1  are 
upregulated  in  the  HNSCC  cultures  when  compared  with  normal  cultures;  whilst 
ZNF185,  CUGBP2,  PLCID4,  HOP  and  CYP27131  are  all  downregulated.  All 
these  gene  expression  changes  still  require  to  be  validated  by  another  method. 
There  is  evidence  for  the  involvement  of  some  of  these  genes  in  other  cancers, 
but  how  these  changes  might  contribute  to  HNSCC  development  is  unclear. 
For  example,  FOX  members  are  known  to  be  deregulated  in  various  cancers 
(Katoh,  2004).  SIX1,  is  believed  to  stimulate  proliferation  via  activation  of  Cyclin 
Al  (Coletta  et  al.,  2004).  It  is  overexpressed  in  breast  cancers,  particularly 
metastases  and  is  also  involved  in  determination  of  the  metastatic  phenotype  of 
rhabdomyosarcomas  (Yu  et  al.,  2004).  CUGBP2/ETR-3  is  a  regulator  of 
nuclear  and  cytoplasmic  RNA  processing  events  (Ladd  &  Cooper,  2004)  and 
has  been  implicated  in  translational  silencing  of  COX-2  during  radiation  induced 
apoptosis  (Mukhopadhyay  et  al.,  2003).  CYP27131  is  increased  in  skin  SCCs 
(Reichrath  et  al.,  2004)  and  colon  cancers  (Reichrath  et  al.,  2004),  whilst  HOP 
is  a  potential  transcription  cofactor,  downregulated  in  hypopharyngeal 
carcinoma  (Lemaire  et  al.,  2004). 
7.6  Markers  of  immortality 
Our  previous  work  has  shown  that  p53  mutations  are  closely  associated  with 
immortality  in  the  dysplasia  and  carcinoma  cultures.  Some  of  the 
dysplasia/HNSCC  immortality  markers  are  known  p53  target  genes,  for 
example,  ALD1A3  (Okamura  et  al.,  1999).  Other  known  p53  target  genes  also 
differ  in  expression  level  between  mortal  and  immortal  HNSCCs  or  clysplasias. 179 
The  pattern  of  these  differences  in  gene  expression  varies,  but  in  general,  p53 
target  genes  that  show  differences  between  mortal  and  immortal  HNSCCs  are 
involved  in  the  control  of  the  cell  cycle,  replication  or  cell  cycle  arrest,  whereas 
those  that  show  little  change  are  often  those  genes  whose  function  may  be 
related  to  apoptosis.  Loss  of  expression  of  RAR-,  B  is  also  strongly  associated 
with  immortality,  although  its  level  of  expression  is  barely  detectable  in  the 
microarray  experiments  (Figure  6.1). 
Many  of  the  novel  markers  of  the  immortal  phenotype  seen  in  our  cultures  have 
been  related  to  cancer  biology  in  some  way  in  the  literature.  What  is  most 
striking  is  the  extent  of  over-representation  of  cell  cycle  associated  genes 
amongst  those  more  highly  expressed  in  the  immortal  cells.  These  cells  are 
proliferating  faster,  and  this  is  reflected  in  a  shorter  doubling  time  in  vitro  (data 
not  shown).  However,  there  are  some  genes  which  have  been  relatively  under- 
investigated,  including  GOS2,  Keratin  23  and  RHCG,  amongst  others. 
Microarray  analysis  of  mortal  cells  as  they  approach  senescence  has  been 
conducted  in  many  cell  types,  including  normal  oral  keratinocytes  (NHOKs) 
(Kang  et  al.,  2003:  13aek,  2003  #365).  These  analyses  have  shown  that  the 
gene  expression  profile  of  NHOKs  as  they  approach  senescence  does  in  some 
respects  mirror  that  seen  in  our  mortal  cultures  when  compared  with  the 
immortal  cultures.  In  the  paper  by  Kang  et  al,  there  is  profound  downregulation 
of  cell  cycle  genes,  and  upregulation  of  some  MMPs  and  collagens,  amongst 
others  (Kang  et  al.,  2003).  The  analysis  by  Baek  et  al  shows  a  similar  pattern  of 
changes,  but  with  less  overlap  of  the  gene  expression  profile  in  our  mortal  cells 
(Baek  et  al.,  2003).  This  raises  the  question  of  the  extent  to  which  genes 
associated  with  senescence  influence  the  overall  GEPs. 
Microarray  analysis  of  luminal  mammary  epithelial  cells  before  and  after 
immortalisation  with  SV40,  demonstrated  a  spectrum  of  changes  in  gene 
expression  with  some  overlap  with  our  immortality  markers  (Park  et  al.,  2004). 
Indeed  many  of  the  over  expressed  genes  in  the  immortalised  cells  are  related 
to  cell  cycle  and  mitosis,  as  in  the  immortal  cultures.  Similarly,  those  genes 
whose  expression  falls  on  SV40  immortalisation  include  genes  related  to 
differentiation  and  some  which  also  are  downregulated  in  our  immortal  cells, 
such  as  ALIDWA3.  Although  the  particular  genes  altered  only  overlap  to  some 180 
extent,  presumably  as  the  cells  are  of  different  tissue  type  and  the  process  of 
SV40  immortalisation  is  different  from  that  occurring  in  our  cultures,  it  appears 
that  very  similar  pathways  have  been  affected.  This  indicates  that  the 
distinctive  GEP  of  the  immortal  cultures  is  not  solely  due  to  the  presence  of 
senescent  cells  in  the  mortal  cultures. 
The  profound  downregulation  of  many  markers  related  to  differentiation  may  be 
of  clinical  note  as  it  is  known  that  poorly  differentiated  tumours  tend  to  behave 
more  aggressively.  If  the  basis  for  this  is  closely  linked  with  immortalisation, 
this  analysis  provides  an  underlying  biological  explanation  for  how  tumours  may 
become  poorly  differentiated,  and  for  the  link  between  loss  of  differentiation  and 
poor  prognosis.  Rheinwald  and  co-workers  showed  that  all  cell  lines  derived 
from  HNSCC  have  a  subnormal  rate  of  commitment  to  terminal  differentiation  in 
suspension  culture  when  compared  to  normal  cells  (Rheinwald,  1982).  Whilst 
all  the  cell  lines  in  the  study  by  Rheinwald  and  co-workers  did  eventually  enter 
terminal  differentiation,  it  is  clear  that  their  ability  to  do  so  was  greatly 
compromised. 
The  capability  of  some  of  our  immortal  cultures  to  differentiate  was  tested  in 
growth  as  xenografts  in  nude  mice  (data  not  shown).  This  demonstrated  a 
variation  in  the  capability  of  these  cultures  (mostly  immortal  carcinomas)  to 
undergo  terminal  differentiation;  BICR56  and  BICR31  formed  large  keratin  filled 
cysts  whereas  BICR22  grew  as  solid  nests  with  no  keratinisation  evident.  In 
addition,  the  fact  that  the  expression  of  RAR-,  8  in  the  immortal  dysplasia 
cultures  (either  in  monolayer  or  in  organotypic  culture)  did  not  match  that  in  the 
corresponding  tissue,  suggests  that  the  link  between  immortality  and  a  lack  of 
differentiation  may  neither  be  strong  nor  causal  and  may  be  profoundly  affected 
by  the  microenvironment  and/or  time.  This  requires  further  work,  perhaps 
utilising  more  sophisticated  organotypic  culture  systems,  for  example  with 
tumour  fibroblasts  and  other  stromal  elements,  to  attempt  a  more  complete 
recapitulation  of  the  microenvironment,  as  indicated  earlier. 
7.7  Markers  of  high  risk  in  clysplastic  lesions 
A  GEP  of  dysplastic  lesions  in  relation  to  progression  to  carcinoma  has  not 
been  reported  in  the  literature.  The  first  published  data  on  the  gene  expression 
profile  of  PMLs  in  comparison  to  HNSCCs  was  that  by  Ha  and  coworkers  (Ha  et 181 
al.,  2003).  However,  there  was  no  follow-up  data  given  in  this  study  to  allow  for 
assessment  of  "high  risk"  markers  of  transformation  to  HNSCC.  This  analysis 
suggested  that  the  gene  expression  pattern  of  the  dysplastic  lesions  became 
progressively  more  like  that  of  HNSCCS  with  increasing  grade  of  dysplasia. 
Indeed,  the  number  of  significant  differences  in  gene  expression  between  the 
dysplastic  and  HNSCC  samples  was  very  small.  Additionally,  the  GEP  of 
clinically  normal  tissue  adjacent  to  dysplastic  lesions  was  very  different  for  true 
normal  tissue.  However,  in  both  cases,  the  number  of  samples  was  small. 
There  are  two  possible  explanations  for  these  patterns  of  gene  expression: 
heterogeneity  due  to  large  variation  in  the  expression  profiles  of  PMLs  or  little 
real  difference.  Despite  the  authors'  emphasis  on  the  latter,  it  is  clear  that  there 
was  appreciable  heterogeneity  in  the  dysplasia  samples  reported  in  the  study. 
Despite  the  existence  of  outliers  in  the  cluster  analysis,  it  appears  that  all  the 
dysplasia  samples  were  used  in  the  comparison  with  HNSCCs,  presumably,  as 
the  numbers  were  too  small  to  give  any  statistical  significance  without  the 
inclusion  of  the  outliers.  Thus,  the  size  of  the  final  gene  list,  and  the  genes 
contained  within  it,  may  be  a  little  misleading.  Despite  this,  we  have  also  found 
that  the  difference  between  the  dysplastic  and  invasive  samples  (mortal  or 
immortal)  is  much  smaller  than  for  comparisons  of  the  same  samples  with 
normal  cells. 
The  completeness  of  follow-up  data  in  the  cases  that  progressed  to  carcinoma 
is  vital  in  establishing  a  true  relationship  between  each  patient's  dysplastic 
lesion  and  any  subsequent  malignant  disease.  In  the  case  of  the  three  immortal 
dysplastic  cultures  from  patients  who  developed  a  carcinoma  (D19,  D20  and 
D35),  the  follow-up  data  clearly  demonstrates  that  the  original  dysplastic  lesion 
and  the  carcinoma  were  from  the  same  anatomical  site  in  the  mouth.  The 
provenance  of  these  lesions  as  is  progressors"  is,  therefore,  good.  However,  it 
has  not  been  possible  to  obtain  follow-up  data  beyond  one  year  for  the  mortal 
erythroplakia  cultures  and  therefore  the  clinical  history  of  the  patients  and  the 
natural  history  of  their  lesions  cannot  be  stated  with  any  degree  of  certainly. 
This  must  be  borne  in  mind  when  extrapolating  from  this  data  into  the  clinical 
situation. 
Analysis  of  the  gene  expression  profiles  of  the  cultures  derived  from  the 
clysplastic  lesions  that  progressed  to  HNSCC  is  ongoing.  This  work,  presently 182 
being  continued  by  Dr  Paul  Drake,  is  attempting  to  identify  a  genetic  pattern  that 
is  a  signature  of  high  risk  of  progression  to  carcinoma  in  a  dysplastic  lesion. 
This  is  complicated  by  the  identification  of  the  two  possible  pathways  to  HNSCC 
development,  as  described  earlier.  The  small  number  of  changes  seen  within 
the  two  pathways  and  the  large  number  of  differences  between  the  pathways, 
as  shown  in  Figure  7.2,  means  that  consistent  markers  of  high  risk  of  dysplasia 
progression,  regardless  of  proliferative  lifespan,  are  unlikely  to  be  identified. 
Thus,  two  different  panels  may  emerge  -  one  specific  to  the  mortal  lesions  and 
another  to  immortal  lesions.  In  practical  terms,  this  would  result  in  lesions  first 
being  screened  for  markers  of  the  mortal  or  immortal  phenotype,  before  the  use 
of  the  appropriate  high  risk  panel  of  markers. 
The  small  number  of  samples  at  our  disposal  is  an  obvious  limitation  of  such 
analysis.  However,  the  retrospective  and  prospective  studies  will  be  useful  in 
the  validation  of  any  potential  markers.  The  establishment  of  new  dysplasia 
cultures  may  also  be  beneficial,  but  this  is  dependent  on  careful  follow-up  of 
lesions  with  no  guarantee  that  the  patient  from  whom  the  culture  was 
established  will  develop  a  carcinoma,  as  only  a  small  proportion  of  the  lesions 
will  progress  to  HNSCC.  Thus,  establishing  whether  high  risk  lesions  are  mortal 
or  immortal  (or  mixed)  may  be  important  as  a  first  stage  in  analysis  of  dysplastic 
lesions,  with  markers  of  high  risk  used  subsequent  to  this. 183 
7.8  Future  work 
7.8.1  Completion  of  validation  steps 
The  future  direction  of  the  project  depends  largely  on  the  completion  of 
validation  of  the  gene  expression  profiles  and  exploration  of  many  of  the 
possible  hypotheses  and  molecular  mechanisms  outlined  above.  Validation  of 
the  selected  novel  immortality  markers  in  dysplastic  tissue  related  to  the 
cultures  is  a  vital  step.  Where  commercial  antibodies  are  not  available,  other 
gene  expression  changes  of  interest  must  be  validated  by  quantitative  RT-PCR 
and  a  decision  made  as  to  the  necessity  of  raising  antibodies  for  future 
immunoblotting  and  immunohistochemistry.  The  completion  of  this  element  will 
allow  decisions  to  be  made  as  to  the  future  direction  of  the  research.  Whilst 
some  of  the  basic  functional  experiments,  such  as  knockout  of  RAFý8  from 
mortal  cultures  have  also  yet  to  be  completed,  the  advent  of  RNAi  in  the  interim 
period  may  allow  such  interventions  to  be  accomplished  more  easily. 
7.8.2  Mechanism  of  invasion 
The  possibility  that  different  mechanisms  of  invasion  are  used  by  mortal  and 
immortal  cells  requires  further  investigation.  However,  this  will  require  the 
derivation  of  more  mortal  carcinoma  cultures,  as  our  current  stocks  are  almost 
exhausted.  New  ethical  approval  for  the  collection  of  material  for  this  purpose 
still  requires  to  be  obtained.  It  may  be  possible  to  immortalise  some  of  the 
remaining  stocks  of  mortal  carcinomas  and  indeed,  Ken  Parkinson  plans  to 
attempt  this  by  ectopic  expression  of  hTERT  in  these  cultures.  However,  it  is 
not  clear  what  effect  this  may  have  on  the  invasive  properties  of  these  cells. 
The  use  of  Matrigel  Invasion  assays  and  scratch  wound  assays  initially  to 
assess  the  movement  of  the  immortal  and  mortal  (where  possible)  cells  would 
be  a  useful  starting  point  in  the  assessment  of  the  different  types  of  migration  in 
these  cells 
7.8.3  Tumour  microenvironment 
Further  organotypic  culture  experimentation  with  a  more  concerted  attempt  at 
reconstitution  of  the  microenvironment  is  required.  This  is  particularly  important 184 
as  the  mortal  cultures  do  not  appear  to  have  the  ability  grow  as  xenografts  in 
nude  mice.  It  may  also  be  possible  to  utilise  the  new  dysplasia  associated 
fibroblast  cultures  collected  in  the  prospective  study.  This  may  help 
demonstrate  the  influence  that  the  microenvironment  has  on  the  cultures.  It 
may  also  be  possible  to  gain  permission  for  the  derivation  of  new  tumour 
associated  fibroblast  cultures  when  the  prospective  study  for  SCC  samples  is 
set  up. 
In  relation  to  the  poor  agreement  of  RAR-,  8  expression  in  the  tissues  related  to 
immortal  cultures,  the  role  of  RAR--fl  in  immortalisation  requires  further 
investigation.  It  may  now  be  possible  to  knock  out  the  expression  of  RAR-fl  in 
mortal  cultures,  for  example  by  use  of  RNAi,  or  ectopically  express  it  in  immortal 
cultures. 
7.8.4  Clinical  studies 
As  indicated  above,  retrospective  and  prospective  studies  have  been 
commenced  for  the  analysis  of  both  dysplastic  and  invasive  oral  lesions.  These 
will  allow  us  to  test  many  of  these  hypotheses  regarding  the  different  pathways 
and  cells  of  origin  in  development  of  HNSCC.  This  material  also  forms  an 
important  part  of  the  ongoing  work  of  the  group  in  terms  of  markers  of  high  disk 
of  dysplasia  progression  to  carcinoma. 
Retrospective  study 
Markers  validated  at  RNA  and  protein  level  in  the  cultures  will  be  tested  in  a 
retrospective  study.  All  patients  since  1990  who  have  developed  a  squamous 
cell  carcinoma  at  the  same  intraoral  site  as  a  previous  dysplastic  biopsy  will  be 
included.  At  present  26  such  patients  have  been  identified  for  inclusion.  These 
patients  will  be  assigned  three  control  dysplastic  lesions  that  have  not 
developed  into  HNSCC.  This  will  be  matched  for: 
o  age 
*  sex 
risk  factors  (smoking  and  alcohol  intake). 
The  markers  will  be  assessed  in  formalin  fixed,  paraffin  embedded  tissue 
sections  by  immunohistochemistry,  with  attention  paid  to  staining  location, 185 
intensity  and  proportions  of  cells  stained,  using  the  Quickscore  method  (Detre 
et  al.,  1995).  This  will  form  part  of  Dr  Paul  Drake's  project. 
Prospective  study 
Markers  which  look  promising  in  the  retrospective  study  will  then  be  forwarded 
into  the  prospective  study.  This  removes  the  unavoidable  bias  of  a 
retrospective  study,  can  allow  for  the  effect  of  clinical  intervention  and  will  also 
allow  a  large  enough  study  sample  to  be  collected  to  allow  conclusions  to  be 
drawn  despite  the  presence  of  clinical  variables.  Ethical  approval  for  this 
project  has  been  obtained.  Both  fresh  and  formalin-fixed  material  will  be 
collected  and  consent  for  access  to  medical  records  (including  ISID  cancer 
registration  data)  will  be  obtained.  Funding  will  be  sought  for  a  new  microarray 
study  on  this  material.  Patients  recruited  must: 
have  a  clinical  indication  for  an  biopsy  of  a  white  or  red  patch. 
be  20-70  years  of  age 
have  no  history  of  previous  HNSCC 
a  confirmed  diagnosis  of  dysplasia  and  no  other  concurrent  oral 
pathology  (e.  g.  candidosis  and  immunological  diseases  are  excluded). 
Assuming  10%  progression  over  10  years,  the  study  requires  to  recruit  250 
patients  to  detect  a  significant  (p<0.05)  difference  in  a  single  marker  with  80% 
power.  The  patients  will  be  followed  for  at  least  5  (hopefully  10  years)  and 
approached  for  donation  of  another  sample  if  a  biopsy  is  clinically  indicated. 
For  the  purposes  of  the  study,  follow-up  will  be  censored  once  a  patient 
develops  a  SCCHN  at  the  same  site  as  the  original  biopsy.  Results  will  be 
analysed  using  the  Cox's  proportional  hazards  model  and  Kaplan  Meier  survival 
curves. 186 
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